Health outcomes associated with cognitive impairment by KAAVYA NARASIMHALU












A	  THESIS	  SUBMITTED	  
	  
FOR	  THE	  DEGREE	  OF	  DOCTOR	  OF	  PHILOSOPHY	  





SAW	  SWEE	  HOCK	  SCHOOL	  OF	  PUBLIC	  HEALTH	  
























































To	  my	  family.	  





















This	  thesis	  would	  not	  be	  possible	  without	  the	  support	  of	  so	  many	  people	  in	  so	  many	  
different	  places.	  	  
	  
Everywhere:	  
None	   of	   this	   could	   have	   been	   possible	   without	   my	   family.	   	   From	   the	   genes,	   the	  
environment,	  and	  everything	  else	   that	   could	  have	  confounded	   this	  undertaking.	  My	  
father,	  for	  inspiring	  me	  with	  his	  own	  academic	  career,	  my	  mother	  for	  her	  unwavering	  
love	  and	  support,	  and	  my	  brother	  for	  picking	  on	  me,	  defending	  me,	  and	  big-­‐brothering	  
me	  so	  that	  I	  remain	  grounded.	  	  
	  
In	  Singapore:	  
Chia	   Kee	   Seng,	  main	   supervisor	   NUS	   and	   KI	   –	   I’m	   still	   amazed	   as	   to	   how	   a	   chance	  
meeting	   turned	   into	   a	   PhD.	   I	   cannot	   thank	   you	   enough	   for	   introducing	   me	   to	  
epidemiology.	  You	  unflinchingly	  allowed	  me	  to	  work	  around	  the	  obstacles	  of	  having	  to	  
do	  the	  MD	  and	  the	  PhD	  at	  the	  same	  time	  and	  helped	  me	  smooth	  over	  tons	  of	  issues.	  
Thank	  you	  so	  much	  for	  everything!	  
	  
Christopher	   Chen,	   co-­‐supervisor	   NUS	   and	   KI	   –	   Thank	   you	   for	   guiding	   me	   through	  
research	  from	  my	  pre-­‐PhD	  days.	  It’s	  been	  a	  very	  productive	  five	  years	  (oh	  wow!	  It	  was	  
five	  years	  ago	  that	  I	  started	  working	  for	  you!)	  and	  I	  couldn’t	  have	  done	  it	  without	  you.	  
Thank	  you	  for	  all	  the	  advice	  and	  career	  planning	  tips	  that	  you	  have	  given	  me!	  
	  
Tan	  Eng	  King,	  co-­‐supervisor	  NUS	  –	  Thank	  you	  Dr	  Tan	  for	  agreeing	  to	  be	  my	  supervisor	  
even	  though	  I	  wasn’t	  directly	  involved	  with	  your	  projects.	  You	  were	  always	  around	  to	  
give	   advice	   and	   make	   me	   smile.	   Your	   patience	   and	   comments	   on	   this	   thesis	   are	  
invaluable.	  Thanks	  again!	  	  
	  
Drs	  Chang	  Hui	  Meng,	  Wong	  Meng	  Cheong,	  Deidre	  de	  Silva,	  Alexander	  Auchus,	  and	  all	  
my	   other	   coauthors	   –	   Thank	   you	   for	   all	   your	   support	   and	   your	   suggestions	   in	   the	  
papers,	   for	   the	   career	   guidance,	   and	   for	   being	   so	   supportive	   in	   all	   my	   research	  
endeavors.	  I	  am	  truly	  grateful	  that	  you	  allowed	  me	  to	  continue	  working	  with	  you	  on	  
projects	  other	  than	  the	  papers	  in	  this	  thesis.	  	  
	  
A	  special	  shout-­‐out	  to	  Sharon,	  Xueling,	  Gek	  Hsiang,	  Wei	  Yen,	  Chuen	  Seng,	  Yang	  Qian,	  
Suo	   Chen,	   Shu	  Mei,	   and	   the	   rest	   of	   the	   CME	   gang	   for	   the	   fun	   times	   at	   GIS,	  MD3,	  
Holland	  Village,	   Crystal	   Jade	   and	  many	  more	   places.	   You	   guys	   are	   awesome!	   I	   look	  
forward	  to	  the	  continuation	  of	  our	  unmentionable	  secret	  society…	  
	  
I	  will	  never	   forget	   the	  craziness	  of	  my	  ex/current	   colleagues:	  Kwong	  Hsia,	   Jas	  &	  DJ.	  
Venting,	   eating,	   jamming,	   poking,	   prawning	   and	   crabbing	   times	   that	   I	   can	   never	  
forget!	  =)	  
	  
	  A	  big	  Thank	  You	  to	  Sandy	  Cook,	  Craig	  Stenberg,	  Bob	  Kamei,	  and	  my	  college	  masters	  
Drs	   Lee	   Kheng	  Hock,	   Lee	   Ee	   Lian	  &	  Ong	   Sin	   Tiong	   and	   the	   rest	   of	   the	   people	   from	  
	  	  
Duke-­‐NUS	  who	  were	  super	  understanding	  and	  paved	  the	  way	  for	  me	  doing	  two	  things	  
at	  one	  time	  without	  losing	  my	  mind!	  Ummm.	  Well,	  not	  losing	  my	  mind	  completely!	  
	  
My	  Duke-­‐NUS	  classmates:	  	  
Melinda	   Tan	   (Mel)—	  my	   pillar	   of	   strength	   through	   the	   rough	   patches!	   You	   are	   the	  
awesomest	   friend	   I	   could	   have	   ever	   asked	   for.	   I	   couldn’t	   have	   asked	   for	   a	   better	  
partner	  through	  med	  school!	  Love	  you!	  
	  
Andrew	  Green	  (Drew)	  –	  I	  don’t	  think	  there’s	  anything	  I	  can	  say	  about	  you	  that’s	  NC16,	  
so	  we’ll	  stick	  with	  a	  big	  thank	  you!	  	  	  
	  
Jing	  Wei	  Lim	  (Jingles)	  –	  Thank	  you	  for	  your	  dorkiness.	  It	  has	  made	  me	  laugh	  too	  many	  
times	  to	  count.	  Knowing	  you’ll	  have	  my	  back	  in	  most	  anything	  makes	  life	  better.	  	  
	  
Cheryl	   Lin	   (Bin)	   –	   The	   crazy,	   the	   sane,	   the	   foolish,	   the	  wise.	   I	   think	   you’ve	   seen	   all	  
possible	  sides	  of	  me	  and	  you’re	  still	  there	  for	  me.	  	  Thank	  you!	  	  
	  
There	  are	  so	  many	  more	  of	  you	  that	  it’s	  difficult	  not	  to	  list	  the	  whole	  class,	  so	  Juliet,	  
Daniel,	  Leong	  Jin,	  Shebani,	  Kizher,	  Jiajun,	  Tertius,	  Valerie,	  Jeanne,	  Esther,	  Wei	  Lin,	  Pei	  
Ling,	  Tu	  Anh,	  Pippa,	  and	  the	  rest	  of	  the	  class	  of	  2012	  and	  all	  the	  other	  classes	  of	  Duke	  
NUS	  –	  THANK	  YOU.	  =)	  
	  
Last	  but	  definitely	  not	  the	  least:	  this	  year	  marks	  15	  years	  of	  wonderful	  friendship	  with	  
a	   bunch	   of	   people	   I	   consider	   my	   best	   friends:	   Jovine,	   Qionghui,	   Virginia,	   Hilda,	  




My	  wonderful	  mentors	   in	   Seattle	  –	  Paul	  Crane	  and	   Laura	  Gibbons,	  who	   started	  me	  
down	  the	  path	  of	  dementia	  research.	  
	  
My	  many	  friends:	  
	  
From	  Wash	  U:	  Deepti,	  Divya,	  Deema,	  Angel,	  Nick,	  Rena	  





Nancy	   Pedersen,	  main	   supervisor	   KI,	   and	  NUS	  –	   I	   cannot	   thank	   you	   enough	   for	   the	  
sheer	  faith	  you	  had	  in	  accepting	  me	  as	  your	  student.	  I’ve	  loved	  working	  at	  MEB,	  and	  
working	  on	  this	  degree	  and	  so	  much	  of	  it	  is	  because	  of	  working	  with	  you	  	  	  Thank	  
you	  for	  the	  wonderful	  opportunity!	  
	  
Anna	   Bennet,	   co-­‐supervisor	   KI	  –	   You	   are	   always	   so	   cheerful	   and	   optimistic	   that	   it’s	  
been	  such	  a	  pleasure	  working	  with	  you.	  Thank	  you	  for	  the	  fika	  breaks,	  the	  comments	  
on	  the	  papers,	  and	  of	  course	  the	  comments	  on	  the	  thesis!	  	  
	  
Alexander	  Ploner	  –	  Drawing	  on	  random	  pieces	  of	  paper,	  drinking	  coffee	  whatever	  time	  
we	   meet,	   scrumptious	   dinners	   at	   your	   house,	   and	   not	   laughing	   at	   my	   stupid	  
questions!	  Thank	  you	  so	  much	  for	  keeping	  me	  from	  tearing	  my	  hair	  out	  when	  doing	  
my	  analyses,	  my	  statistical	  guru.	  I	  shall	  have	  to	  call	  you	  Yoda	  from	  now	  on…	  
	  
Yudi	   &	   Marie	   –	   Thank	   you	   for	   making	   me	   feel	   so	   welcome	   in	   Stockholm.	   Merry	  
dinners,	   insightful	   leads	   in	   research,	   and	  a	   general	   sounding	  board	   for	   all	   questions	  
and	   ideas:	   you	   guys	   are	   so	   caring	   that	   you	  were	  my	   adoptive	   family	   in	   Stockholm.	  
Thank	  you	  so	  much!	  	  
	  
Adina	  –	  You	  definitely	  made	  sure	  I	  wasn’t	  homesick	  this	  time	  around	  in	  Sweden.	  IKEA	  
shopping,	  to	  random	  expeditions,	  movie	  marathons,	  curry	  nights,	  the	  list	  goes	  on	  and	  
on.	   You	   and	   your	  mother	  made	  me	   feel	   like	   family	   and	   there’s	   nothing	   I	   can	  do	   to	  
repay	  that!	  Thank	  you	  so	  much	  darling!	  
	  
Iffat	  –	  Tete-­‐a-­‐tetes	  over	  dinner	  where	  we	  could	  talk	  about	  anything	  and	  everything,	  
you	  were	  always	  there	  for	  me	  to	  bug,	  for	  work	  and	  non-­‐work	  things	  .	  You	  and	  Adina	  
really	   made	   me	   feel	   at	   home	   in	   Stockholm	   that	   I’ll	   miss	   you	   both	   when	   I’m	   in	  
Singapore.	  
	  
To	  the	  fabulous	  bunch	  of	  girls	  who	  made	  up	  my	  hang	  out	  buddies…	  Ida,	  Sara,	  Marie,	  
Tong,	  Suo	  Chen,	  Myeong	  Jee,	  thank	  you	  very	  much	  for	  such	  a	  multitude	  of	  wonderful	  
memories!	  Too	  many	  dinners	  to	  forget!	  
	  
To	   all	   the	   other	   MEBers	   that	   have	   helped	   me	   in	   so	   many	   different	   ways..	   Marie	  
Krushammar,	   Camilla	   Ahlqvist,	   Kamila	   Czene,	   Patrick	   Magnusson,	   Erik	   Inglesson,	  
Jonathan	  Prince,	  Mun	  Gwan	  Hong,	  Gunilla	  Sonnebring,	  Zack	  Yusof,	  Emil	  Rehnberg,	  and	  
Ove	  Strind,	  thank	  you	  so	  much.	  	  
	  
To	   Hatef,	  Maria,	   Edo,	   Lisa,	   Sara,	  Martin,	   Ralf,	   Karin,	   Zongli,	   Stephanie,	   Thomas,	   Ci,	  
Andrea,	  Jiaqi,	  Song	  Huan	  and	  the	  numerous	  other	  PhD	  students	  that	  have	  made	  me	  
feel	  very	  welcome,	  I	  thank	  you	  from	  the	  bottom	  of	  my	  heart.	  	  	  
	  
To	  everyone	  else	  in	  MEB,	  thank	  you	  for	  everything	  you	  did	  for	  me!	  	  
	  	  
ABSTRACT	  
In	   this	   thesis,	   we	   aimed	   to	   determine	   whether	   persons	   with	   cognitive	   impairment	   no	  
dementia	   (CIND)	   were	   at	   higher	   risk	   for	   negative	   health	   outcomes,	   and	   if	   so,	   to	   stratify	  
persons	  with	  CIND	   into	  high	  and	   low	   risk	  groups.	  We	  also	  aimed	   to	  determine	   the	  whether	  
persons	  with	  CIND	  had	  a	  higher	   risk	  of	  negative	  health	  outcomes	  based	  on	   their	  underlying	  
familial	   risk,	   or	   whether	   difficulties	   with	   medication	   played	   a	   part	   in	   the	   development	   of	  
negative	   health	   outcomes.	   Lastly,	   we	   aimed	   to	   determine	   whether	   cardiovascular	   and	  
antidepressant	  medication	  use	  modified	  the	  relationship	  between	  CIND	  and	  dementia.	  	  
	  
In	   Studies	   I	   and	   II,	  non-­‐demented	   stroke	  patients	  who	  were	   recruited	  as	  part	  of	   the	  ESPRIT	  
trial	  were	  followed	  up	  for	  up	  to	  five	  years.	  	  In	  Study	  I,	  a	  novel	  method	  of	  stratifying	  CIND	  based	  
on	   the	   severity	   of	   impairment,	  was	   compared	   to	   established	  MCI	   subtypes	   in	   the	   ability	   to	  
predict	  dementia.	  	  Having	  CIND-­‐moderate	  increased	  the	  risk	  of	  dementia	  more	  than	  six	  times	  
(HR	  6.43,	  CI	  1.30-­‐31.7)	  while	  having	  multiple	  domain	  mild	  cognitive	  impairment	  with	  amnestic	  
components	  increased	  the	  risk	  of	  dementia	  more	  than	  five	  times	  (HR	  5.77,	  CI	  1.19-­‐28.0).	  	  	  
	  
In	  Study	  II,	   the	  effect	  of	  CIND	  and	  CIND	  severity	  on	  dependency,	  vascular	  events,	  and	  death	  
were	  analyzed.	  Patients	  with	  CIND	  were	   three	   times	  more	   likely	   to	  become	  dependent	   (HR	  
3.77	   CI	   1.52	   -­‐9.37)	   and	   three	   times	   more	   prone	   to	   mortality	   (HR	   3.27	   CI	   1.06-­‐10.1).	   CIND	  
severity	   was	   able	   to	   discriminate	   those	   at	   high	   risk	   of	   death,	   with	   patients	   with	   CIND-­‐
moderate	   (HR	   3.81	  CI	   1.14-­‐12.8)	   almost	   four	   times	  more	   likely	   to	   die	   as	   compared	   to	   non-­‐
cognitively	  impaired	  patients.	  
	  
In	  Studies	  III	  and	  IV,	  non-­‐demented	  community	  dwelling	  twins	  who	  were	  assessed	  cognitively	  
as	   part	   of	   a	   dementia	   study,	   HARMONY,	   were	   followed	   up	   negative	   outcomes	   with	  
population-­‐based	   registers.	   In	   Study	   III,	   we	   investigated	   the	   effect	   of	   CIND	   and	   Subjective	  
Cognitive	   Impairment	   (SCI)	   on	   negative	   outcomes.	   CIND	   predicted	   hospitalization	   for	  
dementia,	   death,	   and	   hospitalization	   in	   GEE	   analyses	   but	   not	   in	   within-­‐pair	   analyses.	   	   SCI	  
predicted	  dementia	   in	  both	  GEE	  and	  with	  pair	  analyses	  but	  only	  predicted	  hospitalization	   in	  
GEE	  analyses.	  These	  results	  suggested	  that	  the	  relationship	  between	  CIND	  and	  negative	  health	  
outcomes	   is	   confounded	   by	   genetic	   and	   shared	   environmental	   influences	   while	   SCI	   is	  
independently	   associated	   with	   negative	   health	   outcomes.	   Additionally,	   we	   found	   that	  
difficulty	  with	  medication	  was	  an	  independent	  risk	  factor	  for	  both	  dementia	  and	  death.	  	  
	  
In	  Study	   IV,	  we	  aimed	  to	  determine	  whether	  medication	  use	  was	  associated	  with	  dementia,	  
and	  whether	   individuals	  with	  CIND,	   SCI,	   or	  depression	   received	  more	  medication	   than	   their	  
unimpaired	   counterparts.	   Antidepressant	   use,	   particularly	   the	   use	   of	   Selective	   Serotonin	  
Reuptake	  Inhibitors	  (SSRIs)	  doubled	  the	  risk	  of	  dementia	  regardless	  of	  depression	  or	  cognitive	  
status.	   Cardiovascular	   medications,	   particularly	   antihypertensive	   and	   lipid	   lowering	   agents	  
halved	  the	  risk	  of	  dementia.	  In	  addition,	  we	  find	  that	  persons	  with	  CIND	  and	  SCI	  received	  less	  
cardiovascular	  and	  more	  antidepressant	  medications	  than	  their	  non-­‐impaired	  counterparts.	  	  
	  
Overall,	   this	   thesis	   shows	   that	   persons	   with	   CIND	   are	   at	   increased	   risk	   of	   negative	   health	  
outcomes	   such	   as	   dementia,	   death,	   hospitalization,	   and	   disability.	   	   CIND	   appears	   to	   be	  
associated	  with	  negative	  health	  outcomes	  both	  due	  to	  difficulties	  with	  medication	  and	  due	  to	  
the	  fact	  that	  CIND	  acts	  as	  a	  marker	  of	  underlying	  disease	  processes.	  	  In	  addition,	  we	  find	  that	  
persons	  with	  CIND	  get	  less	  cardiovascular	  medications	  and	  more	  antidepressant	  medications,	  
both	  of	  which	  increase	  the	  risk	  of	  dementia.	  These	  findings	  suggest	  that	  persons	  with	  CIND	  are	  
a	  high-­‐risk	  group	  in	  which	  greater	  vigilance	  by	  health	  professionals	  may	  bring	  benefits.	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1 INTRODUCTION	  
	  
Dementia	   is	   a	   progressive	   debilitating	   syndrome	   that	   can	   affect	  memory	   and	   other	  
parts	  of	  cognitive	  functioning.	  	  Alzheimer’s	  disease	  (AD)	  is	  the	  most	  common	  form	  of	  
dementia,	  accounting	  for	  60-­‐70%	  of	  patients	  with	  dementia,	  while	  vascular	  dementia	  
(VAD)	   is	   the	   second	   most	   common	   form	   of	   dementia.1,2	   In	   AD,	   there	   may	   be	   a	  
prodromal	   phase	   in	   which	   episodic	   memory	   is	   affected.	   In	   recognition	   of	   this,	   the	  
concept	  mild	   cognitive	   impairment	   (MCI)3	  was	   originally	   developed	   to	   describe	   the	  
amnestic	  impairments	  that	  are	  commonly	  seen	  in	  pre-­‐AD	  patients.	  
	  
While	  it	  has	  long	  been	  recognized	  that	  the	  cognitive	  sequelae	  of	  strokes	  result	  in	  pre-­‐
dementia	   states,	   no	   specific	   neuropsychological	   patterns	   of	   cognitive	   impairment	  
have	  been	  identified.	  Therefore,	  amnestic	  MCI	  does	  not	  adequately	  characterize	  the	  
cognitive	  profile	  of	  cognitively	  impaired	  but	  non-­‐demented	  stroke	  patients.	  In	  order	  to	  
better	  characterize	  these	  patients	  and	  patients	  in	  the	  prodromal	  stages	  of	  other	  forms	  
of	  non-­‐AD	  dementia,	  a	  more	  general	  concept	  of	  Cognitive	   Impairment	  No	  Dementia	  
(CIND)	  was	  developed4.	  	  	  
	  
In	   community	   dwelling	   individuals,	   it	   has	   been	   shown	   that	   persons	   with	   CIND	   are	  
more	   likely	   to	  develop	  negative	  health	  outcomes	  such	  dementia,	   institutionalization	  
or	  death5.	  The	  same	  study	  also	  found	  that	  there	  are	  twice	  as	  many	  people	  with	  CIND	  
than	  there	  are	  people	  with	  dementia.	  This	  is	  an	  alarming	  statistic	  as	  it	   indicates	  that	  
many	   people	   are	   at	   high	   risk	   of	   conversion	   to	   dementia	   in	   the	   immediate	   future.	  
Within	  the	  last	  4	  years,	  estimates	  of	  the	  total	  worldwide	  costs	  of	  dementia	  have	  risen	  
from	  315	  billion	  USD6	  to	  422	  billion	  USD7.	  With	  an	  increasing	  aging	  population	  (Figure	  
1	  a	  and	  b),	  the	  prevalence	  of	  CIND	  and	  MCI	  is	  expected	  to	  increase.	  This	   in	  turn	  will	  
probably	  result	  in	  an	  exponential	  increase	  in	  the	  number	  of	  dementia	  patients,	  and	  by	  
extension,	  an	  exponential	  increase	  in	  the	  societal	  costs	  associated	  with	  dementia.	  	  
	  
Therefore,	  it	  is	  important	  now	  more	  than	  ever,	  to	  accurately	  identify	  persons	  who	  are	  
at	  high	  risk	  of	  developing	  dementia,	  as	  these	  are	  the	  persons	  who	  are	  most	  likely	  to	  
benefit	  from	  early	  interventions.	  In	  addition,	  it	  is	  important	  to	  elucidate	  the	  possible	  
1
	  	  
mechanisms	  and	  modifiable	   risk	   factors	  behind	   the	  progression	  of	  MCI	  and	  CIND	  to	  
dementia.	   	   Knowledge	   of	   these	   mechanisms	   will	   enable	   the	   development	   of	  
interventions	  that	  may	  be	  able	  to	  delay	  or	  prevent	  the	  onset	  of	  dementia.	  In	  addition	  
to	   the	   large	   impact	   this	   may	   have	   on	   individuals	   predisposed	   to	   dementia,	   the	  
development	  of	  these	  interventions	  may	  be	  able	  to	  decelerate	  the	  exponential	  growth	  
of	  the	  societal	  costs	  associated	  with	  cognitive	  impairment.	  	  
	  
	  
Figure	  1b:	  Projected	  percentage	  of	  the	  population	  aged	  60	  and	  older	  in	  2050.	  
Source:	  United	  Nations	  Population	  Aging	  and	  Development	  Chart	  2009.	  Department	  of	  Economic	  and	  
Social	  Affairs,	  Population	  Division,	  United	  Nations.	  
Figure	  1a:	  Percentage	  of	  the	  population	  aged	  60	  and	  older	  in	  2009.	  	  
Source:	   United	  Nations	   Population	   Aging	   and	  Development	   Chart	   2009.	   Department	   of	   Economic	  
and	  Social	  Affairs,	  Population	  Division,	  United	  Nations	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2 BACKGROUND	  
	  
THE	  IMPACT	  OF	  DEMENTIA	  
Dementia	   is	   a	   syndrome	   characterized	   by	   the	   development	   of	  multiple	   progressive	  
cognitive	   deficits	   that	   are	   severe	   enough	   to	   interfere	   with	   daily	   functioning.	  
Epidemiological	   studies	   of	   dementia	   have	   shown	   that	   regardless	   of	   geographical	  
location,	  both	  the	  incidence	  and	  the	  prevalence	  of	  dementia	  increase	  with	  increasing	  
age8.	  	  The	  2009	  World	  Alzheimer’s	  Report	  estimated	  that	  were	  would	  be	  35.6	  million	  
people	   worldwide	   living	   with	   dementia	   in	   2010,	   and	   that	   this	   number	   was	   set	   to	  
double	  every	  20	  years	  to	  65.7	  million	  in	  2030	  and	  115.4	  million	  in	  20509.	  	  	  
In	   addition	   to	   the	   increase	   in	   the	   prevalence	   of	   dementia,	   the	   societal	   impact	   is	  
increasing.	  	  In	  the	  span	  of	  6	  years,	  estimates	  of	  worldwide	  dementia	  prevalence	  have	  
increased	  by	  7	  million,6,7,10	  with	  a	  corresponding	   increase	   in	  172	  billion	  USD	   in	   total	  
costs	   (Table	   1).	   	   Even	   if	   inflation	  was	   not	   taken	   into	   account,	   the	   total	   increase	   in	  
societal	  costs	  of	  dementia	  attributable	  to	  the	  increased	  prevalence	  between	  2005	  and	  
2009	  is	  57	  billion	  USD7.	  
	   20036	  	   200510	  	   20097	  	  
Worldwide	  	  
prevalence	  	  
27.7	  million	  	   29.3	  million	  	   34.4	  million	  	  
Direct	  costs	  (USD)	  	   156	  billion	  	   210	  billion	  	   279	  billion	  	  
Indirect	  costs	  
(USD)	  	  
94	  billion	  	   115	  billion	  	   142	  billion	  	  
Total	  cost	  (USD)	  	   250	  billion11	  	   315	  billion	  	   422	  billion	  	  
Table	  1:	  Trends	  in	  worldwide	  costs	  of	  dementia,	  USD	  =	  United	  States	  Dollar	  
Given	  the	  large	  societal	  and	  individual	  impact	  of	  dementia,	  delaying	  or	  preventing	  the	  
onset	  of	  dementia	  would	  have	  profound	  implications.	  Previous	  studies	  have	  suggested	  
that	   if	   the	  onset	  of	  dementia	   is	  postponed	   for	  5	   years,	   the	  prevalence	  of	  dementia	  
could	  be	  halved12.	  Therefore	  interventional	  studies	  are	  required	  in	  the	  pre-­‐dementia	  
stage	  so	  as	   to	  delay	  or	  prevent	   the	  onset	  of	  dementia.	   	   In	  order	   to	  more	  efficiently	  
determine	  the	  efficacy	  of	  any	  such	  intervention,	  subgroups	  of	  persons	  at	  high	  risk	  of	  





COMMON	  TYPES	  OF	  DEMENTIA	  
	  
Alzheimer’s	  disease	  
In	  AD,	  the	  most	  common	  form	  of	  dementia,	  there	  is	  a	  progressive	  loss	  of	  neurons	  in	  
several	  parts	  of	   the	  brain.	   Initially,	   this	   loss	   is	   limited	  to	  the	  hippocampal	   region,	  an	  
area	  of	  the	  brain	  associated	  with	  memory	  formation13.	  Therefore,	  the	  most	  common	  
initial	  symptom	  is	  difficulty	  in	  forming	  new	  memories,	  or	  short-­‐term	  memory	  loss.	  As	  
the	  disease	  progresses,	  the	  neuronal	  loss	  spreads	  first	  to	  the	  neocortical	  regions	  of	  the	  
brain	  (which	  control	  higher	  functions	  such	  as	  language	  and	  spatial	  abilities),	  and	  then	  
to	   the	   remaining	   parts	   of	   the	   brain.	   Correspondingly,	   patients	   with	   AD	   lose	   their	  
language	  skills	  and	  their	  general	  awareness	  and	  become	  increasingly	  withdrawn.	  	  
	  
There	  are	  two	  main	  pathological	  changes	  that	  have	  been	  found	  to	  associated	  with	  the	  
development	   and	   progression	   of	   AD:	   amyloid-­‐β	   (Aβ)-­‐containing	   plaques	   and	  
neurofibrillary	  tangles	  composed	  of	  hyper-­‐phosphorylated	  tau13.	  In	  normal	  conditions,	  
Aβ	  peptides	  are	  formed	  during	  the	  metabolism	  of	  amyloid	  precursor	  protein	  and	  are	  
rapidly	  removed	  from	  the	  brain.	  However,	  when	  Aβ	  peptides	  are	  in	  oversupply,	  they	  
aggregate	  to	  form	  oligomers,	  and	  are	  eventually	  deposited	  as	  plaques14.	   It	  has	  been	  
hypothesized	   that	   the	   aggregated	   Aβ	   are	   able	   to	   damage	   the	   neuronal	   synapses,	  
thereby	   inducing	   neuronal	   death15.	   However,	   the	   exact	   mechanisms	   behind	   the	  
contribution	  of	  plaques	  and	  tangles	  to	  neuronal	  death	  are	  yet	  unknown.	  	  	  
	  
In	   normal	   conditions,	   the	   tau	   protein	   is	   a	   microtubule-­‐associated	   protein	   that	   is	  
involved	  in	  stabilizing	  microtubules	  in	  neurons16.	  Abnormal	  phosphorylation	  of	  the	  tau	  
protein	   near	   the	   C	   terminus	   of	   the	   protein	   results	   in	   the	   formation	   abnormal	   tau	  
aggregates	   that	   in	   turn	   cause	  microtubule	   instability,	   and	   eventually,	   neuronal	   cell	  
death.	   	   The	  ghosts	  of	   these	  aggregated	  hyperphosphorylated	   tau	  proteins	   form	   the	  
neurofibillary	   tangles,	   which	   have	   been	   shown	   to	   be	   correlated	   with	   cognitive	  
deterioration16.	  	  
	  
The	  pathological	  changes	  associated	  with	  AD	  are	  more	  common	  in	  persons	  with	  early	  
onset	   AD	   than	   in	   persons	   with	   late	   onset	   AD17.	   While	   there	   is	   some	   evidence	   of	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increased	  amounts	  of	  plaques	  and	  tangles	  in	  persons	  with	  late	  onset	  AD,	  the	  increase	  
is	  not	  as	  marked	  as	  in	  persons	  with	  early	  onset	  AD.	  Similarly,	  persons	  with	  early	  onset	  
AD	   are	   more	   likely	   to	   have	   a	   genetic	   basis	   of	   AD	   than	   those	   with	   late	   onset	   AD.	  
Therefore,	   in	  most	   studies,	   early	   onset	   AD	   is	   considered	   a	   distinct	   entity	   from	   late	  
onset	  AD.	   In	   the	   studies	   included	   in	   this	   thesis,	   the	  AD	  patients	   are	   those	  with	   late	  
onset	  AD	  (Studies	  III	  and	  IV).	  	  
	  
Vascular	  Cognitive	  Impairment	  
Vascular	   Cognitive	   Impairment	   (VCI)18,19	   encompasses	   a	  wide	   spectrum	   of	   cognitive	  
impairment	   (mild	   to	  severe)	   that	   is	  presumably	  due	   to	  cerebrovascular	  disease.	  The	  
etiology	   of	   the	   dysfunction-­‐causing	   vascular	   lesion	   is	   diverse,	   ranging	   from	  
symptomatic	   strokes,	   to	   silent	   infarcts,	   to	   white	   matter	   lesions,	   to	   small	   vessel	  
disease.	  	  Initially,	  the	  term	  multi-­‐infarct	  dementia	  was	  used	  to	  describe	  dementia	  that	  
was	  associated	  with	  cerebrovascular	  disease.	  As	  the	  term	  implies,	  it	  was	  assumed	  that	  
several	  infarcts	  contributed	  to	  the	  emergence	  of	  cognitive	  dysfunction.	  However,	  as	  it	  
became	  apparent	   that	  single	  strategically	  placed	   infarcts	  could	  result	   in	  dementia	   in	  
addition	  to	  large	  territorial	  infarcts,	  the	  term	  multi-­‐infarct	  dementia	  evolved	  into	  VAD.	  	  
	  
However,	  since	  there	  was	  no	  terminology	  to	  describe	  two	  new	  emerging	  trends:	   (1)	  
the	   recognition	   of	   persons	  with	   CIND	   due	   to	   vascular	   causes,	   and	   (2)	   persons	  with	  
mixed	  Alzheimer’s	  and	  Vascular	  pathology,	  O’Brien	  and	  colleagues18	  coined	  the	  term	  
VCI.	  Post	  stroke	  cognitive	  impairment	  (PSCI)	  is	  a	  particular	  form	  of	  VCI	  that	  is	  used	  to	  
describe	  impairments	  in	  stroke	  patients	  that	  are	  apparent	  only	  after	  the	  stroke.	  	  
	  
Recently,	  there	  seems	  to	  be	  an	  increasing	  consensus	  that	  both	  neurodegenerative	  and	  
vascular	   pathologies	   are	   responsible	   in	   giving	   rise	   to	   dementia	   in	   the	   elderly.	   Apart	  
from	  persons	  with	  early	  onset	  AD,	  most	  persons	  with	  a	  diagnosis	  of	  AD	  have	   some	  
neuropathological	  changes	  that	  are	  vascular	  in	  nature20.	  	  	  	  
	  
STROKE	  
Stroke	  is	  a	  leading	  cause	  of	  mortality	  and	  morbidity	  worldwide.21,22	  Strokes	  are	  caused	  
by	  a	   lack	  of	  blood	  to	  regions	  of	  the	  brain.	   	  The	  lack	  of	  blood	  supply	  can	  be	  due	  to	  a	  
hemorrhage	  (hemorrhagic	  stroke)	  or	  a	  blood	  vessel	  occlusion	  from	  a	  clot	  or	  due	  to	  the	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narrowing	   of	   the	   blood	   vessels	   due	   to	   atherosclerosis	   (ischemic	   stroke).	   As	   strokes	  
often	   cause	   cell	   death	   in	   the	   regions	   of	   the	   brain	   that	   lack	   blood	   supply.	   This	   cell	  
death,	  particularly	  when	  involving	  neurons,	  often	  results	  in	  physical	  manifestations	  of	  
stroke	  such	  as	  weakness	  and	  numbness.	  	  These	  physical	  manifestations	  of	  stroke	  are	  
often	   dependent	   on	   the	   location	   and	   severity	   (size	   of	   the	   affected	   region)	   of	   the	  
stroke.	  While	  strokes	  commonly	  present	  with	  slurred	  speech,	  weakness	  or	  numbness	  
of	  the	  face	  and	  limbs,	  they	  can	  also	  be	  “silent”	  (with	  no	  symptoms).	  Such	  silent	  strokes	  
are	   identifiable	   on	   neuroimaging	   such	   as	   Magnetic	   Resonance	   Imaging	   (MRI)	   or	  
Computer	  Tomography	  (CT)	  scans.	  	  
	  
In	   addition	   to	   the	  physical	   symptoms	  of	   a	   stroke,	   there	   can	  be	   cognitive	   symptoms	  
including	  aphasia	  (the	   inability	  to	  speak).	  Approximately	  one	  third	  of	  stroke	  patients	  
have	  dementia	  a	  year	  after	   their	   stroke23	  and	  approximately	  a	  quarter	  have	  CIND24.	  	  
Stroke	   patients	   are	   also	   twice	   as	   likely	   to	   develop	   dementia	   compared	   to	   persons	  
without	   stroke25.	   Therefore	   stroke	   patients	   represent	   a	   high-­‐risk	   subgroup	   of	   the	  
general	  population	  for	  the	  development	  of	  dementia.	  
	  	  
PRE	  DEMENTIA	  
Cognitive	   impairment	   can	   either	   be	   a	   person’s	   subjective	   complaint	   of	   poorer	  
cognitive	  functioning	  or	  an	  objective	  deficit	  in	  neuropsychological	  testing.	  	  A	  person’s	  
cognitive	  status	  can	  range	  from	  no	  cognitive	  impairment	  (NCI),	  to	  a	  transitional	  phase	  
with	   some	   cognitive	   impairment,	   to	  dementia.	   The	   transitional	   period	  between	  NCI	  
and	   dementia	   is	   commonly	   described	   using	   two	   concepts	   of	   objective	   deficits:	  MCI	  
and	  CIND.	  	  
	  
Subjective	  Cognitive	  Impairment	  (SCI)	  
Subjective	   Cognitive	   Impairment	   (SCI)	   is	   one	  measure	   of	   cognitive	   impairment.	   The	  
effect	  of	  SCI	  on	  dementia	   is	  not	  firmly	  established,	  as	  several	  studies	  have	  found	  no	  
association	   between	   SCI	   and	   dementia	  while	   others	   have	   found	   an	   association.26,27	  
Studies	  that	  have	  looked	  at	  the	  temporal	  relationship	  between	  dementia	  shown	  that	  
subjective	  complaints	  of	  memory	  impairment	  often	  precede	  the	  development	  of	  any	  
objective	  cognitive	  deficits26,	  especially	  in	  persons	  who	  are	  highly	  educated.	  As	  most	  
of	   the	   studies	   that	   have	   found	  no	   association	  between	   SCI	   and	  dementia	   have	  had	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shorter	   follow	   up	   times	   than	   the	   studies	   that	   found	   significant	   associations,	   there	  
seems	   to	   be	   an	   increasing	   consensus	   that	   SCI	   is	   an	   early	   risk	   factor	   for	   developing	  
dementia.	  	  
	  
There	   are	   several	   challenges	   associated	  with	   the	  measurement	  of	   SCI.	   Firstly,	   there	  
are	   no	   standardized	   definitions	   of	   SCI.	  Most	   current	   studies	   ask	   participants	   if	   they	  
have	  noticed	  a	  change	  in	  their	  memory	  or	  cognitive	  well	  being	  in	  the	  preceding	  years	  
(range	   1-­‐5	   years).	   Secondly,	   there	   is	   no	   consensus	   as	   to	   whether	   the	   subjective	  
complaint	   should	   be	   elicited	   from	   the	   affected	   individual,	   or	   from	   an	   informant.	  
Studies	   have	   shown	   that	   there	   is	   poor	   correlation	   between	   the	   self-­‐reported	   and	  
informant-­‐reported	   measures	   of	   SCI28.	   The	   development	   of	   a	   standardized	   tool	   to	  
measure	  SCI	  would	  improve	  the	  ability	  of	  studies	  to	  accurately	  measure	  the	  predictive	  
abilities	  of	  SCI.	  	  
	  
Mild	  Cognitive	  Impairment	  (MCI)	  
MCI	   was	   originally	   identified	   as	   a	   precursor	   to	   AD	   and	   defined	   as	   a	   complaint	   of	  
defective	   memory	   with	   an	   abnormal	   memory	   function	   for	   age,	   along	   with	   normal	  
activities	   of	   daily	   living,	   normal	   general	   cognitive	   functioning	   and	   absence	   of	  
dementia3.	   However,	   recently,	   a	   more	   detailed	   classification	   of	   MCI	   has	   been	  
described	   consisting	   of	   the	   following	   four	   categories:	   amnestic	   MCI,	   non-­‐amnestic	  
single	  domain	  MCI,	  multiple	  domain	  amnestic	  MCI,	  and	  multiple	  domain	  non	  amnestic	  
MCI29.	  These	  different	  MCI	  categories	  vary	  by	  the	  number	  of	  domains	  impaired	  as	  well	  
as	  by	  the	  presence	  of	  memory	  impairments	  as	  detailed	  in	  the	  Table	  2.	  
	   Single	  Domain	  	   Multiple	  Domain	  	  
Memory	  Impaired	  	   Amnestic	  MCI	   Multiple	  domain	  amnestic	  
MCI	  




Table	  2:	  MCI	  categories	  
While	  persons	  with	  MCI	  are	  in	  general	  at	  high	  risk	  of	  conversion	  to	  dementia,	  persons	  
with	   amnestic	   forms	   of	   MCI	   seem	   to	   be	   at	   an	   even	   higher	   risk	   of	   conversion	   to	  
dementia30.	   In	   persons	   with	  MCI,	   the	   decline	   in	   cognitive	   functioning	   seems	   to	   be	  
paralleled	  by	  increase	  in	  disability31.	  In	  addition	  to	  the	  effect	  of	  MCI	  on	  dementia	  and	  
disability,	  MCI	  seems	  to	  confer	  an	  increased	  risk	  of	  mortality32.	  	  This	  risk	  of	  mortality	  
7
	  	  
seems	   to	   be	   particularly	   increased	   in	   persons	   with	  multiple	   domain	   amnestic	  MCI.	  	  
However,	   the	  mechanism	  behind	  which	  MCI	   confers	   an	   increased	   risk	   of	   dementia,	  
disability,	  and	  death	  is	  yet	  unknown.	  	  
	  
Cognitive	  Impairment	  No	  Dementia	  (CIND)	  
CIND4	   is	   a	   more	   recent	   concept	   with	   a	   broader	   scope,	   which	   is	   used	   to	   define	  
impairments	   in	  any	  objective	  cognitive	  domains	   in	  neuropsychological	   testing	   in	   the	  
absence	  of	  dementia.	  Unlike	  MCI,	  persons	  with	  CIND	  do	  not	  have	  to	  have	  a	  subjective	  
complaint	   in	   addition	   to	   an	   objective	   impairment	   on	   neuropsychological	   testing.	  
Previous	  studies	  have	  shown	  that	  CIND	  may	  be	  an	  unstable	  group,	  with	  some	  persons	  
with	  CIND	  progressing	  rapidly	   to	  dementia	  while	  others	  experience	  a	  more	   indolent	  
course.33,34	   While	   previous	   studies	   have	   defined	   subtypes	   of	   CIND	   based	   on	   the	  
causative	  etiologies,5,35	  no	  studies	  have	  classified	  persons	  with	  CIND	  based	  on	  severity	  
or	  risk	  of	  conversion	  to	  dementia.	   	  While	  population	  based	  studies	  have	  shown	  that	  
persons	  with	  CIND	  are	  at	   increased	  risk	  of	  dementia,	  hospitalization,	  and	  mortality5,	  
the	  mechanisms	  behind	  this	  increased	  risk	  are	  unknown.	  	  
	  
Controversies	  and	  developments	  in	  pre-­‐dementia	  nomenclature	  
There	   has	   been	   much	   debate	   as	   to	   the	   standardization	   of	   the	   various	   current	  
definitions	  of	  pre-­‐dementia36.	  Within	  a	  specific	  concept,	  for	  example,	  MCI,	  there	  can	  
be	  variation	  in	  several	  aspects	  such	  as	  the	  tests	  and	  cutoffs	  used	  to	  derive	  MCI	  status,	  
the	  etiology	  behind	  the	  MCI,	  and	  the	  effect	  of	  age,	  education,	  and	  cultural	  standards	  
on	  the	  measurement	  of	  MCI.	  Additionally,	  even	  if	  the	  same	  tests	  are	  used	  in	  different	  
studies,	   the	   same	   test	  may	  be	   considered	  a	   test	  of	   executive	   function	   in	  one	   study	  
while	   it	   may	   be	   considered	   a	   test	   of	   visual	   abilities	   in	   another	   study.	   These	  
inconsistencies	   make	   it	   difficult	   to	   compare	   results	   across	   studies.	   However,	  
standardization	  is	  also	  not	  entirely	  possible	  due	  to	  the	  effect	  of	  culture,	  language,	  and	  
education	  in	  the	  measurement	  of	  cognitive	  functioning.	  
	  
Recently,	   the	   National	   Institute	   of	   Aging	   and	   the	   Alzheimer’s	   association	   have	  
published	  updated	  recommendations	  regarding	  diagnostic	  criteria	  for	  AD	  and	  MCI	  due	  
to	  AD37.	  The	  new	  criteria	  incorporate	  clinical,	  pathological,	  radiological	  and	  biomarker	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information	  in	  order	  to	  better	  characterize	  the	  level	  of	  impairment	  in	  persons	  with	  AD	  
and	  MCI	  due	  to	  AD.	  	  The	  characterization	  of	  biomarkers	  in	  persons	  with	  pre-­‐dementia	  
may	  provide	  a	  basis	  by	  which	  studies	  that	  use	  differing	  neuropsychological	  tests	  may	  
be	  compared.	  	  
For	  the	  purposes	  of	  this	  thesis,	  persons	  with	  either	  MCI	  or	  CIND	  or	  will	  be	  referred	  to	  
as	   persons	  with	   objective	   cognitive	   Impairment	   (OCI)	  while	   persons	  with	   subjective	  
complaints	   of	  memory	   disturbances	   will	   be	   referred	   to	   as	   having	   SCI.	   	   In	   addition,	  





DEPRESSION	  AND	  DEMENTIA	  
Several	  studies	  have	  shown	  that	  persons	  with	   late	   life	  depression	  have	  an	   increased	  
risk	   of	   dementia.	   However,	   there	   has	   been	   an	   ongoing	   debate	   as	   to	   whether	  
depression	  is	  a	  prodrome	  or	  a	  risk	  factor	  for	  dementia38.	  Recent	  studies	  suggest	  that	  
late-­‐life	   depression	   may	   be	   a	   prodrome	   rather	   than	   a	   risk	   factor	   for	   dementia39.	  	  
Although	  it	  has	  been	  established	  that	  depression	  is	  related	  to	  dementia	  development,	  
several	   studies	   to	   date	   have	   shown	   that	   depression	   does	   not	   have	   a	   role	   in	   the	  
progression	  of	  MCI	  to	  dementia.40,41	  
	  
Figure	  2:	  Cognitive	  Impairment	  definitions	  used	  in	  this	  thesis	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COGNITION	  AND	  NEGATIVE	  HEALTH	  OUTCOMES	  
While	   there	  are	  several	  possible	  negative	  health	  outcomes	   that	  can	  be	  studied,	   this	  
thesis	  focuses	  on	  the	  outcomes	  of	  mortality,	  dementia,	  vascular	  events,	  dependency,	  
and	   hospitalization.	   The	   outcomes	   of	   dementia,	   dependency,	   and	   hospitalization	  
highlight	   the	   societal	   and	   individual	   level	   impact	  of	   cognitive	   impairment,	  while	   the	  
outcomes	  of	  mortality	  and	  vascular	  events	  highlight	  the	  individual	  impact	  of	  cognitive	  
impairment.	  
	  
Mechanisms	  behind	  the	  increased	  risk	  of	  negative	  health	  outcomes	  
There	  are	  several	  mechanisms	  that	  may	  explain	  why	  persons	  with	  CI	  may	  experience	  
negative	  health	  outcomes.	  Firstly,	  CI	   could	  directly	   impact	   the	  ability	  of	  a	  person	   to	  
comply	  with	  medications	  prescribed,	  thereby	   increasing	  their	   risk	  of	  negative	  health	  
outcomes	  (Figure	  2a).	  Similarly,	  CI	  could	  directly	  impact	  the	  ability	  of	  a	  person	  to	  alter	  
their	   lifestyle	   and	   exercise	   habits,	   again	   increasing	   the	   risk	   of	   negative	   health	  
outcomes.	  The	  direct	  effects	  of	  CI	  on	  compliance	  to	  prescribed	  medications	  and	  the	  
ability	  to	  alter	  one’s	  lifestyle	  are	  potentially	  modifiable	  by	  better	  caregiver	  training	  or	  
innovative	  pharmaceutical	  devices.	  However,	  no	   studies	   to	  date	  have	  examined	   the	  
relationship	   between	   CI	   and	   medication	   use	   and	   compliance.	   As	   a	   recent	   expert	  
panel42	  has	  concluded	  that	  there	  are	  currently	  no	  modifiable	  factors	  to	  prevent	  AD	  or	  
cognitive	  decline,	  the	  identification	  of	  modifiable	  risk	  factors	  may	  improve	  outcomes	  
in	  high	  risk	  populations.	  	  
	  
A	  second	  possible	  mechanism	  that	  may	  explain	  why	  persons	  with	  CI	  may	  experience	  
negative	   health	   outcomes	   is	   that	   the	   same	   underlying	   disease	   process	   (e.g.	  
atherosclerosis	  or	  neurodegeneration)	  that	  contributes	  to	  the	  development	  of	  CI	  may	  
similarly	  contribute	  to	  the	  development	  of	  negative	  health	  outcomes	  (Figure	  2b).	  	  As	  
genetic	   and	   environmental	   factors	   that	   contribute	   to	   common	   diseases	   are	   usually	  
shared	   by	  members	   of	   the	   same	   family,	   familial	   studies	   may	   be	   able	   to	   study	   the	  
determine	   if	   the	   relationship	   between	  CI	   and	   negative	   health	   outcomes	   are	   due	   to	  
underlying	  disease	  processes.	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Figure	   3a:	   Cognitive	   Impairment	   causes	   poor	   health	   outcomes	   via	   difficulties	   with	   medication	   or	  
inability	  to	  alter	  lifestyle	  
	  
	  
Figure	  3b:	   	  Cognitive	   Impairment	  and	  poor	  health	  outcomes	   cause	  by	   the	   same	  underlying	  disease	  
process	  
	  
Stroke	  patients	  –	  A	  high	  risk	  subgroup	  
Stroke	  patients	  often	  have	  an	  overall	   poor	  prognosis,	  with	   approximately	   a	   third	  of	  
stroke	  patients	  dying	  and	  a	  third	  becoming	  dependent	  within	  the	  first	  year	  after	  the	  
index	  stroke43.	  	  This	  may	  be	  particularly	  important	  in	  ischemic	  stroke	  patients,	  as	  they	  
are	  likely	  to	  have	  more	  vascular	  co-­‐morbidities	  than	  their	  healthy	  counterparts	  44.	  PSCI	  
may	  be	   a	  manifestation	  of	   the	   extent	   of	   cortical	   damage	   associated	  with	   the	   initial	  
stroke.	  	  This	  damage	  can	  be	  directly	  due	  to	  cell	  death	  related	  to	  the	  ischemia	  during	  
the	   stroke,	   or	   it	   may	   be	   due	   to	   inflammatory	   response	   to	   the	   ischemia.	   	   Stroke	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patients	  therefore	  are	  a	  high-­‐risk	  subgroup	  of	  the	  general	  population	  that	  is	  likely	  to	  
experience	  negative	  health	  outcomes.	  	  
	  
Medication	  use	  and	  dementia	  
As	  an	  increasing	  number	  of	  studies	  have	  demonstrated	  that	  cardiovascular	  risk	  factors	  
are	  associated	  with	  an	  increased	  risk	  of	  dementia45,	  recent	  studies	  have	  examined	  the	  
effect	   of	   cardiovascular	   medication	   use	   on	   risk	   of	   dementia.	   Several	   large	   cohort	  
studies	   have	   now	   shown	   that	   use	   of	   cardiovascular	   medications,	   particularly	  
antihypertensive	   and	   lipid-­‐lowering	   agents,	   reduces	   the	   risk	   of	   dementia46,47.	  	  
However,	   no	   studies	   to	   date	   have	   examined	  whether	   persons	  with	   CI	   are	   receiving	  
more	   or	   less	   cardiovascular	   medications	   when	   compared	   to	   their	   unimpaired	  
counterparts.	  	  
	  
On	  the	  other	  hand,	  little	  is	  known	  about	  the	  effect	  of	  antidepressant	  therapy	  on	  the	  
risk	  of	  dementia.	  While	  clinical	  trials	  48	  have	  estimated	  the	  efficacy	  of	  antidepressant	  
therapy	  in	  ameliorating	  depressive	  symptoms	  in	  AD	  or	  CI	  patients,	  only	  one	  study	  has	  
examined	  the	  effect	  of	  antidepressant	  therapy	  on	  the	  risk	  of	  dementia.	  	  In	  that	  study,	  
using	   population	   based	   inpatient,	   outpatient,	   and	   prescription	  medication	   registers,	  
the	  study	  authors	  were	  able	  to	  show	  that	  use	  of	  antidepressant	  therapy	  increases	  the	  
risk	  of	  dementia.	  However,	  as	  the	  study	  was	  a	  register-­‐based	  study,	  they	  were	  unable	  
to	  control	  for	  depression	  or	  cognitive	  status.	  	  
	  
TWIN	  METHODS	  
Twin	  studies	  provide	  a	  good	   framework	   to	  study	   the	  underlying	   influences	  of	  genes	  
and	   familial	   environment	   on	   a	   disease	   process.	   Fundamental	   to	   twin	   studies	   is	   the	  
assumption	   that	   dizygotic	   twins	   (twins	   from	   two	   different	   fertilized	   eggs)	   share	  
approximately	  50%	  of	  their	  genetic	  information	  and	  100%	  of	  the	  familial	  environment	  
while	  monozygotic	  twins	  (twins	  from	  the	  same	  fertilized	  egg)	  share	  100%	  of	  both	  their	  
genetic	   information	   and	   their	   familial	   environment.	   	   Therefore,	   if	   genetic	   factors	  
influence	   a	   particular	   disease,	   it	   is	   likely	   that	   both	   twins	   (concordance)	   in	   a	  
monozygotic	  pair	  will	  have	  the	  disease	  more	  often	  than	  both	  twins	  in	  a	  dizygotic	  pair.	  
Conversely,	  one	  can	  conclude	  that	  genetics	  is	  less	  important	  in	  the	  development	  of	  a	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I. To	  identify	   ischemic	  stroke	  patients	  who	  are	  at	  highest	  risk	  for	  conversion	  to	  
dementia	  based	  on	  CIND	  severity	  and	  MCI	  subtypes	  (Study	  I)	  
II. To	  determine	  if	  CIND	  and	  CIND	  severity	  predicts	  vascular	  events,	  dependency,	  
and	  death	  in	  ischemic	  stroke	  patients	  (Study	  II)	  
III. To	  determine	   if	  CIND,	  SCI,	  and	  difficulties	  with	  medication	  predict	  dementia,	  
hospitalization,	   vascular	   events,	   and	   death	   in	   a	   general	   population	   and	  
whether	   these	   associations	   are	   confounded	   by	   genetics	   and	   shared	  
environment.	  (Study	  III)	  
IV. To	   determine	   if	   cardiovascular	   and	   antidepressant	  medication	   influence	   the	  
development	   of	   dementia	   in	   the	   general	   population	   and	   if	   the	   prescription	  
patterns	  of	  cardiovascular	  and	  antidepressant	  medications	  are	  associated	  with	  
cognitive	  status	  (Study	  IV)	  
14
	  	   	   	  
4 MATERIALS	  AND	  METHODS	  
	  
DATA	  SOURCES	  
In	  this	  thesis,	  the	  data	  used	  in	  Studies	  I	  and	  II	  are	  derived	  from	  Singapore,	  while	  the	  
data	  used	  in	  Studies	  III	  and	  IV	  are	  derived	  from	  Sweden.	  	  Studies	  I	  and	  II	  are	  based	  on	  
a	   cohort	   of	   ischemic	   stroke	   patients	   who	   were	   enrolled	   at	   one	   center	   of	   a	   multi-­‐
centric	  randomized	  controlled	  trial.	  	  In	  contrast,	  Studies	  III	  and	  IV	  are	  based	  on	  a	  study	  
of	   dementia	   in	   the	   Swedish	   elderly	   (HARMONY)49,	   which	   aimed	   to	   completely	  
ascertain	  dementia	  in	  twins	  65	  years	  and	  older.	  	  
	  
Studies	  I	  and	  II	  
The	   Stroke	   Group	   at	   the	   Singapore	   General	   Hospital	   Campus	   of	   the	   National	  
Neuroscience	  Institute,	  a	  tertiary	  hospital,	  recruited	  non-­‐disabled	  ischemic	  stroke	  and	  
Transient	  Ischemic	  Attack	  patients	  for	  the	  European	  Australasian	  Stroke	  Prevention	  in	  
Reversible	   Ischemia	   Trial	   (ESPRIT-­‐main)50	   between	   1999	   and	   2005.	   Patients	   with	   a	  
score	  of	  less	  than	  or	  equal	  to	  3	  on	  the	  modified	  Rankin	  Scale	  (MRS)51	  were	  considered	  
non-­‐disabled	  (Table	  3).	  	  
MRS	  Score	   Description	  
0	   No	  symptoms	  at	  all	  
1	   No	  significant	  disability	  despite	  symptoms;	  able	  to	  carry	  out	  all	  usual	  
duties	  and	  activities	  
2	   Slight	  disability;	  unable	  to	  carry	  out	  all	  previous	  activities,	  but	  able	  to	  
look	  after	  own	  affairs	  without	  assistance	  
3	   Moderate	  disability;	   requiring	   some	  help,	  but	  able	   to	  walk	  without	  
assistance	  
4	   Moderately	  severe	  disability;	  unable	  to	  walk	  without	  assistance	  and	  
unable	  to	  attend	  to	  own	  bodily	  needs	  without	  assistance	  
5	   Severe	   disability;	   bedridden,	   incontinent	   and	   requiring	   constant	  
nursing	  care	  and	  attention	  
6	   Dead	  
Table	  3:	  Modified	  Rankin	  Scale	  
The	   ESPRIT-­‐main	   trial	   was	   a	   two-­‐armed	   trial	   in	   which	   patients	   with	   no	  
contraindications	   to	   anticoagulation	   therapy	   (age>75,	   moderate	   to	   severe	  
leukoariaosis,	  contraindications	  to	  warfarin	  therapy)	  were	  enrolled	  in	  Arm	  A	  and	  were	  
randomized	   to	   warfarin,	   aspirin,	   or	   aspirin	   plus	   dipyridamole.	   Patients	   with	   any	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contraindications	  to	  warfarin	  therapy	  were	  enrolled	  in	  Arm	  B,	  in	  which	  patients	  were	  
randomized	  to	  aspirin	  or	  aspirin	  plus	  dipyridamole.	  	  
	  
Patients	   recruited	   into	   the	   ESPRIT-­‐main	   study	   were	   eligible	   to	   enter	   the	   cognitive	  
substudy,	   ESPRIT-­‐cog,	   if	   they	   did	   not	   have	   any	   of	   the	   exclusion	   criteria	   for	   the	  
cognitive	  substudy.	  The	  exclusion	  criteria	  for	  the	  cognitive	  substudy	  were	  confusion,	  
severe	   aphasia	   (expressive	   or	   receptive),	   major	   psychoses	   diagnosed	   according	   to	  
Diagnostic	  and	  Statistical	  Manual	  of	  Mental	  Disorders-­‐	  4th	  Edition	  (DSM-­‐IV)	  criteria52,	  
or	  dominant	  upper	  limb	  paralysis.	  Patients	  who	  consented	  to	  enroll	  in	  the	  ESPRIT-­‐cog	  
substudy	   received	   their	   baseline	   cognitive	   assessment	   three	   months	   after	   their	  
qualifying	  event	  and	  were	   followed	  up	  with	  annual	  neuropsychological	   assessments	  
for	  up	  to	  five	  years.	  	  
	  
Figure	  4:	  Study	  population	  of	  Studies	  I	  and	  II	  
Figure	  4	   summarizes	   the	  patient	  population	  of	   Studies	   I	   and	   II.	  Briefly,	   458	  patients	  
were	  recruited	  into	  ESPRIT-­‐main,	  of	  which	  432	  enrolled	  in	  the	  cognitive	  substudy.	  	  As	  
Study	   I	  required	  follow-­‐up	  neuropsychological	  testing,	  only	  the	  362	  patients	  with	  no	  
dementia	  at	  baseline	  and	  at	  least	  1	  follow	  up	  neuropsychological	  visit	  were	  included.	  	  
All	   419	   non-­‐demented	   patients	   were	   included	   in	   Study	   II	   regardless	   of	  
neuropsychological	  follow	  up	  status.	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Studies	  III	  and	  IV	  
Participants	   in	   Studies	   III	   and	   IV	  were	   part	   of	  HARMONY,	   a	   study	  which	   derived	   its	  
participants	  from	  the	  Swedish	  Twin	  Registry	  (STR)53,	  a	  population	  based	  register	  that	  
comprises	   over	   170,000	   Swedish	   twins	   born	   after	   1886.	   	   Detailed	   methodology	   of	  
HARMONY	  has	  been	  described	  elsewhere49.	  Briefly,	  all	  members	  of	  the	  STR	  aged	  65	  
and	   above	   were	   screened	   for	   cognitive	   impairment	   in	   a	   2.5-­‐year	   period	   beginning	  
March	   1998	   (screening	   phase).	   Participants	   who	   were	   suspected	   of	   cognitive	  
impairment,	   their	   twin	   partners,	   and	   a	   subset	   of	   cognitively	   intact	   controls	   were	  
invited	  for	  a	  clinical	  workup	  (clinical	  phase)	  in	  which	  dementia	  status	  was	  ascertained.	  	  
All	   participants	   who	   were	   deemed	   to	   have	   dementia	   or	   “questionable	   dementia”	  
during	  the	  clinical	  phase	  were	  excluded	  from	  this	  study.	  	  
Figure	  5:	  Study	  population	  of	  Studies	  III	  and	  IV	  
Figure	   5	   summarizes	   the	   patient	   population	   of	   Studies	   III	   and	   IV.	   Briefly,	   20,269	  
persons	   aged	  65	  and	  above	  at	  baseline	  were	  eligible	   for	   inclusion	   in	  HARMONY.	  Of	  
these	   20,269	   persons,	   5,771	   were	   not	   contactable,	   712	   were	   contactable	   but	   not	  
interviewable,	   30	   had	   missing	   data,	   and	   221	   were	   recently	   seen	   in	   other	   studies,	  
resulting	  in	  a	  total	  of	  13,535	  persons	  with	  screening	  information.	  Of	  these,	  530	  were	  
found	   to	   have	   dementia	   and	   a	   further	   170	   had	   “questionable”	   dementia,	   leaving	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12,835	   non-­‐demented	   participants.	   	   These	   12,835	   participants	   made	   up	   the	   study	  
population	   in	   Study	   III.	   	   	  However,	   as	   information	   from	   the	   telephone	   screen	  alone	  
(and	   not	   the	   informant	   reports)	   was	   used	   to	   derive	   the	   CIND	   status,	   persons	   with	  
inadequate	  answers	  to	  the	  telephone	  screen	  had	  no	  CIND	  status	  and	  were	  therefore	  
excluded	   from	   Study	   IV.	   Therefore,	   the	   1,569	   persons	  with	   no	   CIND	   status	   and	   the	  
further	   105	   persons	   with	   no	   depression	   information	  were	   excluded	   from	   Study	   IV,	  
resulting	  in	  a	  study	  population	  of	  11,151	  in	  Study	  IV.	  	  
	  
NEUROPSYCHOLOGICAL	  TESTING	  	  
Studies	  I	  and	  II	  
Neuropsychological	  Test	  Battery	  
The	  neuropsychological	  test	  battery	  that	  was	  administered	  in	  Studies	  I	  and	  II	  consisted	  
of	   six	   domains,	   two	   memory	   domains,	   and	   four	   non-­‐memory	   domains.	   Education	  
adjusted	   cutoffs	   of	   1.5	   standard	   deviations	   below	   established	   normal	   means	   were	  
used	  on	   individual	  tests.	   	  Failure	   in	  at	   least	  half	  of	  the	  tests	   in	  a	  domain	  constituted	  
failure	  in	  that	  domain.	  The	  assessment	  was	  administered	  in	  English,	  Malay,	  Mandarin,	  
or	   Chinese	   dialects	   according	   to	   the	   subject’s	   habitual	   language.	   The	   entire	   battery	  
took	  under	  an	  hour	  and	  a	  half	  to	  complete.	  The	  lists	  of	  tests	  used	  in	  each	  domain	  are	  
detailed	  below	  in	  Table	  4.	  	  
	  
Derivation	  of	  CIND	  and	  MCI	  statuses	  
Patients	  with	  CIND	  were	   impaired	   in	  at	   least	  one	  domain	  of	   the	  neuropsychological	  
test	   battery,	   but	   did	   not	   meet	   criteria	   for	   dementia4.	   On	   the	   basis	   of	   the	   sample	  
median,	  CIND	  was	  divided	  into	  CIND-­‐mild	  (1-­‐2	  domains	  impaired)	  and	  CIND-­‐moderate	  
(3-­‐6	   domains	   impaired).	   	   Patients	   were	   also	   classified	   by	   MCI	   subtypes	   (amnestic	  
single-­‐domain	  MCI,	   non-­‐amnestic	   single	   domain	  MCI,	  multiple	   domain	  MCI	  with	   an	  
amnestic	   component,	   and	   non-­‐amnestic	   multiple	   domain	   MCI)	   according	   to	   the	  
revised	  MCI	   criteria29.	   Since	   all	   patients	   with	   CIND	   had	   cognitive	   complaints,	   there	  
were	  no	  patients	  with	  CIND	  who	  did	  not	  meet	   the	   criteria	   for	  MCI.	  Additionally,	   to	  
facilitate	  the	  comparison	  between	  CIND	  and	  MCI,	  both	  definitions	  used	  cutoffs	  of	  1.5	  
standard	  deviations	  below	  education-­‐adjusted	  means.	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Domain	   Neuropsychological	  Tests	  
Attention	   Digit	  Span	  Forwards	  and	  Backwards54,	  Visual	  Memory	  Span	  
Forwards	  and	  Backwards54,	  Auditory	  Detection55	  
Language	   Modified	  Boston	  Naming	  Test56,	  Verbal	  Fluency	  Test	  (Animals	  
and	  Food	  subtasks)57	  
Verbal	  Memory	   Word	  List	  Recall	  (Immediate,	  Delayed,	  Recognition)58,	  Story	  
Recall	  (Immediate	  and	  Delayed)54	  
Visual	  Memory	   Picture	  Recall	  (Immediate,	  Delayed,	  Recognition)54,	  WMS-­‐R	  
Visual	  Reproduction	  (Immediate,	  Delayed,	  Recognition)54	  
Visuoconstruction	   WMS-­‐R	  Visual	  Reproduction	  (Copy)54,	  Clock	  Drawing,	  WAIS-­‐R	  
Block	  Design59	  
Visuomotor	  Speed	   Digit	  Cancellation	  Task60,	  Digit	  Symbol	  Modalities	  Test61,	  
Maze	  Task62	  
Table	  4:	  Domains	  in	  the	  neuropsychological	  test	  battery	  
	  
Studies	  III	  and	  IV	  
Screening	  phase	  	  
Cognitive	   Screening	   was	   performed	   over	   the	   telephone	   with	   the	   TELE	   cognitive	  
screening	  instrument	  63,64.	  The	  TELE	  consists	  of	  a	  10-­‐item	  mental	  status	  questionnaire	  
(MSQ),	  three	  other	  cognitive	  domains	  (three	  word	  recall,	  three	  word	  pair	  similarities,	  
counting	  backwards	  in	  threes),	  and	  questions	  about	  health	  and	  daily	  functioning.	  The	  
TELE	   also	   includes	   a	   section	   investigating	   cognitive	   complaints,	   including	   a	   general	  
question	   investigating	   subjective	   cognitive	   change	   “Have	  you	  noticed	  any	   change	   in	  
your	  memory	  during	  the	  last	  three	  years?”.	  For	  participants	  who	  were	  impaired	  on	  the	  
TELE,	  an	  informant	  was	  interviewed	  with	  the	  Blessed	  Dementia	  Rating	  Scale	  (BDRS)65.	  	  
The	   TELE	   and	   BDRS	   were	   then	   combined	   into	   an	   ordinal	   scale	   (ORD)	   with	   scores	  
ranging	   from	   0	   (cognitively	   intact)	   to	   3	   (cognitively	   impaired).	   The	   following	   are	  
examples	  of	  what	   constituted	   an	  ORD	   score	  of	   3:	  More	   than	  3	   errors	   on	   the	  MSQ;	  
functional	   impairment	   in	  activities	  of	  daily	   living	  due	  to	  memory	   impairments;	   failed	  
one	  third	  of	  the	  items	  on	  the	  TELE	  or	  impaired	  in	  2	  domains	  of	  the	  MSQ	  with	  a	  BDRS	  





Individuals	  with	  an	  ORD	  score	  of	  3	  were	  referred	  for	  clinical	  workup.	  If	  the	  individual	  
was	   suspected	   of	   dementia,	   his	   or	   her	   twin	   partner	  was	   invited	   for	   clinical	  workup	  
regardless	  of	  screen	  status.	  Additionally,	  a	  sample	  of	  35	  normal	  control	  twin	  pairs	   in	  
which	  both	  twin	  members	  screened	  negative	  were	  included	  in	  the	  clinical	  phase.	  The	  
clinical	   phase	   comprised	   of	   physical	   and	   neurological	   examinations,	  
neuropsychological	   evaluations	   including	   screening	   for	   depression,	   biochemical	  
evaluations,	  as	  well	  as	  referrals	  for	  neuroimaging.	  Clinical	  diagnoses	  of	  dementia	  were	  
made	  in	  consensus	  conferences	  based	  on	  the	  above	  information	  in	  accordance	  to	  the	  
DSM-­‐IV	  criteria52.	  An	  additional	   category	  of	  “questionable	  dementia”	  was	  added	   for	  
individuals	   who	   did	   not	   fulfill	   one	   of	   the	   three	   DSM-­‐	   IV	   diagnostic	   criteria,	   but	   did	  
exhibit	   at	   least	   two	  of	   the	   criteria:	  memory	  problems,	   problems	   in	   another	   area	   of	  
cognition,	  or	  functional	  impairments.	  	  
	  
Derivation	  of	  CIND,	  SCI,	  and	  Depression	  status	  
Participants	  were	  classified	  as	  having	  CIND	  if	  they	  performed	  two	  standard	  deviations	  
below	  the	  age	  and	  education	  adjusted	  means	  in	  any	  of	  the	  four	  cognitive	  tasks	  in	  the	  
TELE	  but	  did	  not	  fulfill	  the	  criteria	  for	  dementia4.	  Participants	  were	  classified	  as	  having	  
SCI	   if	   they	   responded	   positively	   to	   the	   following	   question	   “Have	   you	   noticed	   any	  
change	  in	  your	  memory	  during	  the	  last	  three	  years?”	   	  Participants	  were	  classified	  as	  
having	   had	   depression	   if	   they	   fulfilled	   four	   or	   more	   criteria	   on	   the	   International	  
Diagnostic	   Interview	   Short	   Form	   adapted	   to	   asses	   lifetime	  major	   depression66,67,	   or	  
had	   a	   score	   of	   eight	   points	   or	   above	   on	   the	   eleven	   item	   version	   of	   the	   Center	   for	  




Studies	  I	  and	  II	  
Dementia	  
In	   order	   to	   exclude	   persons	   with	   dementia	   at	   baseline	   in	   Studies	   I-­‐IV,	   consensus	  
conferences	   that	   considered	   neuropsychological,	   clinical,	   neurological,	   biochemical,	  
and	  imaging	  studies	  were	  considered.	  Dementia	  was	  diagnosed	  according	  to	  the	  DSM-­‐
IV	  criteria.	  In	  Study	  I,	  the	  same	  criteria	  are	  applied	  to	  derive	  the	  outcome	  of	  dementia.	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Dependency,	  Death,	  and	  Vascular	  Events	  
In	   Study	   II,	   information	   pertaining	   to	   dependency	   and	   vascular	   events	   were	  
ascertained	  at	  either	  at	  clinic	  visits	  or	  at	  6	  monthly	  telephone	  calls.	  	  Dependency	  was	  
measured	   by	   the	  MRS51,	   and	   was	   dichotomized	   into	   good	   outcome	   (0-­‐2)	   and	   bad	  
outcome	  (3-­‐6).	  	  Patients	  with	  a	  MRS	  of	  3	  at	  baseline	  were	  considered	  dependent	  only	  
if	   they	   progressed	   to	   MRS	   scores	   >3.	   	   If	   a	   recurrent	   vascular	   event	   had	   occurred,	  
detailed	  hospital	  records	  were	  obtained	  to	  verify	  the	  occurrence	  of	  the	  vascular	  event.	  	  
Strokes,	  peripheral	  artery	  disease,	  intracranial	  bleeds,	  and	  any	  cardiac	  ischemia	  (stable	  
and	  unstable	  angina,	  myocardial	   infarctions)	  or	  deaths	   from	  any	  of	   the	  above	  were	  
considered	   to	   be	   a	   recurrent	   vascular	   event.	   	   Information	   pertaining	   to	   death	   was	  
collected	  either	  verbally	  and	  confirmed	  with	  hospital	  and/or	  death	  registry	  records	  at	  
the	  end	  of	  the	  study.	  	  
	  
Studies	  III	  and	  IV	  	  
In	   Studies	   III	   and	   IV,	  outcomes	  were	  ascertained	   through	   the	   linkage	  of	  population-­‐
based	  registers	   to	   the	  Swedish	  Twin	  Registry.	   	  The	  National	  Patient	  Register	   (NPR)69	  
covers	  all	  hospital	  discharges	  in	  Sweden	  since	  1987	  (with	  partial	  coverage	  since	  1964)	  
and	  the	  Cause	  of	  Death	  Register	  (CDR)70	  covers	  all	  deaths	  since	  1961.	  At	  the	  time	  of	  
the	  study	  the	  NPR	  was	  available	  until	  the	  end	  of	  2009	  and	  the	  CDR	  was	  available	  until	  
the	  end	  of	  2008.	   In	   the	   registers,	   the	  primary	  cause	  of	  hospitalization	  or	  underlying	  
cause	  of	  death	  is	  recorded	  in	  addition	  to	  up	  to	  6	  contributory	  causes	  in	  the	  NPR	  and	  
up	   to	   20	   contributory	   causes	   in	   the	  CDR.	  Diagnoses	   are	   recorded	  with	   the	   Swedish	  
versions	  of	   International	  Classification	  of	  Diseases	   (ICD)	  codes.	  The	  major	  difference	  
between	   the	   Swedish	   and	   the	   international	   version	   of	   ICD	   is	   that	   in	   ICD9	   the	   last	  
character	  of	  the	  code	  is	  a	  letter	  instead	  of	  a	  number.	  The	  equivalents	  are	  as	  follows:	  
0=A,	  1=B,	  2=C,	  3=D,	  4=E,	  8=W,	  9=X.	  	  The	  list	  of	  ICD	  codes	  that	  were	  used	  to	  identify	  
dementia	  and	  vascular	  events	  are	  summarized	  below	  in	  Table	  5.	  	  
	  
Dementia	  and	  vascular	  events	  were	  ascertained	  through	  the	  combination	  of	  the	  NPR	  
and	   CDR.	   Only	   about	   half	   of	   all	   dementia	   cases	   are	   captured	   in	   the	   registers	   since	  
hospitalization	   or	   death	   due	   to	   dementia	   as	   the	   primary	   cause	   is	   relatively	  
uncommon.	   The	   specificity	   and	  positive	   predictive	   value	   of	   dementia	   diagnoses	   are	  
close	  to	  100%71.	  Previous	  validation	  studies	  have	  shown	  capture	  is	  much	  better	  with	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vascular	   events	   such	   as	   stroke	   and	   myocardial	   infarctions72,73.	   Hospitalization	   was	  
ascertained	   through	   the	   NPR	   and	   death	   was	   ascertained	   through	   linkage	   with	   the	  
Swedish	  Population	  Register,	  for	  which	  data	  was	  available	  until	  the	  end	  of	  2010.	  
	  
	   ICD7	   ICD8	   ICD9	   ICD10	  
Dementia	   	   	   	   	  
Alzheimer’s	  Disease	   305,304	   290	   290A/B/X,	  
331A	  
F00,	  G30,	  F03	  
Vascular	  Dementia	   306	   293.0,	  293.1	   290E	   F01	  
Other	  Dementia	   	   	   294B,	   290W,	  
331B/C/X	  
F02,	   G311,	  
G318A,	  F051	  
Vascular	  Event	   	   	   	   	  
Hemorrhagic	  Stroke	   331	   432-­‐434	   432-­‐434	   I61	  
Ischemic	  Strokes	   332	   431	   431-­‐432	   I63	  
Transient	  Ischemic	  
Attack	  
333	   435	   435	   G45X,	   I66,	  
G46	  
Myocardial	  Infarction	  
or	  Unstable	  Angina	  
420	   410-­‐411	   410-­‐411	   I21,	  I22	  
Stable	  Angina	  or	  
Ischemic	  Heart	  
Disease	  
420	   412-­‐414	   412-­‐414	   I20,	  I24,	  I25	  
Table	  5:	  ICD	  codes	  that	  are	  used	  in	  Studies	  III	  and	  IV.	  ICD=	  International	  Classification	  of	  Diseases	  
	  
Information	   on	   the	   use	   of	   the	   cardiovascular	   medication	   was	   derived	   from	   the	  
Prescription	   Drug	   Register	   (PDR)74.	   The	   PDR	   contains	   individual-­‐based	   data	   for	   all	  
prescriptions	  dispensed	  to	  the	  whole	  population	  of	  Sweden.	  	  We	  used	  information	  on	  
medication	  use	  from	  the	  when	  the	  registry	  started	  on	  July	  1st	  2005	  to	  July	  1st	  2009.	  In	  
the	   registry,	   medications	   are	   categorized	   by	   the	   Anatomical	   Therapeutic	   Chemical	  
(ATC)	  Classification	  system	  as	  recommended	  by	  the	  World	  Health	  Organization75.	  	  
	  
Antidepressants	  were	   identified	  by	  the	  ATC	  code	  N06A,	  and	  two	  different	  subtypes,	  
tricyclic	   antidepressants	   (TCAs)	   with	   the	   ATC	   code	   N06AA,	   and	   Selective	   Serotonin	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Reuptake	  Inhibitors	  (SSRIs)	  with	  the	  ATC	  code	  N06AB	  were	  identified.	  Cardiovascular	  
mediations	   were	   identified	   by	   the	   following	   ATC	   codes:	   C01AA	   (digitalis),	   C03A	  
(thiazide	  diuretics),	   C03C	   (loop	  diuretics),	   C03D	   (potassium	   sparring	  diuretics),	   C07A	  
(beta	  blockers),	  C08	  (calcium	  channel	  blockers),	  C09A	  (Angiotensin	  Converting	  Enzyme	  
inhibitors),	   C09C	   (angiotensin	   II	   inhibitors),	   and	   C10A	   (lipid	   lowering	   agents).	   	   For	  
subtypes	   of	   cardiovascular	   medication,	   we	   combined	   all	   the	   antihypertensives	   into	  
one	   subtype	   (thiazide,	   loop,	   and	   potassium	   sparring	   diuretics,	   calcium	   channel	  
blockers,	  ACE	  inhibitors,	  and	  angiotensin	  II	  antagonists),	  and	  considered	  digitalis,	  beta-­‐
blockers,	   and	   lipid	   lowering	   agents	   as	   separate	   subtypes.	   Medication	   use	   was	  
stratified	   into	   intervals	  of	  6	  months	  corresponding	   to	   the	  1st	   and	  2nd	  halves	  of	  each	  




All	   statistical	   analyses	   were	   performed	   with	   the	   statistical	   package	   STATA76,	   with	  
versions	  10.0	  used	  in	  Studies	  I	  and	  II	  and	  11.0	  used	  in	  Studies	  III	  and	  IV.	  	  
	  
Logistic	   models	   are	   commonly	   used	   to	   study	   the	   effect	   of	   predictor	   variables	   on	  
categorical	  outcomes.	  While	  logistic	  models	  are	  used	  in	  Study	  III,	  the	  majority	  of	  the	  
analyses	  in	  this	  thesis	  use	  Cox	  proportional	  hazards	  models.	  	  
	  
Cox	  Regression	  Analyses	  
The	   Cox	   Proportional	   Hazards	  models	   are	   one	   form	   of	   survival	   analysis.	   In	   survival	  
analysis	   models,	   instead	   of	   the	   traditional	   dichotomous	   (yes/no)	   outcome	   seen	   in	  
logistic	  models,	   the	  model	   is	  based	  on	   time	  to	  event.	  The	   time	  to	  event	  among	   the	  
cases	   is	   the	   time	  passed	  between	  baseline	  and	   the	  outcome.	  For	  non-­‐cases	  who	  do	  
not	  experience	  the	  outcome,	  the	  time	  contributed	  to	  the	  analyses	  is	  calculated	  as	  the	  
time	   passed	   from	   baseline	   to	   either	   death,	   loss	   to	   follow-­‐up,	   or	   end	   of	   study.	  In	  
survival	  analysis,	  the	  main	  effect	  measure	  is	  the	  Hazards	  Ratio	  (HR).	  	  	  The	  HR	  is	  defined	  
as	  the	  hazards	  in	  the	  exposed	  group	  divided	  by	  the	  hazards	  in	  the	  unexposed	  group.	  	  
The	  Cox	  proportional	  hazards	  model	   is	   a	   semi-­‐parametric	  model,	  which	  means	   that	  
the	  baseline	  hazards	  function	  (i.e.	  the	  shape	  of	  the	  underlying	  survival	  curve)	  does	  not	  





One	  of	  the	  fundamental	  assumptions	  that	  most	  analytical	  models	  is	  that	  the	  persons	  
in	   the	   analyses	   are	   independent	  of	   one	  another.	   In	   twin	   studies,	   this	   assumption	   is	  
violated.	  Thankfully,	  there	  are	  several	  approaches	  to	  model	  the	  underlying	  correlation	  
between	   the	   twins	   in	  order	   to	  use	   the	   conventional	  models	  without	   violating	   these	  
assumptions.	  	  
	  
General	  Estimating	  Equations	  (GEE)	  is	  an	  iterative	  method	  in	  which	  different	  statistical	  
weights	  are	  assigned	  to	  each	  cluster	  (in	  this	  case,	  twin	  pair).	  	  	  These	  weights	  are	  then	  
used	   to	   calculate	   the	   variance,	   covariance,	   and	   correlations	   in	   the	   sample.	   The	  
estimated	  correlation	   is	   then	  used	  to	  re-­‐estimate	  the	  weights	   in	  the	  next	  cycle.	  This	  
process	  is	  repeated	  until	  the	  estimates	  stabilize.	  Once	  stabilized,	  the	  final	  estimate	  of	  
the	  correlation	  is	  used	  to	  estimate	  the	  standard	  error.	  In	  most	  cases,	  the	  use	  of	  GEE	  
will	  increase	  the	  standard	  errors	  while	  leaving	  the	  estimates	  unchanged.	  GEE	  is	  used	  
to	  correct	  for	  the	  clustering	  due	  to	  the	  presence	  of	  twins	  in	  Studies	  III	  and	  IV.	  	  
	  
Another	  method	  of	  controlling	  for	  the	  underlying	  correlations	   in	  twins	   is	   to	  perform	  
matched	   analyses.	   	   Conditional	   logistic	   regression	   is	   used	   to	   analyze	  matched	  data,	  
and	   when	   used	   with	   twin	   data,	   is	   commonly	   referred	   to	   as	   either	   co-­‐twin	   control	  




Figure	   6	   summarizes	   the	   study	   designs	   of	   the	   four	   studies	   in	   this	   thesis.	   Briefly,	   all	  
studies	   included	   in	   this	   thesis	  had	  a	  cohort	  design.	  Studies	   I	  and	   II	  were	  based	  on	  a	  
cohort	  of	  Singaporean	  stroke	  patients	  while	  Studies	  III	  and	  IV	  were	  based	  on	  a	  cohort	  
of	  Swedish	  twins.	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Figure	  6:	  Summary	  of	  study	  designs	  used	  in	  Studies	  I	  –	  IV.	  Abbreviations:	  VE=	  Vascular	  Events,	  CIND	  =	  
Cognitive	   Impairment	   No	   Dementia,	   MCI	   =	   Mild	   Cognitive	   Impairment,	   SCI	   =	   Subjective	   Cognitive	  
Impairment,	  GEE	  =	  General	  Estimating	  Equations	  
Study	  I:	  Severity	  of	  CIND	  versus	  MCI	  subtypes	  in	  predicting	  dementia	  
In	  Study	  I,	  we	  aimed	  to	  determine	  whether	  CIND	  severity	  predicted	  dementia	  among	  
post-­‐stroke	  patients.	  We	  also	  aimed	  to	  compare	  CIND	  and	  MCI	  subtypes	  as	  predictors	  
of	   dementia.	   Lastly,	   we	   also	   assessed	   the	   ability	   of	   cognitive	   domains	   to	   predict	  
dementia.	  	  These	  aims	  were	  evaluated	  in	  a	  cohort	  of	  362	  ischemic	  stroke	  patients	  who	  
were	   recruited	   at	   the	   Singapore	   General	   Hospital	   between	   1999	   and	   2005.	   CIND	  
severity	  (CIND-­‐mild	  and	  CIND-­‐moderate),	  MCI	  subtypes,	  and	  the	  6	  cognitive	  domains	  
were	  the	  main	  exposures	  of	  interest.	  	  
	  
In	  addition	  to	  the	  main	  exposures	  of	  interest,	  the	  following	  covariates	  were	  examined	  
for	   their	   association	  with	   incident	   dementia:	   age,	   gender,	   stroke	   subtype,	   diabetes	  
mellitus,	   hypertension,	   smoking,	   recurrent	   stroke	   during	   study	   follow	   up,	   baseline	  
MRS	   score,	   baseline	   mini-­‐mental	   state	   examination	   score,	   and	   previous	   vascular	  
events	  (stroke,	  myocardial	  infarct,	  angina,	  ischemic	  heart	  disease,	  or	  peripheral	  artery	  
disease).	   	   Information	   on	   these	   covariates	   was	   determined	   at	   baseline	   from	   a	  




Univariate	  Cox	  regression	  analyses	  were	  performed	  to	  identify	  significant	  predictors	  of	  
incident	   dementia.	   Exposures	   that	   were	   significant	   in	   the	   univariate	   stage	   were	  
included	   in	   multivariable	   analyses	   that	   controlled	   for	   treatment	   allocation.	   	   The	  
exposures	   of	   interest	   were	   entered	   into	   separate	   regression	   models	   due	   to	  
colinearity.	  Significance	  was	  determined	  with	  a	  two-­‐tailed	  alpha	  of	  0.05	  in	  analysis	  of	  
CIND	   severity	   and	   MCI	   subtypes	   while	   Bonferroni	   adjustment	   for	   multiple	  
comparisons	   yielded	   an	   alpha	   of	   0.008	   for	   domain	   analyses.	   Lastly,	   uniform	   scores	  
were	  derived	  for	  each	  domain	  and	  averaged	  across	  the	  patients	  in	  different	  MCI	  and	  
CIND	   severity,	   after	   which	   receiver-­‐operating	   curves	   were	   plotted	   to	   compare	   the	  
area	  under	  curve	  of	  the	  different	  classifications.	  	  
	  
Study	  II:	  CIND,	  CIND	  severity	  and	  negative	  health	  outcomes	  
In	  Study	  II,	  we	  aimed	  to	  determine	  whether	  CIND	  severity	  predicted	  negative	  health	  
outcomes	  other	  than	  dementia	  among	  post-­‐stroke	  patients.	  The	  specific	  outcomes	  of	  
interest	   were	   dependency	   (MRS>3),	   vascular	   events,	   and	   death.	   Furthermore,	   we	  
aimed	   to	  determine	   if	   specific	  domains	  of	   cognitive	   impairment	   could	  predict	   these	  
outcomes.	  These	  aims	  were	  evaluated	  in	  a	  cohort	  of	  419	  ischemic	  stroke	  patients	  who	  
were	  recruited	  at	  the	  Singapore	  General	  Hospital	  between	  1999	  and	  2005.	  CIND,	  CIND	  
severity	  (CIND-­‐mild	  and	  CIND-­‐moderate),	  and	  the	  6	  cognitive	  domains	  were	  the	  main	  
exposures	  of	  interest.	  	  
	  
In	  addition	  to	  the	  main	  exposures	  of	  interest,	  the	  following	  covariates	  were	  examined	  
for	   their	   association	   with	   negative	   health	   outcomes:	   age,	   gender,	   stroke	   subtype,	  
diabetes	   mellitus,	   hypertension,	   smoking,	   recurrent	   stroke	   during	   study	   follow	   up,	  
baseline	   MRS	   score,	   baseline	   mini-­‐mental	   state	   examination	   score,	   and	   previous	  
vascular	   events	   (stroke,	   myocardial	   infarct,	   angina,	   ischemic	   heart	   disease,	   or	  
peripheral	   artery	   disease).	   	   Information	   on	   these	   covariates	   was	   determined	   at	  
baseline	  from	  a	  combination	  of	  self-­‐report	  and	  medical	  records.	  	  
	  
Univariate	  Cox	  regression	  analyses	  were	  performed	  to	  identify	  significant	  predictors	  of	  
negative	   outcomes.	   Exposures	   that	   were	   significant	   in	   the	   univariate	   stage	   were	  
included	   in	   multivariable	   analyses	   that	   controlled	   for	   treatment	   allocation.	   	   The	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exposures	   of	   interest	   were	   entered	   into	   separate	   regression	   models	   due	   to	  
colinearity.	  Significance	  was	  determined	  with	  a	  two-­‐tailed	  alpha	  of	  0.05	  in	  analysis	  of	  
CIND	   and	   CIND	   severity	   while	   Bonferroni	   adjustment	   for	   multiple	   comparisons	   in	  
domain	  analysis	  yielded	  an	  alpha	  of	  0.008.	  	  
	  
Study	  III:	  Why	  does	  Cognitive	  Impairment	  lead	  to	  negative	  health	  outcomes?	  
In	   Study	   III,	   we	   aimed	   to	   determine	   the	   reasons	   why	   persons	   with	   CIND	   or	   SCI	  
experience	   negative	   health	   outcomes.	   Specifically,	  we	  wanted	   to	   ascertain	  whether	  
difficulties	   with	   medication	   or	   underlying	   genetic	   and	   environmental	   factors	   were	  
associated	   the	   development	   of	   negative	   health	   outcomes	   of	   dementia,	   death,	  
hospitalization,	  and	  vascular	  events.	  	  These	  aims	  were	  evaluated	  in	  a	  cohort	  of	  12,835	  
non-­‐demented	   Swedish	   twins	  who	  were	   evaluated	   for	   cognitive	   status	   as	   part	   of	   a	  
population	  based	  study,	  HARMONY.	  	  
	  
The	  main	  exposures	  of	  interest,	  CIND	  and	  SCI,	  were	  entered	  into	  separate	  models.	  In	  
order	   to	   examine	   whether	   difficulties	   with	   medication	   affected	   negative	   health	  
outcomes,	  an	  indicator	  of	  having	  difficulties	  with	  medication	  was	  also	  entered	  into	  yet	  
another	   model.	   To	   determine	   whether	   difficulties	   with	   medication	   modified	   the	  
association	   between	   negative	   health	   outcomes	   and	   CIND	   or	   SCI,	   the	   indicator	   of	  
difficulties	  with	  medication	  was	  also	  entered	  in	  the	  same	  model	  as	  CIND	  or	  SCI.	  	  The	  
indicator	  of	  difficulties	  with	  medication	  was	  derived	   from	  a	   self-­‐reported	  answer	   to	  
the	  question	  “Have	  you	  had	  problems	  with	  taking	  your	  medication”.	  	  
	  
In	   addition	   to	   the	  main	   exposures	   of	   interest,	   all	  multivariable	  models	   adjusted	   for	  
age,	  gender,	  and	  education.	  	  Additionally,	  models	  that	  predicted	  dementia	  controlled	  
for	  previous	  strokes	  while	  models	  that	  predicted	  death	  and	  vascular	  events	  controlled	  
for	   previous	   vascular	   events.	   Multivariate	   regression	   analyses	   were	   performed	   in	  
three	   different	   ways:	   1)	   Cox	   Regression	   Analysis	   with	   GEE	   adjustments;	   2)	   Logistic	  
Regression	   Analysis	   with	   GEE	   adjustments;	   and	   3)	   Co-­‐twin	   controlled	   Conditional	  
Logistic	   Regression	  Analysis	   in	  which	   twins	   discordant	   for	   both	   cognitive	   status	   and	  
outcome	   are	   analyzed	   in	   a	   matched	   case-­‐control	   fashion	   in	   MZ	   Twins	   (within-­‐pair	  
analysis).	   To	   determine	   whether	   genetics	   and	   shared	   environment	   modified	   the	  
relationship	  between	  negative	  health	  outcomes	  and	  CNID	  or	  SCI,	  estimates	  from	  the	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logistic	   regression	   analyses	   were	   compared	   with	   estimates	   from	   the	   within-­‐pair	  
analyses.	  	  
	  
In	  this	  study,	  we	  included	  both	  Cox	  and	  Logistic	  models	  with	  GEE	  as	  we	  believed	  that	  
in	  certain	  outcomes,	  time	  to	  failure	  may	  be	  more	  important	  than	  failure.	  However,	  as	  
the	  Cox	  regression	  analyses	  with	  GEE	  adjustments	  are	  not	  directly	  comparable	  to	  the	  
conditional	  logistic	  regression	  analyses	  in	  the	  within-­‐pair	  analyses,	  we	  chose	  to	  include	  
logistic	  regression	  analyses	  with	  GEE	  adjustments.	  In	  the	  within-­‐pair	  analyses,	  pairs	  in	  
which	  the	  control	  twin	  was	  not	  alive	  when	  his	  or	  her	  partner	  became	  demented,	  was	  
hospitalized,	  or	  experienced	  a	  vascular	  event	  were	  excluded	  from	  the	  analyses.	  	  
	  
Study	  IV:	  Medication	  use	  and	  dementia	  
In	  Study	  IV,	  we	  aimed	  to	  determine	  whether	  use	  of	  antidepressant	  or	  cardiovascular	  
medications	  were	  associated	  with	  dementia.	  We	  also	  aimed	  to	  evaluate	  whether	  use	  
of	   antidepressant	   or	   cardiovascular	   medication	   changed	   the	   association	   between	  
dementia	   and	   either	   CIND,	   SCI,	   or	   depression.	   	   Lastly,	   we	   aimed	   to	   determine	   if	  
individuals	   with	   CIND,	   SCI,	   or	   depression	   received	   more	   antidepressant	   or	  
cardiovascular	  medications	  compared	  to	  their	  unimpaired	  counterparts.	   	  These	  aims	  
were	   evaluated	   in	   a	   cohort	   of	   11,151	   non-­‐demented	   Swedish	   twins	   who	   were	  
evaluated	   for	   cognitive	   status	   as	   part	   of	   a	   population	   based	   study,	   HARMONY.	   Of	  
these	  11,151,	  only	  9,112	  were	  alive	  and	  non-­‐demented	  at	  the	  start	  of	  the	  PDR.	  	  
	  
The	  main	  exposures	  of	  interest	  were	  CIND,	  SCI,	  depression,	  use	  of	  any	  antidepressant	  
medication,	  and	  use	  of	  any	  cardiovascular	  medication.	  	  Medication	  use	  (dichotomous)	  
was	  considered	  a	  time	  varying	  exposure.	  Multivariable	  analyses	  were	  performed	  using	  
Cox	  Regression	  Analyses	  in	  three	  stages.	  In	  the	  first	  stage,	  CIND,	  SCI,	  and	  depression	  
were	   entered	   in	   separate	   multivariable	   models	   that	   controlled	   for	   age,	   education,	  
gender,	   and	  previous	   stroke.	   In	   the	   second	   stage,	   the	  models	   from	   stage	  one	  were	  
adjusted	  for	  use	  of	  any	  antidepressant	  medications	  or	  cardiovascular	  medications.	  In	  
the	  third	  stage	  of	  analysis,	   subtypes	  of	  antidepressant	  medications	   (SSRIs	  and	  TCAs)	  
and	  cardiovascular	  medications	   (antihypertensives,	  beta	  blockers,	  digitalis,	  and	   lipid-­‐
lowering	   agents)	   were	   added	   into	   the	   models	   from	   stage	   one.	   Lastly,	   the	   Mann	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Whitney	   U	   test	   was	   used	   to	   compare	   the	   number	   of	   prescriptions	   (ordinal)	   for	  






5 RESULTS	  AND	  DISCUSSION	  
	  
Study	  I:	  Severity	  of	  CIND	  versus	  MCI	  subtypes	  in	  predicting	  dementia	  
Study	   I	   aimed	   to	   determine	  whether	   CIND	   severity	   predicted	   dementia	   in	   ischemic	  
stroke	  patients	  and	  whether	  CIND	  severity	  or	  MCI	  subtypes	  were	  better	  at	  predicting	  
dementia.	  	  
	  
Of	   the	  362	  patients	   (mean	  age	  60	  ±	  11	  years,	  30%	  women)	   in	   this	  study,	  179	   (49%)	  
had	  cognitive	  impairment	  at	  baseline.	  In	  terms	  of	  CIND	  severity,	  94	  patients	  had	  CIND-­‐
mild	  while	  85	  had	  CIND-­‐moderate.	   In	   terms	  of	  MCI	   subtypes,	  20	  had	   single	  domain	  
amnestic	   MCI,	   33	   had	   single	   domain	   non-­‐amnestic	   MCI,	   99	   had	   multiple	   domain	  
amnestic	   MCI,	   and	   27	   had	   multiple	   domain	   non-­‐amnestic	   MCI.	   The	   proportion	   of	  
patients	   with	   cognitive	   impairment	   was	   larger	   than	   expected	   considering	   that	   only	  
persons	  with	  non-­‐disabling	  stroke	  were	   involved	   in	  this	  study.	  Previous	  studies	  have	  
shown	  that	  the	  prevalence	  of	  post	  stroke	  CIND	  ranges	  from	  20%	  to	  79%24,33,77,78.	  This	  
range	  is	  particularly	  wide	  due	  to	  differences	  in	  study	  design,	  particularly	  with	  regards	  
to	   the	   time	  point	   chosen	   in	   relation	   to	   the	   time	  of	   stroke.	  As	  most	  of	   the	  cognitive	  
recovery	   occurs	  within	   3	  weeks	   to	   3	  months	   after	   a	   stroke79,	   studies	   that	  measure	  
cognitive	  status	  closer	  to	  the	  onset	  of	  stroke	  tend	  to	  find	  a	  higher	  prevalence	  of	  post	  
stroke	  CIND.	  	  
	  
During	  the	  course	  of	  the	  study,	  24	  patients	  converted	  to	  dementia.	  The	  incidence	  of	  
dementia	   in	   patients	   with	   no	   impairments	   at	   baseline	   was	   11	   per	   1,000	   while	   the	  
incidence	   of	   dementia	   in	   patients	  with	   CIND-­‐mild	   and	   CIND-­‐moderate	  were	   42	   per	  
1,000	   and	  212	  per	   1,000	   respectively.	   In	  multivariable	   analyses,	   the	   risk	   of	   incident	  
dementia	  for	  persons	  with	  CIND-­‐mild	  was	  not	  significantly	  different	  from	  those	  with	  
no	   impairments	   (HR	   1.04,	   95%	  Confidence	   Interval	   (CI)	   0.17-­‐6.37).	   	   However,	   those	  
with	  CIND-­‐moderate	  were	  at	   six	   times	   increased	   risk	  of	   incident	  dementia	   (HR	  6.43	  
95%	  CI	  1.30-­‐31.7).	  	  Therefore	  CIND	  severity	  was	  able	  to	  discriminate	  those	  at	  high	  risk	  
of	   dementia	   from	   those	   who	   were	   not	   at	   high	   risk.	   While	   previous	   studies	   have	  
stratified	  CIND	  subtypes	  based	  on	  etiology,	  no	  studies	  have	  attempted	  to	  stratify	  CIND	  
into	  subtypes	  based	  on	  severity.	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The	  incidence	  rates	  of	  dementia	  in	  the	  various	  MCI	  subtypes	  were	  as	  follows:	  50	  per	  
1,000	   in	   amnestic	   single	   domain	  MCI,	   30	   per	   1,000	   in	   non-­‐amnestic	   single	   domain	  
MCI,	   181	  per	  1,000	   in	  multiple	  domain	   amnestic	  MCI,	   and	  71	  per	  1,000	   in	  multiple	  
domain	  non-­‐amnestic	  MCI.	  In	  multivariable	  analysis,	  the	  risk	  of	  incident	  dementia	  was	  
significantly	   increased	   in	   only	   the	  multiple	   domain	   amnestic	  MCI	   subtype	   (HR	   5.77	  
95%	   CI	   1.19-­‐28.0).	   Comparisons	   between	   CIND	   severity	   and	  MCI	   subtypes	   showed	  
that	   CIND-­‐moderate	   is	   not	   significantly	   better	   than	   multi-­‐domain	   amnestic	   MCI	   in	  
predicting	  incident	  dementia.	  However,	  since	  memory	  impairments	  are	  more	  relevant	  
in	  populations	  at	  risk	  for	  AD,	  and	  as	  stroke	  populations	  are	  more	  likely	  to	  convert	  to	  
VAD	  or	  mixed	   dementia	   rather	   than	  AD,	   CIND	   severity	  may	   be	   a	  more	   appropriate	  
measure	  than	  MCI	  subtypes	  in	  a	  post	  stroke	  setting.	  Fourteen	  percent	  of	  patients	  with	  
CIND	  moderate	  only,	  4%	  of	  patients	  with	  multiple	  domain	  amnestic	  MCI	  only	  and	  17%	  
of	  patients	  with	  both	  CIND	  moderate	  and	  multiple	  domain	  amnestic	  MCI	  converted	  to	  
dementia.	  
	  
In	  multivariable	  domain	  specific	  analysis,	  visual	  memory	  (HR	  6.92,	  p<0.001)	  and	  verbal	  
memory	   (HR	  4.25,	  p=0.002)	  were	  significant	  predictors	  of	  dementia.	   	  These	   findings	  
were	  in	  agreement	  with	  previous	  stroke	  studies	  that	  have	  shown	  that	  verbal	  memory	  
was	  more	  likely	  to	  deteriorate	  in	  ischemic	  stroke	  patients	  who	  convert	  to	  dementia80.	  	  
However,	   it	   is	   unclear	   whether	   this	   result	   is	   an	   artifact	   due	   to	   the	   requirement	   of	  
memory	  impairment	  for	  the	  diagnosis	  of	  dementia.	  	  	  
	  
Study	  II:	  CIND,	  CIND	  severity	  and	  negative	  health	  outcomes	  
Having	   shown	   that	   CIND	   severity	   discriminates	   those	   at	   high	   risk	   of	   dementia	   from	  
those	  at	  low	  risk	  of	  dementia	  in	  a	  post	  stroke	  setting,	  we	  aimed	  to	  determine	  whether	  
CIND	   severity	   discriminates	   those	   at	   high	   risk	   for	   negative	   health	   outcomes	   in	   the	  
same	  population.	  	  
	  
Of	   the	   419	   patients	   in	   this	   study,	   207	   (49%)	   of	   patients	   had	   CIND	   (109	   (26%)	  with	  
CIND-­‐mild	  and	  98	   (23%)	  with	  CIND-­‐moderate)	   at	  baseline.	  During	   the	   course	  of	   the	  
study,	   28	   patients	   died,	   62	   had	   a	   vascular	   event,	   and	   48	   became	   dependent.	   The	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incidence	   of	   death,	   vascular	   events	   and	   dependency	   by	   baseline	   cognitive	   status	   is	  
summarized	  in	  Table	  6.	  	  
	  
	  
	   Death	   Vascular	  events	   Dependency	  
No	  impairments	   0.2	   1.0	   0.3	  
CIND-­‐mild	   0.9	   1.8	   1.9	  
CIND-­‐moderate	   1.4	   2.1	   2.2	  
Table	  6:	  Incidence	  rates	  per	  1,000	  person	  years	  
In	  multivariable	  analyses,	  patients	  with	  CIND	  were	  at	  an	  increased	  risk	  of	  dependency	  
(HR	   3.77	   95%	   CI	   1.53-­‐9.37),	   but	   CIND	   severity	  was	   unable	   to	   discriminate	   between	  
those	  at	  high	  and	  low	  risk	  of	  dependency,	  as	  patients	  with	  both	  CIND-­‐mild	  and	  CIND-­‐
moderate	   were	   an	   increased	   risk	   of	   dependency.	   Additionally,	   in	   domain	   specific	  
analyses,	   impairments	   in	   visuomotor	   speed	   predicted	   dependency.	   These	   findings	  
were	   in	   agreement	   with	   previous	   studies	   in	   stroke	   patients	   that	   have	   shown	   that	  
visual	  perception	  and	  constructional	  difficulties	  independently	  predict	  disturbances	  in	  
instrumental	  activities	  of	  daily	  living81.	  	  	  
	  
We	  also	  found	  that	  patients	  with	  CIND	  were	  at	  increased	  risk	  of	  death	  (HR	  3.27	  95%	  CI	  
1.06-­‐10.1)	   as	   compared	   to	   those	  without	   impairments.	   	   Furthermore,	  CIND	   severity	  
was	  able	   to	  discriminate	  between	  those	  at	  high	  and	   low	  risk	  of	  death,	  with	  persons	  
with	  CIND-­‐moderate	  at	   approximately	   four	   times	   the	   risk	  of	  death	   (HR	  3.81	  95	  %CI	  
1.13-­‐12.8)	  as	  compared	  to	  unimpaired	  persons.	  However,	  there	  were	  no	  independent	  
cognitive	  domains	  that	  predicted	  death.	  	  
	  
However	   persons	   with	   CIND	   were	   not	   at	   an	   increased	   risk	   of	   vascular	   events	   as	  
compared	   to	   unimpaired	   persons.	   Similarly,	   CIND	   severity	   and	   domain	   specific	  
impairments	  showed	  no	  association	  to	  the	  risk	  of	  vascular	  events.	  These	  results	  were	  
unexpected	   since	   we	   had	   hypothesized	   that	   persons	   with	   CIND	   would	   be	   less	  
compliant	  to	  medication	  regimens	  and	  lifestyle	  changes.	  However,	  in	  the	  Singaporean	  
context,	  as	  elderly	  persons	  live	  within	  family	  units	  as	  opposed	  independently,	  factors	  
such	   as	   forgetting	  medication	   and	   apathy	   to	   lifestyle	   changes	  may	   have	   less	   of	   an	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impact	  on	  the	  patient’s	  health	  than	  in	  other	  countries.	  The	  association	  between	  CIND	  
and	   vascular	   events	   (HR	   1.67	   CI	   0.93-­‐3.00)	   improved,	   but	   remained	   non	   significant	  
when	  analyses	  was	  restricted	  to	  those	  with	  fatal	  vascular	  events	  (HR	  1.73	  CI	  0.61-­‐5.02)	  
suggesting	   that	   another	   possible	   explanation	   for	   the	   lack	   of	   significant	   association	  
between	  CIND	  and	  vascular	  events	  is	  that	  we	  may	  have	  been	  underpowered	  to	  detect	  
a	  significant	  effect	  on	  vascular	  events.	  	  	  
	  
Study	  III:	  Why	  does	  Cognitive	  Impairment	  lead	  to	  negative	  health	  outcomes?	  
The	  main	  aim	  of	  Study	  III	  was	  to	  test	  two	  possible	  hypotheses	  that	  attempt	  to	  explain	  
why	  persons	  with	  CIND	  and	  SCI	  have	  negative	  health	  outcomes.	  The	  first	  hypothesis	  
involved	   persons	   with	   CIND	   and	   SCI	   having	   more	   difficulties	   with	   medication	   and	  
therefore	   experiencing	   worse	   outcomes.	   The	   second	   hypothesis	   was	   that	   the	  
underlying	   genetic	   and	   shared	   environmental	   factors	   in	   twins	   would	   explain	   the	  
association	  between	  CIND	  and	  negative	  health	  outcomes.	  	  
In	  the	  12,835	  non-­‐demented	  twins	  in	  this	  study,	  993	  developed	  dementia	  (314	  within	  
the	  first	  5	  years).	   In	  multivariable	  analyses,	  CIND	  (OR	  1.73	  95%	  CI	  1.48-­‐2.01)	  and	  SCI	  
(OR	   1.69	   95%	   CI	   1.44-­‐1.99)	   were	   significant	   predictors	   of	   dementia.	   In	   within-­‐pair	  
analyses	  in	  MZ	  twins	  only,	  SCI	  remained	  a	  significant	  predictor	  of	  dementia	  (OR	  3.17	  
95%	  CI	  1.22-­‐8.22)	  but	  CIND	  was	  no	  longer	  associated	  with	  dementia	  (OR	  1.03	  95%	  CI	  
0.45-­‐2.35),	  suggesting	  that	  much	  of	  the	  association	  between	  CIND	  and	  dementia	  can	  
be	  explained	  by	  genetics	   and	   shared	  environmental	   factors.	  Analyses	  with	  DZ	   twins	  
showed	  results	  in	  between	  that	  of	  MZ	  twins	  and	  cohort	  analyses	  (Table	  7),	  suggesting	  
that	  genetics	  are	  more	  likely	  to	  explain	  the	  association	  between	  CIND	  and	  dementia	  
Table	  7:	  Associations	  between	  cognitive	  exposures	  and	  odds	  of	  dementia	  in	  cohort	  analyses	  and	  
within	  pair	  analyses	  in	  DZ	  and	  MZ	  twin7s	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than	  environment.	  Difficulties	  with	  medication	  predicted	  time	  to	  dementia	   (HR	  2.49	  
95%	  CI	  1.58-­‐3.92)	  but	  when	  added	   into	  models	  that	  tested	  the	  association	  between	  
dementia	   and	  either	  CIND	  or	   SCI,	   did	  not	  modify	   the	   estimates.	   	   This	   suggests	   that	  
while	  difficulties	  with	  medication	  are	  associated	  with	  time	  to	  dementia,	  the	  effect	  of	  
difficulties	   with	   medication	   on	   dementia	   is	   independent	   of	   CIND	   or	   SCI.	   The	  
conceptualized	   associations	   between	   CIND,	   SCI,	   difficulty	   with	   medication,	   and	  
dementia	  can	  be	  summarized	  in	  Figure	  7.	  	  
	  
To	  our	  knowledge,	  no	  studies	  have	  previously	  attempted	  to	  elucidate	  the	  mechanisms	  
behind	   the	   progression	   of	   CIND	   and	   SCI	   to	   dementia.	   Taken	   together,	   our	   results	  
suggest	   that	   while	   difficulties	   with	   medication	   may	   be	   one	   mechanism	   by	   which	  
persons	   increase	   their	   risk	   of	   dementia,	   other	  mechanisms,	   particularly	   genetic	   and	  
shared	  environmental	  factors,	  may	  be	  more	  important	  in	  the	  progression	  of	  CIND	  to	  
dementia.	  Since	  we	  are	  not	  be	  able	  to	  change	  a	  person’s	  underlying	  genetic	  risk,	  CIND	  
can	   be	   considered	   a	  marker	   of	   the	   underlying	   genetic	   risk.	   However,	   as	   difficulties	  
with	  medication	   is	   an	   independent	   risk	   factor	   for	   dementia,	   persons	   at	   high	   risk	   of	  
dementia	  (i.e.	  persons	  with	  CIND)	  should	  be	  offered	  tools	  by	  which	  they	  may	  be	  able	  
to	   reduce	  medication	   errors,	   thereby	   possibly	   delaying	   the	   onset	   of	   dementia.	  One	  
possible	  mechanism	  would	   be	   to	   enable	   elderly	   persons	   to	   access	   their	  medication	  
using	  multi-­‐dose	  drug	  dispensing	  methods	  such	  as	  Sweden’s	  “Apodos”	  system82.	  	  	  
	  
	  
Figure	  7:	  Conceptualized	  associations	  between	  CIND,	  SCI,	  difficulties	  with	  medication	  and	  dementia	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One	   of	   the	  more	   clinically	   relevant	   findings	   in	   this	   study	   was	   the	   increased	   risk	   of	  
dementia	  associated	  with	  SCI,	  which	  was	  not	  explained	  by	  genetic	  and	  environmental	  
factors.	   	  The	   increased	  risk	  of	  dementia	  was	  present	   in	   those	  with	  SCI	   regardless	  of	  
CIND.	  These	  results	  confirm	  the	  results	  from	  previous	  studies	  that	  show	  that	  memory	  
complaints	   are	   predictive	   of	   cognitive	   decline	   and	   dementia83-­‐86.	   These	   results	   also	  
suggest	  that	  it	  may	  be	  clinically	  useful	  for	  general	  physicians	  to	  ask	  the	  question	  “Have	  
you	  noticed	  any	  change	  in	  your	  memory	  during	  the	  last	  three	  years”	  as	  a	  quick	  screen	  
in	  order	  to	  identify	  persons	  at	  increased	  risk	  of	  dementia.	  	  However,	  this	  should	  not	  be	  
a	  substitute	  for	  more	  extensive	  neuropsychological	  screening.	  	  
	  
A	   total	   of	   5,125	   study	   participants	   died	   during	   the	   course	   of	   the	   study.	   	   As	   with	  
dementia,	  CIND	  was	  predictive	  of	  mortality	  in	  cohort	  analyses	  (OR	  1.43	  95%	  CI	  1.30-­‐
1.57)	  but	  not	  associated	  with	  mortality	   in	  within-­‐pair	  analysis	   (OR	  0.91	  95%	  CI	  0.57-­‐
1.43).	   Our	   finding	   that	   CIND	   predicts	   mortality	   confirms	   existing	   reports	   in	   the	  
literature5,34,87.	   While	   some	   of	   the	   effects	   of	   CIND	   on	   mortality	   were	   explained	   by	  
difficulties	  with	  medication,	  both	  CIND	  and	  difficulties	  with	  medication	  (OR	  5.01	  95%	  
CI	   3.26-­‐7.71)	   were	   independent	   predictors	   of	   mortality.	   	   This	   suggests	   that	   the	  
increased	   risk	   of	   mortality	   from	   having	   CIND	   may	   be	   both	   due	   to	   difficulties	   with	  
medication	   use	   and	   due	   to	   the	   fact	   that	   CIND	  may	   be	   a	  marker	   for	   an	   underlying	  
disease	  process.	  	  	  
	  
In	   this	   study,	  we	  also	   found	  that	  both	  CIND	  (HR	  1.10	  95%	  CI	  1.05-­‐1.15)	  and	  SCI	   (HR	  
1.09	   95%	   CI	   1.04-­‐1.13)	   predicted	   time	   to	   hospitalization.	   Comparison	   with	   other	  
studies	   is	   difficult,	   as	   no	   previous	   reports	   have	   examined	   the	   association	   between	  
CIND	  or	  SCI	  and	  hospitalization.	  However,	  one	  study	  found	  that	  persons	  with	  CIND	  are	  
two	  and	  a	  half	  more	  times	  likely	  to	  get	  institutionalized	  in	  nursing	  homes	  as	  compared	  
to	  persons	  with	  no	  cognitive	  impairment	  5.	  	  Additionally,	  as	  with	  Study	  II,	  we	  found	  no	  
association	   between	   vascular	   events	   and	   SCI	   or	   CIND.	   The	   strongest	   predictor	   of	  
having	  a	  vascular	  event	  was	  having	  already	  had	  a	  vascular	  event,	  which	  would	  further	  
explain	   why	   we	   see	   no	   association	   between	   CIND	   severity	   and	   vascular	   events	   in	  




Study	  IV:	  Medication	  use	  and	  dementia	  
Study	   IV	   had	   three	   main	   aims:	   1)	   to	   determine	   whether	   antidepressant	   or	  
cardiovascular	  medications	  were	  associated	  with	  dementia;	  2)	  to	  determine	  whether	  
the	  use	  or	  antidepressant	  medication	  changed	  the	  association	  between	  dementia	  and	  
CIND,	   SCI,	   or	   depression;	   and	   3)	   whether	   individuals	   with	   CIND,	   SCI,	   or	   depression	  
received	   more	   prescriptions	   for	   antidepressant	   or	   cardiovascular	   medications	   than	  
their	  unimpaired	  counterparts.	  	  
	  
Of	   the	   11,151	   persons	   in	   this	   study	   (whole	   cohort),	   9,112	   were	   alive	   and	   non-­‐
demented	   (restricted	   cohort)	   at	   the	   start	   of	   the	   PDR.	   In	   both	  whole	   and	   restricted	  
cohort	   analyses,	   use	   of	   any	   antidepressant	   medication	   (HR	   2.05	   95%	   CI	   1.59-­‐2.79)	  
doubled	  the	  risk	  of	  dementia.	  In	  analyses	  looking	  at	  the	  subtypes	  of	  antidepressants,	  
SSRIs	   double	   the	   risk	   of	   dementia	   (HR	   2.23	   95%	  CI	   1.55-­‐3.21)	  while	   TCAs	  were	   not	  
associated	   with	   dementia	   (HR	   0.35	   95%	   CI	   0.05-­‐2.46).	   	   However	   the	   use	   of	  
antidepressants	  does	  not	  modify	  the	  association	  between	  dementia	  and	  SCI.	  Persons	  
with	   CIND,	   SCI	   and	   depression	   all	   received	   more	   prescriptions	   for	   antidepressant	  
medication	  than	  their	  unimpaired	  counterparts.	  	  
	  
Our	   finding	   that	   SSRIs	   doubled	   the	   risk	   of	   dementia	   agrees	   with	   the	   only	   large	  
population-­‐based	  study	  that	  has	  evaluated	  the	  effect	  of	  antidepressant	  medication	  on	  
dementia88.	  	  However,	  as	  their	  study	  was	  entirely	  registry	  based,	  they	  were	  not	  able	  
to	  correct	   for	  cognitive	  or	  depressive	  status	   in	  their	  analyses	  as	  we	  do	   in	  this	  study.	  
While	  antidepressant	  treatment	  has	  been	  shown	  to	  have	  a	  strong	  effect	  on	  severely	  
depressed	  patients,	   recent	  meta-­‐analyses	   indicate	   that	   there	   is	  a	   slight	  or	  negligible	  
effect	  on	  persons	  with	  mild	  to	  moderate	  depression89.	  	  In	  light	  of	  these	  findings,	  and	  
in	  light	  of	  the	  fact	  that	  late-­‐onset	  depression	  may	  be	  a	  prodrome	  of	  dementia	  rather	  
than	  a	  risk	  factor,	  one	  wonders	  whether	  the	  late-­‐onset	  depression	  should	  be	  treated	  
at	  all.	  While	  they	  may	  alleviate	  depressive	  symptoms,	  antidepressant	  use	  may	  tip	  an	  
elderly	  person	  at	  high	  risk	  to	  manifest	  dementia.	  	  This	  is	  why	  it	  is	  particularly	  alarming	  
that	   persons	  with	   CIND	   and	   SCI	   receive	  more	   antidepressant	  medication	   than	   their	  
unimpaired	  counterparts.	  	  
	  
36
	  	   	   	  
In	   both	  whole	   and	   restricted	   cohort	   analyses,	   use	   of	   any	   cardiovascular	  medication	  
(HR	   0.56	   CI	   95%	   0.45-­‐0.70)	   halved	   the	   risk	   of	   dementia.	   In	   analysis	   looking	   at	   the	  
subtypes	   of	   cardiovascular	   medications,	   only	   antihypertensive	  medication	   (HR	   0.68	  
95%	  CI	  0.51-­‐0.89)	   and	   lipid-­‐lowering	  agents	   (HR	  0.48	  95%	  CI	  0.31-­‐0.73)	   showed	   the	  
same	   protective	   effect.	   However,	   the	   use	   of	   cardiovascular	   medications	   does	   not	  
modify	  the	  association	  between	  dementia	  and	  CIND	  or	  SCI.	  Persons	  with	  CIND	  or	  SCI	  
received	   significantly	   less	   prescriptions	   for	   cardiovascular	   medication	   than	   their	  
unimpaired	  counterparts.	  	  
	  
Our	   results	   that	   cardiovascular	  medications,	   particularly	   antihypertensives	   and	   lipid	  
lowering	  agents,	  reduce	  the	  risk	  of	  dementia	  confirm	  the	  results	  of	  previous	  studies	  
on	  the	  same	  subject	   46,47.	  However,	   the	   fact	   that	  persons	  with	  CIND	  and	  SCI	   receive	  
less	   of	   these	   medications	   than	   their	   unimpaired	   counterparts	   is	   further	   cause	   for	  
worry.	   Persons	  with	   cognitive	   impairment	  may	  not	   be	   as	   attentive	  or	   vocal	   in	   their	  
interactions	  with	  their	  physicians,	  and	  these	  results	  suggest	  that	  physicians	  may	  need	  
to	   pay	   closer	   attention	   to	   the	   overall	   medication	   regimens	   that	   their	   cognitively	  





In	  studies	  I	  and	  II,	  the	  use	  of	  the	  ESPRIT	  cohort	  introduced	  limitations	  into	  the	  studies.	  
The	   inclusion/exclusion	   criteria	   limit	   recruitment	   to	   those	   without	   dominant	   upper	  
limb	   paralysis	   and	   who	   had	   a	   baseline	   mRS≤3.	   Hence	   the	   study	   samples	   do	   not	  
represent	   a	   general	   stroke	   sample	   and	   therefore	   the	   studies	   are	   not	   generalizable.	  
The	  use	  of	   the	   inclusion/exclusion	   criteria	   have	   resulted	   in	   a	   younger	   population	   in	  
ESPRIT	  than	  most	  stroke	  populations.	  	  
	  
Another	   limitation	   of	   this	   study	   was	   that	   we	   were	   underpowered	   to	   examine	   the	  
interaction	   of	   recurrent	   vascular	   event	   and	   CIND-­‐moderate	   status	   at	   baseline.	  
However,	   as	   we	   controlled	   for	   the	   recurrence	   of	   stroke	   as	   well	   as	   the	   history	   of	  
previous	   strokes,	   we	   believe	   that	   our	   sample	   size	   will	   not	   affect	   our	   conclusions.	  
Whilst	  pre-­‐stroke	  dementia	  was	  excluded,	  we	  were	  unable	   to	  control	   for	  pre-­‐stroke	  
cognitive	   impairment.	   Furthermore,	   although	   the	   cognitive	   battery	   utilized	   was	  
validated	  by	  administration	  to	  an	  elderly	  community	  dwelling	  population	  in	  Singapore	  
in	  order	  to	  elicit	  formal	  structural	  domains,	   identify	   items	  that	  may	  not	  be	  culturally	  
relevant,	  and	  to	  replace	  those	   items	  with	  culturally	  appropriate	   items;	  more	  studies	  
need	   to	   be	   performed	   using	   other	   cognitive	   instruments	   to	   confirm	   the	   predictive	  
abilities	  of	  the	  CIND-­‐moderate	  classification.	  	  
	  
We	  recognize	  that	  our	  findings	  may	  be	  due	  to	  the	  definitions	  of	  CIND	  severity	  and	  MCI	  
subgroups,	   which	   results	   in	   CIND-­‐moderate	   representing	   more	   global	   cognitive	  
impairments	   than	   either	   form	   of	   multi-­‐domain	   MCI,	   and	   also	   results	   in	   CIND	   mild	  
overlapping	   with	   multi-­‐domain	   MCI.	   As	   there	   are	   four	   MCI	   subclassifications	  
compared	   to	   the	   two	  CIND	  subclassifications	   that	  we	  proposed,	   this	  may	  result	   in	  a	  
loss	   of	   power	   in	   this	   study	   for	   the	   MCI	   subclassification,	   which	   could	   explain	   our	  
results.	  Additionally,	  we	  recognize	   that	  our	  classifications	  of	  CIND	  did	  not	  adopt	   the	  
typical	   threshold	   of	   less	   than	   one	   standard	   deviation	   from	   the	   mean,	   but	   instead	  




	  	   	   	  
Study	  II	  
In	   addition	   to	   the	   limitations	   mentioned	   above,	   we	   did	   not	   have	   information	  
pertaining	   to	   the	  baseline	  NIHSS	   score	   in	   the	   study	   sample,	   and	   therefore	  we	  were	  
unable	   to	   control	   for	   neurological	   impairments	   amongst	   this	   stroke	   cohort.	   The	  
inability	   to	   control	   for	   neurological	   impairments	   may	   confound	   the	   association	  
between	   baseline	   cognitive	   status	   and	   death,	   dependency,	   and	   recurrent	   vascular	  
events.	  	  
	  
Unlike	   in	   Study	   I,	   we	   did	   not	   utilize	   MCI	   subtypes	   (amnestic	   single	   domain	   MCI,	  
amnestic	   multiple	   domain	   MCI,	   non	   amnestic	   single	   domain	   MCI,	   non	   amnestic	  
multiple	   domain	   MCI)	   in	   our	   analysis,	   as	   the	   number	   of	   outcomes	   was	   small.	   	   In	  
addition,	  we	  chose	  to	  examine	  CIND	  and	  not	  MCI	  as	  strokes	  may	  produce	  a	  spectrum	  
of	   cognitive	   changes,	   but	   may	   not	   necessarily	   produce	   prominent	   amnesia,	   as	   is	  
emphasized	  in	  the	  MCI	  subtypes.	  	  
	  
Furthermore,	  the	  use	  of	  the	  conservative	  Bonferroni	  correction	  method	  in	  all	  analyses	  
pertaining	   to	   domain	   specific	   impairments	  may	   underestimate	   the	   contributions	   of	  
these	   domains.	   In	   this	   study,	   without	   the	   use	   of	   a	   correction	   method,	   there	   was	  
an	  effect	  of	  the	  language	  domain	  on	  vascular	  events	  as	  well	  as	  the	  verbal	  memory	  on	  
death.	  However,	  we	  suggest	  that	  such	  findings	  require	  further	  confirmation.	  	  	  
	  
Study	  III	  
The	  outcome	  of	  dementia	  in	  this	  study	  should	  be	  considered	  to	  be	  hospitalization	  for	  
or	  death	  due	  to	  dementia,	  as	  it	  was	  derived	  from	  population	  based	  registers	  (NPR	  and	  
CDR).	  Previous	  studies	  have	  estimated	  that	  only	  about	  half	  of	  all	  dementia	  cases	  are	  
captured	  in	  the	  registers	  since	  hospitalization	  or	  death	  due	  to	  dementia	  as	  the	  primary	  
cause	  is	  relatively	  uncommon	  (the	  specificity	  and	  positive	  predictive	  value	  of	  dementia	  
diagnoses	  are	  close	  to	  100%)71.	   In	  addition,	  dementia	  cases	  that	  are	  captured	   in	  the	  
NPR	  are	  likely	  to	  be	  more	  severe.	  	  
	  
Another	  limitation	  is	  that	  persons	  who	  had	  an	  ORD	  score	  of	  3	  in	  this	  study	  fell	  into	  the	  
following	  categories:	  (a)	  false	  positives,	  meaning	  that	  they	  were	  visited	  and	  worked	  up	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and	   it	  was	   determined	   that	   they	  were	   not	   demented;	   (b)	   those	  who	   refused	   to	   be	  
worked	  up;	  (c)	  those	  who	  were	  deliberately	  not	  worked	  up	  because	  their	  twin	  partner	  
was	   already	   dead.	   This	   introduces	   the	   possibility	   that	   some	   of	   those	   with	   an	   ORD	  
score	  of	  3	  were	  actually	  demented,	  and	   therefore	   should	  have	  been	  excluded	   from	  
the	  study.	  However,	  the	  presence	  of	  a	  dose	  response	  relationship	  between	  the	  ORD	  
score	  and	  the	  risk	  of	  dementia,	  death,	  or	  hospitalization	  suggests	  that	  the	  underlying	  
findings	  are	  valid.	  We	  also	  performed	  additional	  analyses	  limiting	  the	  cohort	  analyses	  
to	  the	  persons	   in	  the	  within-­‐pair	  analyses	  to	  ensure	  that	  the	  underlying	  findings	  are	  
valid	  and	  not	  the	  result	  of	  a	  smaller	  sample	  size.	  	  An	  example	  of	  cohort	  and	  within	  pair	  
analyses	  restricted	  to	  the	  same	  sample	  is	  presented	  in	  Table	  8.	  	  	  
In	  addition,	  while	  the	  use	  of	  the	  TELE	  facilitates	  cognitive	  testing	  in	  large-­‐scale	  studies	  
such	  as	  HARMONY,	  they	  do	  not	  allow	  for	  subtype	  analyses	  that	  may	  be	  undertaken	  if	  
neuropsychological	   test	   batteries	   were	   used	   instead.	   Unfortunately,	   we	   only	   have	  
genetic	  data	   for	   those	  who	  underwent	  clinical	  workup,	  and	   therefore	  are	  unable	   to	  
directly	  examine	  the	  role	  of	  genes	   in	  this	  study.	  Lastly,	   the	  cross	  sectional	  nature	  of	  
our	  cognitive	  data	  limits	  our	  ability	  to	  disentangle	  the	  effect	  of	  cognitive	  status	  from	  
that	  of	  cognitive	  decline	  in	  attempting	  to	  look	  at	  the	  relationship	  between	  cognition	  
and	  negative	  health	  outcomes.	  	  
	  
Study	  IV	  
In	  addition	  to	  the	  limitations	  discussed	  in	  Study	  III,	  additional	  limitations	  exist	  for	  the	  
analyses	  presented	  in	  Study	  IV.	  Firstly,	  the	  cross	  sectional	  nature	  of	  our	  cognitive	  and	  
depression	  data	  limits	  our	  ability	  to	  disentangle	  the	  effects	  of	  the	  temporal	  evolutions	  
Table	   8:	   Cohort	   and	  MZ	  only	   analyses	   of	   the	   association	  between	  
cognitive	  exposures	  and	  dementia	  limited	  to	  the	  same	  persons	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of	  depression	  and	  cognitive	  impairment	  in	  this	  study.	  Secondly,	  the	  large	  gap	  in	  time	  
between	  the	  evaluation	  of	  the	  cognitive	  and	  depressive	  symptoms	  and	  the	  beginning	  
of	  the	  PDR	  may	  introduce	  biases	  in	  the	  dataset	  as	  persons	  may	  have	  evolved	  in	  both	  
depressive	  and	  cognitive	  status.	  However,	  as	  we	  were	  able	  to	  see	  strong	  associations	  
between	   medication	   use	   in	   both	   whole	   cohort	   and	   the	   restricted	   analyses	   and	  
therefore	  do	  not	  believe	  that	  these	  results	  are	  an	  artifact.	  	  Thirdly,	  the	  use	  of	  the	  PDR	  
for	   ascertainment	  of	  medication	  use	  poses	   several	   problems:	   	  while	  we	  are	   able	   to	  
ascertain	  who	  purchased	   the	   antidepressant	   and	   cardiovascular	  medication,	  we	   are	  
unable	  to	  determine	  whether	  these	  medications	  are	  actually	  consumed;	  the	  duration	  
of	  treatment	  and	  the	  dose	  of	  medication	  could	  also	  not	  be	  determined.	  	  	  
In	   addition,	   while	   the	   results	   of	   this	   study	   suggest	   that	   antidepressant	   use	   is	  
associated	  with	  dementia,	  it	  is	  possible	  that	  the	  results	  are	  confounded	  by	  indication.	  
It	   is	   therefore	   possible	   that	   the	   underlying	   depression	   that	   warranted	   the	  
antidepressant	   prescription	   is	   associated	   with	   dementia	   rather	   than	   the	  
antidepressant	   itself.	   In	   order	   to	   disentangle	   these	   results,	   we	   present	   results	  
Table	  9:	  Association	  between	  cognitive	  and	  pharmaceutical	  exposures	  and	  risk	  of	  dementia	  when	  controlling	  





stratified	  by	  depression	  status	  in	  Table	  9	  that	  indicates	  that	  antidepressant	  medication	  
use	   increases	   the	   risk	   of	   dementia	   even	   in	   persons	   without	   depression.	   	   However,	  
even	  with	  stratified	  analyses,	  it	  is	  possible	  that	  confounding	  by	  indication	  persists.	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7 GENERAL	  DISCUSSION	  &	  REFLECTIONS	  
The	  manuscripts	   in	   this	   thesis	  have	  all	  examined	  various	  aspects	  of	   the	  associations	  
between	   cognitive	   impairment	   and	   negative	   health	   outcomes	   such	   as	   dementia,	  
death,	  dependency,	  hospitalization,	  and	  vascular	  events.	  The	  overall	  aim	  of	  this	  thesis	  
was	  to	  highlight	  the	  fact	  that	  persons	  with	  cognitive	   impairment,	  even	   in	  the	  milder	  
forms	  (i.e.	  not	  dementia),	  have	  poorer	  outcomes	  than	  their	  unimpaired	  counterparts.	  
As	  current	  medical	  practices	  do	  not	  provide	  these	  subjects	  with	  a	  higher	  level	  of	  care,	  
these	  subjects	  may	  represent	  a	  neglected	  group	  where	  changes	  in	  public	  health	  focus	  
may	  bring	  benefits.	  
	  
In	   Studies	   I	   and	   II	  we	  were	  able	   to	   show	  within	   stroke	  patients,	  patients	  with	  CIND	  
have	  an	   increased	  risk	  of	  dementia,	  death,	  and	  dependency	   (Figure	  8).	   	  Even	  within	  
patients	  with	  CIND,	  we	  were	  able	  to	  identify	  a	  subset	  of	  patients	  that	  were	  particularly	  
at	  risk	  for	  dementia	  and	  death.	  Using	  cognitive	  status	  to	  identify	  these	  persons	  at	  high	  
risk	  will	  enable	  healthcare	  workers	  and	  family	  members	  to	  prepare	  for	  the	  patient’s	  
eventual	   care	  needs.	   	   Additionally,	   it	   identifies	   a	   group	  of	   patients	  most	   in	   need	  of	  
interventions	  to	  delay	  the	  progression	  of	  disease.	  
	  
Figure	  8:	  Summarized	  findings	  from	  Studies	  I	  and	  II	  
In	  Studies	  III	  and	  IV,	  we	  were	  able	  to	  confirm	  previous	  reports	  that	  persons	  with	  CIND	  
are	  at	  an	  increased	  risk	  of	  negative	  health	  outcomes.	  However,	  we	  were	  able	  to	  build	  
on	  these	  studies	  by	  attempting	  to	  understand	  the	  mechanisms	  behind	  this	  increased	  





Figures	   9a	   and	   b	   summarize	   the	   main	   findings	   of	   Studies	   III	   and	   IV.	   CIND	   can	   be	  
interpreted	   as	   a	  marker	   of	   underlying	   disease	   process	   that	   predisposes	   persons	   to	  
dementia,	   death,	   and	   hospitalization.	   On	   the	   other	   hand,	   SCI	   appears	   to	   be	   an	  
independent	   predictor	   of	   dementia.	   Difficulties	   with	   medication	   appear	   to	   be	   one	  
mechanism	   by	   which	   CIND	   is	   associated	   with	   dementia.	   	   However,	   it	   is	   a	   strong	  
predictor	   of	   mortality	   and	   pharmaceutical	   aids	   that	   facilitate	   the	   proper	   usage	   of	  
medications	  may	   improve	  mortality	   rates	  among	   the	  elderly.	   Lastly,	   the	   finding	   that	  
persons	   with	   SCI	   and	   CIND	   get	   more	   antidepressant	   and	   less	   cardiovascular	  
medication	  highlights	  the	  fact	  that	  the	  persons	  who	  may	  need	  these	  interventions	  the	  
most	  are	  not	  getting	  them.	  	  
	  
Figure	  9a:	  Summarized	  findings	  from	  Studies	  III	  and	  IV—Dementia	  
Ultimately,	  regardless	  of	  the	  mechanisms	  behind	  the	  increased	  risk	  of	  negative	  health	  
outcomes,	  one	  thing	  is	  clear:	  	  People	  with	  cognitive	  impairment	  (both	  in	  the	  general	  
population	  and	   in	  high	  risk	  subgroups	  such	  as	  stroke	  patients)	  should	  be	  seen	  more	  
regularly	  by	  their	  healthcare	  professionals	  than	  currently	  practiced.	  Since	  many	  of	  the	  
non-­‐demented	   persons	   with	   cognitive	   impairment	   are	   relatively	   independent,	   it	   is	  
unclear	   whether	   they	   receive	  more	   attention	   from	   their	   healthcare	   providers	   than	  
persons	  without	  cognitive	   impairments.	  While	   it	  may	  be	  argued	   that	   the	  healthcare	  
infrastructures	  in	  most	  countries	  may	  not	  be	  able	  to	  support	  such	  close	  follow	  up	  of	  
cognitively	   impaired	   persons,	   I	   believe	   that	   more	   emphasis	   needs	   to	   be	   given	   to	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persons	   with	   pre-­‐dementia	   than	   is	   currently	   being	   given	   because	   that	   is	   our	   one	  
opportunity	  to	  delay	  or	  prevent	  dementia.	  	  
	  
	  
Figure	  9b;	  Summarized	  findings	  from	  Studies	  III	  and	  IV	  –	  Death,	  Hospitalization,	  and	  Vascular	  Events	  
	  
Personally,	   I	   believe	   that	   a	   good	   analogy	   for	   pre-­‐dementia	   and	   dementia	   is	   the	  
different	   stages	   of	   cancer.	   I	   think	   of	   persons	   with	   pre-­‐dementia	   as	   having	   the	  
equivalent	  of	  a	  stage	  one	  or	  two	  cancer.	  	  Although	  there	  is	  a	  potential	  for	  progression	  
to	   stage	   three	   or	   four,	   there	   is	   also	   a	   chance	   that	   you	   can	   reverse	   or	   arrest	   the	  
progression	  of	  the	  disease.	  The	  focus	  should	  be	  on	  aggressive	   interventions	  so	  as	  to	  
delay	   or	   prevent	   the	   onset	   of	   more	   severe	   disease	   (i.e.	   dementia).	   Once	   you’ve	  
reached	  the	  later	  stages,	  and	  have	  developed	  dementia,	  the	  goal	  of	  therapy	  changes	  
to	  one	  of	  a	  more	  supportive	  nature.	   	  However,	  as	  with	  cancer,	   it	  may	  be	   that	  early	  
detection	   and	   treatment	   of	   cognitive	   impairment	   may	   only	   result	   in	   an	   apparent	  
improvement	   of	   outcomes	   due	   to	   complications	  with	   lead-­‐time	  bias.	  However,	   it	   is	  





Part	  of	  the	  problem	  with	  this	  analogy	  is	  that	  we	  currently	  lack	  the	  aggressive	  therapy	  
that	   is	   needed	   to	   prevent	   or	   delay	   the	   onset	   of	   dementia.	   	   	   In	   the	   last	   ten	   years,	  
medical	  research	  has	  focused	  on	  reducing	  mortality.	  Much	  of	  the	  research	  (in	  terms	  of	  
personnel,	   publications,	   and	   funding)	   has	   focused	   on	   cancer	   and	   heart	   disease	   in	  
particular,	  two	  diseases	  that	  are	   leading	  causes	  of	  mortality	   in	  the	  developed	  world.	  
Accordingly,	   the	   fields	   of	   cardiology	   and	   oncology	   have	   seen	   considerable	  
improvement	   in	   unraveling	   the	   mechanisms	   behind	   disease.	   This	   has	   led	   to	  
improvements	   in	   the	   availability	   of	   therapies	   in	   the	   respective	   fields.	   (Figure	   10)	  
Neurological	  disorders,	  however,	  have	  not	  seen	  the	  same	  level	  of	  growth	  in	  terms	  of	  
research.	   	  Perhaps	  ten	  years	  down	  the	  road,	  with	  an	  ever-­‐extending	  life	  expectancy,	  
greater	  interest	  will	  be	  shown	  in	  diseases	  that	  have	  high	  morbidity.	  	  	  One	  wonders	  if	  
that	  will	  be	  too	  little	  too	  late.	  	  
	  
46




Figure	   10:	   Correlation	   of	   research	   effort	   (publications	   from	   last	   10	   years)	   with	   contributions	   to	  





In	   general,	   this	   thesis	   shows	   that	   persons	   with	   cognitive	   impairment	   have	   poorer	  
health	   outcomes	   than	   their	   cognitively	   normal	   counterparts.	   	   In	   particular,	   persons	  
with	   cognitive	   impairment	   are	   at	   increased	   risk	   of	   dementia,	   death,	   and	   disability.	  	  
Persons	  with	  cognitive	  impairment	  are	  at	  additional	  risk	  of	  negative	  health	  outcomes	  
due	  to	  difficulties	  with	  medication	  and	  because	  cognitive	  impairment	  acts	  as	  a	  marker	  
of	  underlying	  disease.	  	  In	  addition,	  we	  were	  able	  to	  show	  that	  persons	  with	  cognitive	  
impairment	   get	   less	   cardiovascular	   medications	   and	   more	   antidepressant	  
medications,	  both	  of	  which	  increase	  the	  risk	  of	  dementia.	  The	  specific	  conclusions	  are	  
as	  follows:	  
	  
In	  stroke	  patients	  	  
 CIND	  predicts	  dementia,	  dependency,	  and	  death.	  	  
 CIND	  severity	  discriminates	  patients	  who	  are	  at	  high	  risk	  of	  dementia	  and	  
death	  
 CIND	  severity	  performs	  as	  well	  as	  MCI	  subtypes	  in	  a	  stroke	  population	  
o But	  given	  the	  emphasis	  on	  memory	  in	  MCI	  and	  the	  simplicity	  of	  CIND	  
severity,	  CIND	  severity	  may	  be	  more	  relevant	  in	  a	  post	  stroke	  setting	  
	  
In	  the	  general	  population	  
 CIND	  predicts	  dementia	  and	  death	  and	  time	  to	  hospitalization	  
o This	  association	  is	  explained	  mostly	  by	  genetic	  and	  shared	  
environmental	  factors	  
 SCI	  predicts	  dementia	  and	  time	  to	  hospitalization	  independent	  of	  genetic	  and	  
shared	  environmental	  factors	  
 Difficulties	  with	  medication	  predict	  mortality	  and	  dementia	  and	  may	  be	  a	  
modifiable	  risk	  factor.	  	  
 Selective	  Serotonin	  Reuptake	  Inhibitors	  (SSRIs)	  double	  the	  risk	  of	  dementia	  
o Persons	  with	  CIND	  and	  SCI	  receive	  more	  of	  these	  medications	  than	  
their	  unimpaired	  counterparts	  
 Antihypertensives	  and	  lipid-­‐lowering	  agents	  are	  protective	  for	  dementia	  
o Persons	  with	  CIND	  and	  SCI	  receive	  less	  of	  these	  medications	  than	  their	  
unimpaired	  counterparts	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Background: The utility of poststroke cognitive status, namely dementia, cognitive impairment no
dementia (CIND), mild cognitive impairment (MCI), and no cognitive impairment (NCI), in predicting
dementia has been previously examined. However, no studies to date have compared the ability of
subtypes of MCI and CIND to predict dementia in a poststroke population.
Methods: A cohort of ischemic stroke patients underwent neuropsychological assessment annu-
ally for up to 5 years. Dementia was defined using the DSM-IV criteria. Univariate and multivari-
able Cox proportional regression was performed to determine the ability of MCI subtypes, CIND
severity, and individual domains of impairment to predict dementia.
Results: A total of 362 patients without dementia were followed up for a mean of 3.4 years (17%
drop out), with 24 developing incident dementia. Older age, previous and recurrent stroke, and
CIND andMCI subtypes were significant predictors of dementia. In multivariable analysis control-
ling for treatment allocation, patients who were older, had previous or recurrent stroke, and had
either CIND moderate or multiple domain MCI with amnestic component were at elevated risk for
dementia. In multivariable domain analysis, recurrent strokes, age, and previous strokes, verbal
memory, and visual memory were significant predictors of dementia. Receiver operating characteris-
tic curve analysis showed thatCINDmoderate (area under the curve: 0.893) andmultiple domainMCI
with amnestic component (area under the curve: 0.832) were significant predictors of conversion to
dementia. All other classifications of cognitive impairment had areas under the curve less than 0.7.
Conclusion:Stroke patients with cognitive impairment no dementia (CIND) moderate are at higher
risk of developing dementia, while CIND mild patients are not at increased risk of developing
dementia. Neurology® 2009;73:1866–1872
GLOSSARY
AD  Alzheimer disease; AUC  area under the curve; CI  confidence interval; CIND  cognitive impairment no dementia;
DSM-IV  Diagnostic and Statistical Manual of Mental Disorders, 4th edition; ESPRIT  European Australasian Stroke
Prevention in Reversible Ischemia Trial;ESPRIT-CogEuropean Australasian Stroke Prevention in Reversible Ischemia Trial,
cognitive substudy; HR  hazard ratio; LACI  lacunar infarct; MCI  mild cognitive impairment; mRS  modified Rankin
scale; NCI  no cognitive impairment; OCSP  Oxfordshire Community Stroke Project; PACI  partial anterior circulation
infarct; POCI posterior circulation infarct; ROC receiver operating curve; TACI total anterior circulation infarct; VaD
vascular dementia;WAIS-RWechsler Adult Intelligence Scale–Revised;WMS-RWechsler Memory Scale–Revised.
Dementia, mild cognitive impairment (MCI), and cognitive impairment no dementia (CIND)
are frequently underdiagnosed and their incidence is likely to increase in aging populations.
CIND and MCI are concepts that are commonly used to define the transitional period be-
tween normal aging and dementia. CIND has a broad scope, and is used to define impairments
in any objective cognitive domains in neuropsychological testing in the absence of dementia.1
MCI was originally identified as a precursor to Alzheimer disease (AD) and defined as a
complaint of defective memory with an abnormal memory function for age, along with normal
activities of daily living, normal general cognitive functioning, and absence of dementia.2 More
recently, MCI definitions have been categorized into 4 subtypes: amnestic MCI, nonamnestic
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Epidemiology and Biostatistics (K.N.), Karolinska Institute, Sweden; Duke-NUS Graduate Medical School (K.N.), Singapore; National Neuroscience
Institute (S.A., D.A.D., H.-M.C.), Singapore General Hospital Campus; National Cancer Center (M.-C.W.), Singapore; and Department of
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single domain MCI, multiple-domain MCI
with amnestic component, and nonamnestic
multiple domain MCI.3
While comparisons of the predictive ability
of MCI and CIND have been conducted in
epidemiologic settings,4 they have not been
performed in poststroke patients, who are
known to have a high risk of dementia.5 The
broad definition of CIND has been shown to
be unstable in a poststroke setting.6 We there-
fore aimed to determine which CIND sub-
type predicts for dementia among poststroke
patients. We also aimed to compare CIND
and MCI subtypes as predictors of dementia
and assessed the ability of cognitive domains
to predict dementia.
METHODS Subjects. All patients with recent TIAs or non-
disabling ischemic stroke who were seen in the Singapore Gen-
eral Hospital between 1999 and 2005 were screened for
eligibility for the European Australasian Stroke Prevention in
Reversible Ischemia Trial (ESPRIT). Detailed methodology for
the main study have been previously reported.7 Briefly, patients
were eligible if they were within 6 months of a TIA (including
transient monocular blindness) or nondisabling ischemic stroke
(grade 3 on the modified Rankin scale8) (mRS) of presumed
arterial origin. The exclusion criteria were a possible cardiac
source of embolism, high-grade carotid stenosis for which ca-
rotid endarterectomy or endovascular treatment was planned,
any blood coagulation disorder, any contraindication for aspirin
or dipyridamole, and a limited life expectancy.
Patients recruited into ESPRIT were eligible to enter this
cognitive substudy (ESPRIT-Cog) with the following additional
exclusion criteria: confusion, severe aphasia (expressive or recep-
tive), major psychoses diagnosed according to DSM-IV criteria,9
or dominant upper limb paralysis.
Standard protocol approvals, registrations, and patient
consents. The study protocol was approved by Singapore Gen-
eral Hospital’s Institutional Review Board and Ethics Commit-
tee. Written informed consent was obtained from all patients or
legal guardians. The ESPRIT Trial was registered under clinical-
trials.gov with the identifier NCT00161070.
Neuropsychological test battery. Patients who consented
to ESPRIT-cog received their baseline cognitive assessment 3 to
4 months after their qualifying event and annually thereafter for
up to 5 years. Trained research psychologists administered a neu-
ropsychological test battery that has previously been validated for
use in Singapore.10 The battery assessed 6 domains, 4 of which
were nonmemory domains. Education-adjusted cutoffs of 1.5
standard deviations below established normal means were used
on individual tests. Failure in at least half of the tests in a domain
constituted failure in that domain. The assessment was adminis-
tered in English, Malay, Mandarin, or Chinese dialects accord-
ing to the subject’s habitual language. The entire battery took
under an hour and a half to complete.
The nonmemory domains were Attention, as defined by
Digit Span,11 Visual Span,11 and Auditory Detection; Language,
as defined by Modified Boston Naming and Category Fluency
(Animals and Food subtasks); Visuomotor speed, as defined by
Symbol Digit Modality Test,12 Digit Cancellation,13 and Maze
Task14; and Visuoconstruction, as defined by Wechsler Memory
Scale–Revised (WMS-R)11 subtest Visual Reproduction Copy
task, Clock Drawing, and Wechsler Adult Intelligence Scale–
Revised (WAIS-R)15 Block Design subtest.
The memory domains were Verbal Memory, as defined by
Word List Recall16 (Immediate, Delayed, and Delayed Recogni-
tion) and Story Recall (Immediate and Delayed); and Visual
Memory, as defined by Picture Recall (Immediate, Delayed, and
Delayed Recognition) and WMS-R Visual Reproduction11 (Im-
mediate, Delayed, and Delayed Recognition).
Diagnosis of dementia. Diagnoses of dementia were made at
weekly consensus conferences that were attended by neurolo-
gists, neuropsychologists, research nurses, and research assistants.
Diagnoses were made according to the DSM-IV 9 criteria. CT,
MRI, and magnetic resonance angiography were reviewed as part
of the diagnostic process. The etiologic diagnoses followed the
National Institute of Neurological and Communicative Disor-
ders and Stroke–Alzheimer’s Disease and Related Disorders As-
sociation criteria for AD17 and the National Institute of
Neurological Disorders and Stroke–Association Internationale
pour la Recherche en l’Enseignement en Neurosciences criteria18
for vascular dementia (VaD). The sample without dementia in-
cluded individuals with diagnoses of CIND, MCI, or no cogni-
tive impairment (NCI). Patients with CIND were impaired in at
least one domain of the neuropsychological test battery, but did
not meet criteria for dementia.1 On the basis of the sample me-
dian, CIND was divided into CIND mild (1–2 domains im-
paired) and CIND moderate (3–6 domains impaired). Patients
were also classified by MCI subtypes (amnestic MCI, nonamnes-
tic single domain MCI, multiple domain MCI with an amnestic
component, and nonamnestic multiple domain MCI) according
to the revised MCI criteria.3
Baseline risk factors. Risk factor information was collected at
baseline. Stroke subtype was classified according to the Oxford-
shire Community Stroke Project (OCSP)19 as total anterior cir-
culation infarct (TACI), partial anterior circulation infarct
(PACI), posterior circulation infarct (POCI), or lacunar infarct
(LACI).19 Vascular risk factor data, such as age, diabetes mellitus
status, hypertension, hyperlipidemia, smoking status, ischemic
heart disease, peripheral artery disease, as well as past history of
stroke, angina, and myocardial infarction were obtained verbally
from the patient and confirmed with hospital records.
Outcome measures. Patients were followed up annually for
up to 5 years. Patients underwent full neuropsychological assess-
ment at the outpatient clinic. If a recurrent event had occurred,
detailed hospital records were obtained to verify the occurrence
of the vascular event.
Statistical analysis. Analysis of variance or 2 analysis was
used to test for significant differences among NCI, CIND mild,
and CIND moderate patients. Analysis was done in 3 stages. In
the first stage, univariate regressions were performed to deter-
mine which baseline characteristics were predictive of dementia.
Univariate regression analyses were repeated 3 times, once with
CIND severity as the indicator of baseline cognitive impairment,
then with an indicator of 1 domain of impairment vs multiple
domains of impairment, and again with MCI subtypes as the
indicator of cognitive impairment. In the second stage of analy-
ses, multivariable regression models controlling for treatment al-
location were performed with significant predictors in the
univariate stage being included in the models. Analyses were re-
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peated again with CIND severity and MCI subtypes as indica-
tors of baseline cognitive impairment. In the third stage of
analysis, individual domains of cognition were analyzed for their
ability to predict conversion to dementia in both univariate anal-
yses, and multivariable analyses which adjusted for significant
predictors of dementia from stage 1, and treatment allocation.
Cox proportional hazards models were used in all stages of anal-
yses. Analyses were performed in Stata 10.0,20 and significance
was determined with a 2-tailed alpha of 0.05 in stages 1 and 2 of
analyses while Bonferroni adjustment for multiple comparisons
in stage 3 yielded an alpha of 0.008. Finally, uniform scores were
derived for each domain and averaged across the patients in dif-
ferent MCI and CIND severity, after which receiver operating
curves (ROC) were plotted to compare the area under the curve
(AUC) of the different classifications.
RESULTS A total of 458 patients were recruited
into ESPRIT at the Singapore General Hospital site,
of which 432 consented to participate in the
ESPRIT-cog substudy (figure). Of these 432 pa-
tients, 13 had dementia at baseline, and 57 died or
withdrew from the study before undergoing follow-up
neuropsychological evaluation. We thus present data of
362 patients (mean age 60  11 years, 30% women)
who were followed for an average of 3.2 years.
There were 183 patients with NCI, 94 with CIND
mild, and 85 with CIND moderate. The demo-
graphic characteristics of the study population
stratified by baseline cognitive status are summa-
rized in table 1. Patients with more severe cogni-
Figure Study design

























Age, y, mean (SD) 55 (10) 64 (10) 66 (10) 59 (9) 65 (10) 66 (10) 65 (10) 0.0001‡ 0.001‡
Women 40 (22) 36 (38) 34 (40) 3 (15) 11 (33) 38 (38) 18 (67) 0.002‡ 0.001‡
Diabetes mellitus 57 (31) 43 (46) 44 (52) 7 (35) 15 (45) 49 (49) 16 (59) 0.002‡ 0.006‡
Hypertension 122 (67) 76 (81) 67 (79) 18 (90) 26 (79) 77 (78) 22 (81) 0.017‡ 0.052
Previous stroke 24 (13) 20 (21) 17 (20) 4 (20) 7 (21) 20 (20) 6 (22) 0.154 0.439
Hyperlipidemia 80 (44) 43 (46) 37 (44) 9 (45) 14 (42) 42 (42) 15 (56) 0.940 0.808
Ever smoker 70 (38) 35 (37) 26 (31) 13 (65) 11 (33) 32 (32) 5 (18) 0.464 0.018‡
Previous ischemic heart
disease
17 (9) 10 (11) 11 (13) 3 (15) 4 (12) 11 (11) 3 (11) 0.662 0.93
Previous peripheral artery
disease
4 (2) 2 (2) 3 (4) 0 (0) 1 (3) 4 (4) 0 (0) 0.779 0.682
Previous angina pectoris 16 (9) 7 (7) 6 (7) 3 (15) 3 (6) 6 (6) 2 (7) 0.870 0.708
Previous myocardial
infarction
5 (3) 3 (3) 4 (5) 1 (5) 2 (6) 4 (4) 0 (0) 0.701 0.693
Modified Rankin Scale
score, median (IQR)
0 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 0.0001‡ 0.0001‡
Stroke subtype
TIA 52 (28) 15 (16) 3 (4) 2 (10) 3 (9) 9 (9) 4 (15) 0.0001‡ 0.002‡
POCI/LACI 121 (66) 69 (73) 71 (84) 16 (80) 24 (72) 80 (80) 20 (74)
TACI/PACI 10 (6) 10 (11) 11 (13) 2 (10) 6 (18) 10 (10) 3 (11)
*p Value of comparisons among NCI, CINDmild, and CINDmoderate.
†p Value of comparisons between NCI and MCI subtypes.
‡Significant.
NCI no cognitive impairment; CIND cognitive impairment no dementia; MCImild cognitive impairment; S single domain; Mmultiple domain; IQR
interquartile range; POCI posterior circulation infarct; LACI lacunar infarct; TACI total anterior circulation infarct; PACI partial anterior circulation
infarct.
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tive impairment were significantly older; more
likely to be women, diabetic, and hypertensive;
and more likely to have had more severe stroke.
Among the 179 patients with MCI, 20 had am-
nestic MCI, 33 nonamnestic single domain MCI, 99
multiple-domain MCI with amnestic component,
and 27 nonamnestic multiple domain MCI.
During the course of the study, 24 patients
converted to dementia: 3 AD, 15 VaD, and 6
mixed dementia. The incidence of dementia was
11 per 1,000 in NCI patients, 42 per 1,000 in
CIND mild patients, and 212 per thousand in
CIND moderate patients. By MCI subtypes, the
incidence of dementia for MCI subtypes was 11 in
NCI, 50 in amnestic MCI, 30 in nonamnestic
single-domain MCI, 181 in multiple-domain
MCI with amnestic component, and 74 in
nonamnestic multiple domain MCI patients.
In univariate analysis, older patients, patients
with prior strokes, patients who experienced another
stroke, as well as those with more severe baseline cog-
nitive impairment (CIND moderate, hazard ratio
[HR] 22.5, confidence interval [CI] 5.22–97.2, in
CIND severity; multiple domain MCI with amnestic
component, HR  19.3, CI 4.48–83.4; and
nonamnestic multiple domain MCI, HR 7.87, CI
1.11–55.9, in MCI subtypes, and MMSE, HR 
0.91, CI 0.83–0.99) were at higher risk of conver-
sion to dementia (table 2 [condensed version], table
e-1 on the Neurology® Web site at www.neurology.
org [full version]).
In multivariable analysis controlling for treatment
allocation, age (HR  1.08, CI 1.03–1.14), occur-
rence of a previous stroke (HR  3.01, CI 1.18–
7.67), occurrence of another stroke (HR  2.45, CI
1.02–5.92), and baseline cognitive status as defined
by either CIND moderate (HR  6.43, CI 1.30–
31.7) or multiple domain MCI with amnestic com-
ponent (HR 5.77, CI 1.19–28.0) were significant
predictors of dementia (table 2 [condensed version],
table e-1 [full version]).
Table 3 summarizes impairment of cognitive do-
mains stratified by the number of domains impaired.
Visuomotor speed was the domain that was most
commonly impaired, followed by visuoconstruction
and visual memory. In univariate domain analysis, all
domains were significant predictors of dementia (ta-
ble 3). In multivariable domain analysis, while verbal
memory, visual memory, visuoconstruction, and
visuomotor speed were significant at an alpha of
0.05, only verbal memory (HR  6.92, p  0.001)
and visual memory (HR  4.25, p  0.002) were
significant predictors of dementia after Bonferroni
adjustment (table 3).
ROC curve analysis showed that CINDmoderate
(AUC 0.893) was not significantly better than multi-
ple domain MCI with amnestic component in pre-
dicting dementia (AUC 0.832) (p 0.50). All other
classifications of cognitive impairment had AUCs
less than 0.7.
DISCUSSION In this study, we evaluated the ability
of CIND severity to predict dementia in a poststroke
population. The CIND severity (CIND mild and
CIND moderate) were able to differentiate patients
who were at risk of conversion to dementia. CIND
moderate patients had a sixfold increased risk of conver-
sion to dementia compared to NCI patients while
CIND mild patients’ risk was similar to that of NCI
patients. Both multidomain MCI subtypes and CIND
moderate subtypes were able to predict incident demen-
tia. We confirmed findings from prior studies which
showed that age, the occurrence of a prior stroke, and
Table 2 Results of univariate andmultivariable Cox proportional hazards
models for the prediction of dementia (condensed version)
Univariate Multivariate*
HR 95%CI HR 95%CI
Baseline cognitive status
NCI† 1.00 — 1.00 —
CINDmild 4.39 0.80–24.0 1.04 0.17–6.37
CINDmoderate 22.5 5.22–97.2‡ 6.43‡ 1.30–31.7‡
NCI† 1.00 — 1.00 —
Single domain impairment 3.83 0.53–27.2 1.07 0.14–8.24
Multiple domain impairment 16.9 3.94–72.3‡ 4.72 0.97–22.94
NCI† 1.00 — 1.00 —
Amnestic MCI 4.92 0.45–54.3 2.26 0.18–27.7
Nonamnestic single domain MCI 3.13 0.28–34.5 0.62 0.05–7.58
Multiple domain MCI with amnestic
component
19.3 4.48–83.4‡ 5.77 1.19–28.0‡





Age 1.12 1.07–1.17‡ 1.08 1.03–1.14‡
Baseline modified Rankin Scale score 2.50 1.75–3.55‡ 1.91 1.21–3.01‡
Baseline MMSE score 0.91 0.83–0.99‡ 1.00 0.88–1.15
Previous stroke 2.70 1.18–6.19‡ 3.01 1.81–7.67‡
Recurrent stroke 5.57 2.49–12.4‡ 2.45 1.02–5.92‡
*Controlled for treatment allocation.
†Reference group.
‡Significant.
HR  hazard ratio; CI confidence interval; NCI no cognitive impairment; CIND cogni-
tive impairment no dementia; MCImild cognitive impairment; POCI posterior circulation
infarct; LACI lacunar infarct; TACI total anterior circulation infarct; PACI partial ante-
rior circulation infarct; MMSEMini-Mental State Examination.
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the occurrence of recurrent strokes were all significant
predictors of dementia. We also found that impair-
ments in the domains of verbal and visual memory were
able to predict incident dementia.
While prestroke cognitive decline is associated
with poststroke dementia,21 there have been only a
few studies examining cognitive states after stroke
and their association with incident dementia. One
study22 assessed poststroke survivors without demen-
tia at 3 and 15 months but found that none of the
criteria utilized at baseline (MCI, age-associated cog-
nitive decline, vascular CIND) identified patients at
risk of incident dementia. Another study23 examined
the predictive accuracy of MCI subtypes for demen-
tia in a mixed cohort of memory clinic and post-
stroke patients, and showed that the multiple
domain MCI subtype had a high sensitivity but did
not investigate CIND severity. Finally, a more recent
study24 determined the frequency of CIND in a post-
stroke population and found that it predicted for in-
cident dementia. However, there was no attempt to
differentiate between mild and moderate CIND.
Previous studies comparing patients with incident
AD and patients with VaD have shown few differ-
ences in their preclinical cognitive profiles.25-28 How-
ever, the lack of difference could well be an artifact of
the requirement of memory impairment for a diag-
nosis of dementia in the DSM-IV criteria. An early
analysis of subjects with vascular CIND in the Cana-
dian Study of Healthy Aging found that impairments
in tests of memory and category fluency were associ-
ated with incidence of dementia.29 However, a later
analysis of subjects with NCI from the same study,30
which investigated neuropsychological predictors,
found that while abstract reasoning scores were lower
in the incident vascular cognitive impairment group,
memory test scores were lower in the incident AD
group. Therefore, we suggest that in populations
with cognitive impairment of predominantly vascu-
lar causes, CIND severity be used as opposed to MCI
subtypes, which emphasize an amnestic component.
Larger epidemiologic studies in populations at risk
for cognitive impairment of predominantly vascular
causes are needed to confirm our findings. Addition-
ally, our proposed CIND subtype definitions may be
supplemented with executive functioning and ab-
stract reasoning tests.
In support of our findings that impairments in
the domains of visual memory and verbal memory
were associated with an increased risk of incident de-
mentia, the Sydney Stroke Cohort has shown that
verbal memory was more likely to deteriorate in isch-
Table 3 Distribution of domains of impairment and results of univariate andmultivariable Cox proportional









TIA patients 70 1 (2) 0 (0) 5 (8) 9 (13) 10 (14) 11 (15)
LACI/POCI patients 261 21 (8) 23 (8) 39 (17) 85 (33) 92 (35) 104 (41)
TACI/PACT patients 31 7 (22) 5 (16) 4 (17) 11 (35) 13 (43) 16 (55)
In patients with
1 domain impaired 53 0 (0) 1 (2) 3 (6) 17 (32) 10 (19) 20 (38)
2 domains impaired 41 2 (4) 3 (6) 7 (13) 16 (30) 26 (49) 29 (55)
3 domains impaired 43 6 (14) 2 (5) 10 (23) 32 (74) 38 (88) 40 (93)
4 domains impaired 24 8 (33) 7 (29) 12 (50) 22 (92) 23 (96) 24 (100)
5 domains impaired 12 7 (58) 7 (58) 10 (83) 12 (100) 12 (100) 12 (100)
6 domains impaired 6 6 (100) 6 (100) 6 (100) 6 (100) 6 (100) 6 (100)
Total 179 29 (16) 26 (15) 48 (27) 105 (59) 115 (64) 131 (73)
Regression analysis
Univariate HR 4.96* 5.01* 8.74* 6.45* 6.10* 13.7*
p Value 0.001* 0.001* 0.001* 0.001* 0.001* 0.001*
Multivariable HR† 1.81 3.07 6.92* 4.25* 3.34 4.37
p Value 0.223 0.015 0.001* 0.002* 0.014 0.025
All cells reported as n (%) unless otherwise specified.
*Significant.
†Multivariable models adjusted for age, previous stroke, recurrent stroke, baseline modified Rankin Scale, and treatment
allocation. Frequency of impairment in each cognitive domain stratified by total number of domains impaired.
LACI lacunar infarct; POCI posterior circulation infarct; TACI total anterior circulation infarct; PACI partial anterior
circulation infarct; HR hazard ratio.
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emic stroke or TIA patients who converted to de-
mentia.31 Cognitive impairment in stroke patients
may lead to an increase of mortality and recurrent
cerebrovascular events due to several causes. Cogni-
tively impaired patients may be less compliant with
medication, thereby reducing the effectiveness of sec-
ondary prevention therapies, or be less able to alter
their lifestyle habits, which may lead to poorer con-
trol of vascular comorbidities.21 This is particularly
important in stroke patients, who tend to have more
vascular comorbidities than patients with AD.32
Therefore, while the initial magnitude of cognitive
decline seen among poststroke patients is less than
that of patients with prodromal AD,33 the subse-
quent effect on mortality and morbidity might be
greater than in patients with AD.
Our study has several limitations. The inclusion/
exclusion criteria limit recruitment to those without
dominant upper limb paralysis and who had a base-
line mRS3. Hence this may limit the generalizabil-
ity of our findings as these criteria have resulted in a
younger population in ESPRIT than most stroke
populations. With only 24 patients progressing to
dementia, we were unable to perform separate analy-
sis on patients who progressed to AD, VaD, or mixed
dementia. Larger studies should endeavor to investi-
gate the predictive ability of CIND mild and CIND
moderate separately in patients who progress to AD
and VaD. Another limitation of this study was that
we were underpowered to examine the interaction of
recurrent vascular event and CIND moderate status
at baseline. However, as we controlled for the recur-
rence of stroke as well as the history of previous
strokes, we believe that our sample size will not affect
our conclusions. While prestroke dementia was ex-
cluded, we were unable to control for prestroke cog-
nitive impairment. Furthermore, although the
cognitive battery utilized was validated by adminis-
tration to an elderly community-dwelling population
in Singapore in order to elicit formal structural do-
mains, identify items that may not be culturally rele-
vant, and to replace those items with culturally
appropriate items, more studies need to be per-
formed using other cognitive instruments to confirm
the predictive abilities of the CIND moderate classi-
fication. We recognize that our findings may be due
to the definitions of CIND severity and MCI sub-
groups, which results in CIND moderate represent-
ing more global cognitive impairments than either
form of multidomain MCI, and also results in CIND
mild overlapping with multidomain MCI. As there
are 4 MCI subclassifications compared to the two
CIND subclassifications that we proposed, this may
result in a loss of power in this study for the MCI
subclassification, which could explain our results.
Additionally, we recognize that our classifications of
CIND did not adopt the typical threshold of less
than 1 SD from the mean, but instead adopted the
usual MCI threshold of 1.5 standard deviations
from the mean so as to allow comparison. Hence,
further studies are needed to validate the operational-
ized criteria for MCI and CIND in different popula-
tions that are at high risk of developing dementia.
AUTHOR CONTRIBUTIONS
Statistical analysis was conducted by Dr. Kaavya Narasimhalu.
ACKNOWLEDGMENT
The authors thank the psychologists and trial coordinators who collected
data for this study.
DISCLOSURE
This study was funded by the National Medical Research Council (Singa-
pore). K. Narasimhalu, S. Ang, Dr. De Silva, Dr. Wong, Dr. Chang, and
Dr. Chia report no disclosures. Dr. Auchus has received funding for travel
for lectures or educational activities not funded by industry; serves on the
editorial advisory board of Alzheimer Disease and Associated Disorders; has
served as a consultant to Myriad Genetics, Inc.; serves on a speakers’
bureau for Novartis; received research support from Pfizer Inc., Eisai Inc.,
and Elan Corporation, the NIH/NIA [U01AG10483 (Site PI)],
R01AG030114 (Consultant), and the University of Tennessee Health
Science Center Neuroscience Institute; and served as mentor for the Elli-
son Medical Foundation/American Federation for Aging Research Senior
Postdoctoral Fellows Grant (E07097). Dr. Chen has received honoraria
from Lundbeck Inc., SERVIER, Pfizer Inc., and Elan Corporation.
ReceivedDecember 21, 2008. Accepted in final form September 15, 2009.
REFERENCES
1. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and
severity of cognitive impairment with and without demen-
tia in an elderly population. Lancet 1997;349:1793–1796.
2. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E,
Tangelos EG. Aging, memory, and mild cognitive impair-
ment. Int Psychogeriatr 1997;9 suppl 1:65–69.
3. Petersen RC. Mild cognitive impairment as a diagnostic
entity. J Intern Med 2004;256:183–194.
4. Di Carlo A, Lamassa M, Baldereschi M, et al. CIND and
MCI in the Italian elderly: frequency, vascular risk factors,
progression to dementia. Neurology 2007;68:1909–1916.
5. Sachdev PS, Brodaty H, Valenzuela MJ, et al. Clinical de-
terminants of dementia and mild cognitive impairment
following ischaemic stroke: the Sydney Stroke Study. De-
ment Geriatr Cogn Disord 2006;21:275–283.
6. ThamW, Auchus AP, Thong M, et al. Progression of cog-
nitive impairment after stroke: one year results from a lon-
gitudinal study of Singaporean stroke patients. J Neurol
Sci 2002;203–204:49–52.
7. De Schryver EL. Design of ESPRIT: an international ran-
domized trial for secondary prevention after non-disabling
cerebral ischaemia of arterial origin: European/Australian
Stroke Prevention in Reversible Ischaemia Trial (ESPRIT)
group. Cerebrovasc Dis 2000;10:147–150.
8. Bonita R, Beaglehole R. Modification of Rankin Scale: re-
covery of motor function after stroke. Stroke 1988;19:
1497–1500.
9. American Psychiatric Association. Diagnostic and Statisti-
cal Manual of Mental Disorders: DSM-IV. Washington,
DC: American Psychiatric Association; 1994.
Neurology 73 December 1, 2009 187161
10. Yeo D, Gabriel C, Chen C, Lee S, Loenneker T, Wong M.
Pilot validation of a customized neuropsychological battery in
elderly Singaporeans. Neurol J South East Asia 1997;2:123.
11. Wechsler D. Wechsler Memory Scale: Revised (3rd ed).
San Antonio, TX: Harcourt Brace Jovanovich; 1997.
12. Smith A. Symbol Digit Modalities Test. In: Services WP,
ed. Symbol Digit Modalities Test. Los Angeles, CA: 1973.
13. Diller L, Ben-Yishay Y, Gerstman LJ. Studies in Cognition
and Rehabilitation in Hemiplegia: Rehabilitation Mono-
graph No. 50. New York: New York University Medical
Center Institute of Rehabilitation Medicine; 1974.
14. Porteus SD. The Maze Test and clinical psychology. Palo
Alto, CA: Pacific Books; 1959.
15. Wechsler D. Wechsler Adult Intelligence Scale: Revised.
San Antonio, TX: Harcourt Brace Jovanovich; 1981.
16. Sahadevan S, Tan NJ, Tan TC, Tan S. Cognitive testing of
elderly Chinese from selected community clubs in Singa-
pore. Ann Acad Med Singapore 1997;26:271–277.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price
D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease:
report of the NINCDS-ADRDA Work Group under the
auspices of Department of Health and Human Services Task
Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
18. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular
dementia: diagnostic criteria for research studies: report of
the NINDS-AIREN International Workshop. Neurology
1993;43:250–260.
19. Mead GE, Lewis SC, Wardlaw JM, Dennis MS, Warlow
CP. How well does the Oxfordshire community stroke
project classification predict the site and size of the infarct
on brain imaging? J Neurol Neurosurg Psychiatry 2000;
68:558–562.
20. Statacorp. Stata (ed 10.0). College Station, TX: Statcorp;
2008.
21. Leys D, Henon H, Kowiak-Cordoliani MA, Pasquier F.
Poststroke dementia. Lancet Neurol 2005;4:752–759.
22. Ballard C, Rowan E, Stephens S, Kalaria R, Kenny R. Pro-
spective follow-up study between 3 and 15 months after
stroke: improvements and decline in cognitive function
among dementia-free stroke survivors 75 years of age.
Stroke 2003;34:2440–2444.
23. Rasquin S, Lodder J, Visser P, Lousberg R, Verhey F. Pre-
dictive accuracy of MCI subtypes for Alzheimer’s disease
and vascular dementia in subjects with mild cognitive im-
pairment: a 2-year follow-up study. Dement Geriatr Cogn
Disord 2005;19:113–119.
24. Serrano S, Domingo J, Rodriguez-Garcia E, Castro MD,
del Ser T. Frequency of cognitive impairment without de-
mentia in patients with stroke: a two-year follow-up study.
Stroke 2007;38:105–110.
25. Meyer JS, Xu G, Thornby J, Chowdhury MH, Quach M.
Is mild cognitive impairment prodromal for vascular de-
mentia like Alzheimer’s disease? Stroke 2002;33:1981–
1985.
26. Laukka EJ, Jones S, Fratiglioni L, Backman L. Cognitive
functioning in preclinical vascular dementia: a 6-year
follow-up. Stroke 2004;35:1805–1809.
27. Laukka EJ, Jones S, Small BJ, Fratiglioni L, Backman L.
Similar patterns of cognitive deficits in the preclinical
phases of vascular dementia and Alzheimer’s disease. J Int
Neuropsychol Soc 2004;10:382–391.
28. Sacuiu S, Sjogren M, Johansson B, Gustafson D, Skoog I.
Prodromal cognitive signs of dementia in 85-year-olds us-
ing four sources of information. Neurology 2005;65:
1894–1900.
29. Ingles JL, Wentzel C, Fisk JD, Rockwood K. Neuropsy-
chological predictors of incident dementia in patients with
vascular cognitive impairment, without dementia. Stroke
2002;33:1999–2002.
30. Ingles JL, Boulton DC, Fisk JD, Rockwood K. Preclinical
vascular cognitive impairment and Alzheimer disease: neu-
ropsychological test performance 5 years before diagnosis.
Stroke 2007;38:1148–1153.
31. Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz LM, Ko-
schera A. Progression of cognitive impairment in stroke
patients. Neurology 2004;63:1618–1623.
32. Cechetto DF, Hachinski V, Whitehead SN. Vascular risk
factors and Alzheimer’s disease. Expert Rev Neurother
2008;8:743–750.
33. Schneider LS. Galantamine for vascular dementia: some
answers, some questions. Lancet 2002;359:1265–1266.
Resident & Fellow Section: Call for Teaching Videos
The Neurology Resident section is featured online at www.neurology.org. The Editorial Team of
this section is seeking teaching videos that will illustrate classic or uncommon findings on move-
ment disorders. Such videos will aid in the recognition of such disorders. Instructions for formatting
videos can be found in the Information for Authors at www.neurology.org.
1872 Neurology 73 December 1, 2009 62
    II 
63
Hui-Meng Chang, Kee-Seng Chia, Alexander P. Auchus and Christopher P. Chen
Kaavya Narasimhalu, Sandy Ang, Deidre Anne De Silva, Meng-Cheong Wong,
PatientsDomain-Specific Cognitive Impairments in Nondisabled Ischemic Stroke 
The Prognostic Effects of Poststroke Cognitive Impairment No Dementia and
ISSN: 1524-4628 
Copyright © 2011 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online
Stroke is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
doi: 10.1161/STROKEAHA.110.594671
2011, 42:883-888: originally published online February 17, 2011Stroke 
 http://stroke.ahajournals.org/content/42/4/883
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/reprints




Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
 http://stroke.ahajournals.org//subscriptions/
Subscriptions: Information about subscribing to Stroke is online at 
 at National University of Singapore on December 31, 2011http://stroke.ahajournals.org/Downloaded from 64
Clinical Sciences
The Prognostic Effects of Poststroke Cognitive Impairment
No Dementia and Domain-Specific Cognitive Impairments in
Nondisabled Ischemic Stroke Patients
Kaavya Narasimhalu, BA; Sandy Ang, BPsych; Deidre Anne De Silva, MRCP;
Meng-Cheong Wong, FRCP; Hui-Meng Chang, MRCP; Kee-Seng Chia, MD;
Alexander P. Auchus, MD; Christopher P. Chen, FRCP
Background and Purpose—There is some evidence that poststroke dementia, cognitive impairment no dementia (CIND),
and mild cognitive impairment predict for poor outcomes such as dementia, death, and institutionalization. However,
few studies have examined the prognostic value of CIND, CIND severity, and domain impairments in a poststroke
cohort.
Methods—A cohort of ischemic stroke patients with baseline cognitive assessments 3 months poststroke were followed up
annually for outcomes of dependency, vascular events, and death for up to 5 years. Univariate and multivariate Cox
proportional regression was performed to determine the ability CIND, CIND severity, and domain impairments to
predict dependency, vascular outcomes, and death.
Results—Four-hundred nineteen patients without dementia (mean age 6011 years, 32% female) were followed for a
mean of 3.2 years. Older age, diabetes, more severe strokes, CIND-mild, and CIND-moderate were independently
predictive of dependency. There were no independent predictors of recurrent vascular events. Older age, diabetes, and
CIND-moderate were independently predictive of death. In analyses of individual cognitive domains, impairments in
visuomotor speed were independently predictive of dependency.
Conclusions—In poststroke patients, CIND predicts dependency and death, while CIND severity discriminates patients
with poor survival. Impairments in visuomotor speed independently predict dependency.
Clinical Trial Registration—URL: http://clinicaltrials.gov. Unique Identifier: NCT00161070.
(Stroke. 2011;42:883-888.)
Key Words: dementia  stroke  mild cognitive impairment  cognitive impairment no dementia
Dementia, cognitive impairment no dementia (CIND), andmild cognitive impairment (MCI) have become increas-
ingly prevalent in aging populations. CIND is a broad concept
that has been used to define impairments in any objective
cognitive domain in neuropsychological testing in the absence of
dementia.1 In community-based studies, CIND has been shown
to predict for dementia, death, and institutionalization.2 One
study found that poststroke CIND is a negative predictor of
survival.3 Studies have also shown that poststroke dementia
(PSD) increases the risk of recurrent vascular events.4,5 How-
ever, no studies to date have examined the effect of CIND on
poststroke recurrent vascular events or dependency. We hypoth-
esize that CIND is associated with dependency, recurrent vas-
cular events, and death following ischemic stroke.
In a previous study from this cohort,6 we have shown that
CIND severity predicts incident dementia; CIND-mild pa-
tients shared a similar risk profile with patients with no
cognitive impairment (NCI), and CIND-moderate patients
experienced a 6-fold increase in the risk of incident dementia.
Because PSD has been associated with recurrent vascular
events4 and death,7 we hypothesize that a similar association
may exist with CIND severity and outcomes after stroke.
Previous studies that have examined the prognostic abili-
ties of domain-specific impairments have found that visual
memory impairments predict for disturbances in activities of
daily living,8 whereas executive functioning and visuospatial
impairments3,9 predict for poor survival after stroke. There-
fore, in this study, we aimed to determine domain-specific
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All patients with recent transient ischemic attacks or nondisabling
ischemic stroke who were seen in the Singapore General Hospital
between 1999 and 2005 were screened for eligibility for the
European Australasian Stroke Prevention in Reversible Ischemia
Trial (ESPRIT). Detailed methodology for the main study has been
previously reported.10 Briefly, patients were eligible if they were
within 6 months of a transient ischemic attack (including transient
monocular blindness) or a nondisabling ischemic stroke (grade 3
on the modified Rankin scale11 [mRS]) of presumed arterial origin.
The exclusion criteria were: a possible cardiac source of embolism,
high-grade carotid stenosis for which carotid endarterectomy or
endovascular treatment was planned, moderate to severe leukoarai-
osis on brain imaging (for randomization into anticoagulation), any
blood coagulation disorder, any contraindication for aspirin or
dipyridamole, and a limited life expectancy.
Patients recruited into ESPRIT were eligible to enter a cognitive
substudy (ESPRIT-Cog) with the following additional exclusion
criteria: confusion, severe aphasia (expressive or receptive), major
psychosis diagnosed according to the Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition criteria,12 or dominant
upper-limb paralysis.
Standard Protocol Approvals, Registrations, and
Patient Consents
The study protocol was approved by Singapore General Hospital’s
Institutional Review Board and Ethics Committee. Written informed
consent was obtained from all patients or legal guardians. The
ESPRIT trial was registered under http://clinicaltrials.gov with the
identifier NCT00161070.
Neuropsychological Test Battery
Patients who consented to ESPRIT-Cog received their baseline
cognitive assessment 3 to 4 months after their qualifying event, and
then annually thereafter for up to 5 years. Trained research psychol-
ogists administered a neuropsychological test battery that has been
validated for use in Singapore.13 The battery assessed 6 domains, 4
of which were nonmemory domains. Education-adjusted cutoffs of
1.5 standard deviations below established normal means were used
on individual tests. Failure in at least half of the tests in a domain
constituted failure in that domain. The assessment was administered
in English, Malay, Mandarin, or Chinese dialects according to the
subject’s habitual language. The entire battery took under 90 minutes
to complete.
The nonmemory domains were: Attention, as defined by digit
span,14 visual span,14 and auditory detection15; Language, as defined
by modified Boston naming16 and category fluency17 (animals and
food subtasks); Visuomotor speed, as defined by symbol digit
modality test,18 digit cancellation,19 and maze ask20; and Visuocon-
struction, as defined by Weschler Memory Scale–Revised14 visual
reproduction copy task, clock drawing,21 and Weschler Adult Intel-
ligence Scale–Revised22 subtest of block design.
The memory domains were: Verbal Memory, as defined by word
list recall23 (immediate, delayed, and delayed recognition) and story
recall14 (immediate and delayed); and Visual Memory, as defined by
picture recall14 (immediate, delayed, and delayed recognition) and
Weschler Memory Scale–Revised visual eproduction14 (immediate,
delayed, and delayed recognition).
Determination of CIND
As is commonly defined, patients with CIND were impaired in at
least 1 domain of the neuropsychological test battery, but did not
meet criteria for dementia.1 In keeping with our previous study,
where severity of CIND predicted incident dementia,6 CIND was
divided by a median split into CIND-mild (1 to 2 domains impaired)
and CIND-moderate (3 to 6 domains impaired).
Baseline Risk Factors
Risk factor information was collected at baseline. Stroke subtype
was classified according to the Oxfordshire Community Stroke
Project24 by: total anterior circulation infarct, partial anterior circu-
lation infarct, posterior circulation infarct, or lacunar infarct. All
patients had either computed tomography or magnetic resonance
imaging as part of the diagnostic process. Vascular risk factor data,
such as age, diabetes mellitus status, hypertension, hyperlipidemia,
smoking status, ischemic heart disease, peripheral artery disease, as
well as history of stroke, angina, and myocardial infarction, were
obtained verbally from the patient and were confirmed with hospital
records.
Outcome Measures
Patients were followed up annually for up to 5 years. Patients
underwent full neuropsychological assessment at the outpatient
clinic. If a recurrent vascular event had occurred, detailed hospital
records were obtained to verify occurrence of the vascular event.
Strokes, peripheral artery disease, intracranial bleeds, and any
cardiac ischemia (stable and unstable angina, myocardial infarctions)
or deaths from any of the above were considered to be a recurrent
vascular event. Dependency was measured by the mRS,11 which is a
commonly utilized scale in stroke studies (0no symptoms,
1symptoms, no disability, 2slight disability, 3moderate dis-
ability, 4moderately severe disability, 5severe disability,
6death). The mRS was dichotomized by good outcome (0–2) and
bad outcome (3–6). Patients with a mRS of 3 at baseline were
considered dependent only if they progressed to mRS scores 3.
Information pertaining to death was collected verbally and confirmed
with hospital and/or death registry records at the end of the study.
Statistical Analysis
ANOVA or 2 analysis was used to test for significant differences
between NCI, CIND-mild, and CIND-moderate patients. Analysis
was performed in 3 stages. In the first stage, univariate regressions
were performed to determine which baseline characteristics were
predictive of dependency, recurrent vascular events, and death.
Univariate regression analyses were repeated twice, once with CIND
versus NCI as the indicator of baseline cognitive impairment, then
with CIND severity as the indicator of baseline cognitive impair-
ment. In the second stage of analysis, the analyses were repeated as
multivariate regression models controlling for treatment allocation,
with significant predictors in the univariate stage included in the
models. In the third stage of analysis, individual domains of
cognition were analyzed for their ability to predict dependency,
recurrent vascular events, or death in both univariate analyses and
multivariate analyses (in which domains of cognition were entered
individually into regression models that adjusted for significant
predictors of dementia from stage 1), and treatment allocation. For
the outcome of dependency, we adjusted for stroke subtype, age,
gender, diabetes mellitus, hypertension, and treatment allocation. For
the outcome of vascular events, we adjusted for age, diabetes
mellitus, and treatment allocation. For the outcome of death, we
adjusted for age, gender, diabetes mellitus, hypertension, previous
myocardial infarction, and treatment allocation. Cox proportional
hazards models were used in all stages of analysis. Analyses were
performed in Stata 10.0,25 and significance was determined with a
2-tailed  of 0.05 in stages 1 and 2 of analysis, whereas Bonferroni
adjustment for multiple comparisons in stage 3 yielded an  of 0.008.
Results
A total of 458 patients were recruited into ESPRIT at the
Singapore General Hospital site, of which 432 consented to
participate in the ESPRIT-Cog substudy. Of these 432 pa-
tients, 13 had dementia at baseline and were therefore
excluded from this study. We thus present data of 419
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patients (mean age 6011 years, 32% women) who were
followed for a mean of 3.2 years (Figure). There were 212
patients (51%) with NCI, 109 patients (26%) with CIND-
mild, and 98 patients (23%) with CIND-moderate. The
demographic characteristics of the study population stratified
by baseline cognitive status are summarized in Table 1.
Older, female, diabetic, hypertensive patients and those with
more severe strokes (total/partial anterior circulation infarct)
were more likely to have cognitive impairment.
During the course of the study, 28 patients died, 62 had a
vascular event (40 ischemic stroke, 14 myocardial ischemia,
4 intracerebral hemorrhages, 4 peripheral artery disease), and
48 became dependent. The incidence of death was 0.2 per
1000 in NCI patients, 0.9 per 1000 in CIND-mild patients,
and 1.4 per 1000 in CIND-moderate patients. The incidence
of recurrent vascular events was 1.0 per 1000 in NCI patients,
1.8 per 1000 in CIND-mild patients, and 2.1 per 1000 in
CIND-moderate patients. The incidence of dependency was
0.3 per 1000 in NCI patients, 1.9 per 1000 in CIND-mild
patients, and 2.2 per 1000 in CIND-moderate patients.
Table 2 summarizes the result of univariate and multivar-
iate Cox proportional hazards analysis predicting depen-
dency, vascular events, and death. In univariate analysis, age,
gender, diabetes mellitus, hypertension, stroke subtype, and
cognitive impairments were associated with dependency. In
multivariate analysis, age, stroke subtype, diabetes mellitus,
and all definitions of cognitive impairment were significant
predictors of dependency. In univariate analysis, age, diabetes
mellitus, CIND, and CIND severity were associated with
recurrent vascular events. However, there were no significant
predictors of recurrent vascular events in multivariate analy-
sis. In univariate analysis, age, gender, diabetes mellitus,
hypertension, and cognitive impairments were associated
with death. In multivariate analysis predicting for death, age,
diabetes mellitus, and CIND-moderate were all significant
predictors of death.
Table 3 summarizes the results of the Cox proportional
hazards analysis using domains of cognitive impairment to
predict dependency, vascular events, and death. In univariate
analysis, all domains predicted for dependency, whereas in
multivariate analysis, only visuomotor speed independently
predicted dependency (HR3.49, P0.002). In univariate
analysis, language, visual memory, and visuomotor speed
predicted vascular events; however, none remained signifi-
cant in multivariate analysis. In univariate analysis, language,
visual and verbal memory, visuomotor speed, and visuocon-
struction were significant predictors of death; however, none
remained significant in multivariate analysis.
Discussion
In this study, we determined the prognostic effect of cognitive
impairment in poststroke patients without dementia. Specifi-
cally, we evaluated the effects of CIND, CIND severity, and
domain-specific impairments on dependency, recurrent vas-
cular events, and death.
With regards to dependency, we found that poststroke
CIND predicted for dependency. Both CIND-mild and
CIND-moderate were predictive of poor functional prognosis
when compared with NCI patients. We also found that
visuomotor speed independently predicted for dependency
after stroke. This is in keeping with a previous study8 of
poststroke patients that showed that visual memory and
neglect independently predicted for persistent disturbances in
basic activities of daily living, whereas visual perception and
construction difficulties independently predicted persistent
disturbances in instrumental activities of daily living.
Figure. Study population.
Table 1. Demographic Characteristics of Patient Population









Age, mean (SD) 54 (10) 64 (10) 66 (11) 0.0001
Sex, male 163 (77) 67 (61) 57 (58) 0.001
Diabetes mellitus 67 (32) 51 (47) 51 (52) 0.001
Hypertension 141 (67) 87 (80) 79 (81) 0.007
Previous stroke 29 (14) 25 (23) 20 (20) 0.086
Hyperlipidemia 95 (45) 48 (44) 44 (45) 0.989
Ever smoker 81 (38) 42 (39) 19 (30) 0.290
Previous ischemic
heart disease
21 (10) 12 (11) 13 (11) 0.679
Previous peripheral
artery disease
4 (2) 3 (3) 10 (2) 0.789
Previous angina
pectoris
17 (8) 8 (7) 8 (8) 0.970
Previous myocardial
infarction
6 (3) 3 (3) 4 (4) 0.875
Stroke subtype 0.0001
TIA 59 (28) 20 (18) 5 (5)
POCI/LACI 143 (67) 79 (72) 82 (84)
TACI/PACI 10 (5) 10 (9) 11 (11)
NCI indicates no cognitive impairment; CIND, cognitive impairment no
dementia; TIA, transient ischemic attack; TACI, total anterior circulation infarct;
PACI, partial anterior circulation infarct; POCI, posterior circulation infarct; LACI,
lacunar infarct.
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In the present study, we found that CIND predicted poor
survival. This is in agreement with both population-based2,9
studies and poststroke studies3 in which CIND predicts poor
survival, and with studies of PSD that have shown that PSD
increases the risk of death by 2- to 6-fold.26,27 In addition,
CIND severity was differentially predictive of poor survival,
with CIND-moderate patients 3 to 4 times more likely to die
compared with NCI patients, whereas CIND-mild patients
had a nonsignificant increase in risk. This novel finding is in
line with our previous study that showed that CIND severity
is a prognostic factor for incident dementia in poststroke
patients.6 In our study, there were no independent cognitive
domains that predicted for death. This is in contrast to a
previous study3 of poststroke outcomes, where deficits in
executive functions and visuospatial/construction abilities
independently predicted poor survival. We believe that the
difference in findings could be caused by both the conserva-
tive use of a Bonferroni adjustment and by the relatively
lower rates of death in our study (2 deaths per 1000
patient-years versus 59 per 1000 patient-years in the earlier
study), which could in turn be a reflection of our differing
study lengths (5 years versus 12 years).
In this study, we found no association between CIND,
CIND severity, or individual domains of impairment and
recurrent vascular events. Although there have been no
previous studies that have analyzed the association between
poststroke CIND and recurrent vascular events, PSD has
previously been shown to increase the risk of recurrent
vascular events.4 There remains some controversy regarding
the role of PSD in recurrent vascular events, as leukoaraiosis
has been shown to be more predictive than is PSD for
recurrent vascular events.27
Our study has several limitations. The inclusion/exclusion
criteria limit recruitment to those without dominant upper-
limb paralysis and who had a baseline mRS 3. This may
limit the generalizability of our findings, as these criteria have
resulted in a younger population in ESPRIT than in most
stroke populations. Information pertaining to the baseline
National Institute of Health Stroke Scale (NIHSS) score was
unavailable, and therefore we were unable to control for
neurological impairments among this stroke cohort. How-
ever, we used the Oxfordshire Community Stroke Project
stroke subtype classification as a means of controlling for
stroke severity in our analysis. An additional limitation to our
Table 2. Cox Regression Analysis of Baseline Characteristics Predicting Dependency, Recurrent Vascular Events, and Death
Baseline Cognitive
Status
Dependency (4 Missing) Vascular Events (1 Missing) Death
Univariate Multivariate† Univariate Multivariate† Univariate Multivariate†
HR 0.95 CI HR 0.95 CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
NCI* 1.00 . . . . . . 1.00 . . . . . . 1.00 . . . . . . 1.00 . . . . . . 1.00 . . . . . . 1.00 . . . . . .
CIND 7.72 3.28 18.2 3.77 1.52 9.37 2.04 1.21 3.42 1.67 0.93 3.00 6.48 2.25 18.7 3.27 1.06 10.1
NCI* 1.00 . . . . . . 1.00 . . . . . . 1.00 . . . . . . 1.00 . . . . . . 1.00 . . . . . . 1.00 . . . . . .
CIND-mild 7.22 2.91 17.9 4.05 1.58 10.4 1.93 1.05 3.54 1.62 0.84 3.12 4.97 1.56 15.8 2.56 0.74 8.83
CIND-moderate 8.32 3.35 20.6 3.41 1.27 9.13 2.15 1.18 3.92 1.74 0.89 3.39 7.98 2.63 24.2 3.81 1.14 12.8
Stroke subtype
TIA* 1.00 . . . . . . 1.00 . . . . . . 1.00 . . . . . . 1.00 . . . . . . 1.00 . . . . . .
POCI/LACI 4.10 1.27 13.3 2.65 0.80 8.77 2.04 0.97 4.30 2.04 0.61 6.83
TACI/PACI 5.74 1.44 23.0 4.26 1.02 17.9 1.36 0.41 4.52 2.69 0.54 13.3
Age 1.07 1.04 1.10 1.05 1.01 1.08 1.03 1.00 1.05 1.01 0.99 1.04 1.06 1.03 1.10 1.03 0.99 1.08
Gender 2.42 1.37 4.27 1.63 0.91 2.92 0.91 0.53 1.55 2.25 1.07 4.72 1.64 0.75 3.60
Diabetes mellitus 2.78 1.55 4.99 2.25 1.23 4.13 1.67 1.02 2.73 1.54 0.94 2.53 3.98 1.75 9.03 2.81 1.20 6.58
Hypertension 2.67 1.13 6.28 1.34 0.55 3.26 1.42 0.77 2.61 4.87 1.16 20.5 2.63 0.60 11.5
Previous stroke 1.69 0.89 3.20 1.61 0.92 2.8 1.29 0.52 3.17
Hyperlipidemia 0.87 0.48 1.54 0.99 0.60 1.62 1.25 0.60 2.62
Ever smoker 0.59 0.31 1.13 0.78 0.46 1.34 1.50 0.72 3.16
Previous ischemic
heart disease
1.40 0.63 3.13 0.79 0.34 1.82 2.30 0.93 5.67
Previous peripheral
artery disease
0.79 0.11 5.75 0.58 0.08 4.17 1.46 0.20 10.7
Previous angina
pectoris
1.90 0.85 4.23 1.03 0.44 2.39 2.05 0.71 5.90
Previous myocardial
infarction
0.61 0.08 4.41 0.41 0.06 2.95 4.09 1.23 13.5 3.09 0.45 1.61
HR indicates hazard ratio; CI, confidence interval; NCI, no cognitive impairment; CIND, cognitive impairment no dementia; TIA, transient ischemic attack; TACI, total
anterior circulation infarct; PACI, partial anterior circulation infarct; POCI, posterior circulation infarct; LACI, lacunar infarct.
*Reference group.
†Adjusted for treatment allocation.
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study was that the majority of patients had baseline computed
tomography as opposed to magnetic resonance imaging
scans, which are superior in the determination of stroke
subtypes. We were also unable to control for prestroke
dependency. However, we hypothesize that the inclusion
criteria of mRS 3 would limit the effect of prestroke
dependency in our study population. Furthermore, although
the cognitive battery utilized was validated by administration
to an elderly community population in Singapore, more
studies need to be performed using other cognitive instru-
ments to confirm the predictive abilities of the CIND-
moderate classification. In addition, we recognize that our
classifications of CIND did not adopt the typical threshold of
less than 1 standard deviation from the mean, but instead
adopted the usual MCI threshold of 1.5 standard deviations
from the mean. Hence, additional studies are needed to
validate the operationalized criteria for CIND in different
populations that are at high risk of developing dementia.
Furthermore, we did not utilize MCI subtypes (amnestic
single-domain MCI, amnestic multiple-domain MCI, nonam-
nestic single-domain MCI, nonamnestic multiple-domain
MCI) in our analysis, as the number of outcomes was small.
In addition, we chose to examine CIND and not MCI, as
strokes may produce a spectrum of cognitive changes, but
may not necessarily produce prominent amnesia, as is em-
phasized in the MCI subtypes. Therefore, larger studies may
be required to examine the comparative predictive abilities of
MCI and CIND subtypes. Lastly, the use of the conservative
Bonferroni correction method in all analyses pertaining to
domain-specific impairments may underestimate the contri-
butions of these domains. In this study, without the use of a
correction method, there was an effect of the language
domain on vascular events as well as the verbal memory on
death. However, we suggest that such findings require addi-
tional confirmation. In conclusion, we suggest that CIND
severity is predictive of recurrent dependency and death in a
highly selected population of nondisabled ischemic stroke
patients.
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Table 3. Cox Proportional Hazards Models of Domains of






HR P HR P HR P
Attention 2.77 0.006 1.11 0.798 2.57 0.055
Language 2.94 0.003 2.16 0.018 3.60 0.005
Verbal Memory 2.47 0.009 1.51 0.159 3.45 0.006
Visual Memory 2.04 0.014 1.79 0.011 2.97 0.004
Visuoconstruction 3.52 0.001 1.51 0.069 2.58 0.012




Multivariate* HR P HR P HR P
Attention 1.04 0.925
Language 1.67 0.190 2.17 0.027 2.33 0.072
Verbal Memory 1.45 0.325 2.83 0.027
Visual Memory 1.05 0.870 1.32 0.314 1.74 0.155
Visuoconstruction 1.18 0.215 1.26 0.590
Visuomotor Speed 3.49 0.002 1.48 0.176 1.41 0.444
HR indicates hazard ratio.
*Multivariable models included domains of cognition individually in each
regression model along with treatment allocation as well as variables that were
significant at the univariate stage of analyses.
†Adjusted for stroke subtype, age, sex, diabetes mellitus, hypertension, as
well as the treatment allocation.
‡Adjusted for age, diabetes mellitus, and treatment allocation.
§Adjusted for age, sex, diabetes mellitus, hypertension, previous myocardial
infarction, as well as treatment allocation.
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OBJECTIVE:	  	  To	  test	  two	  hypotheses	  that	  explain	  why	  cognitive	  impairment	  no	  dementia	  (CIND)	  predicts	  
negative	  health	  outcomes:	  1)	  the	  underlying	  genes	  and	  shared	  environment	  that	  predispose	  persons	  to	  
having	  CIND	  also	  predispose	  to	  negative	  health	  outcomes	  and	  2)	  persons	  with	  CIND	  have	  more	  
difficulties	  with	  medication	  (DWM)	  which	  predispose	  them	  to	  have	  negative	  health	  outcomes.	  	  
METHODS:	  	  Members	  of	  the	  Swedish	  Twin	  Registry	  aged	  65	  and	  above	  underwent	  the	  telephone	  
cognitive	  screening	  instrument	  (TELE)	  or	  if	  impaired,	  an	  informant	  interview	  (Blessed	  Dementia	  Rating	  
Scale	  (BDRS)).	  Ordinal	  cognitive	  scores	  (ORD),	  CIND,	  and	  Subjective	  Cognitive	  Impairment	  (SCI)	  statuses	  
were	  derived	  from	  the	  TELE	  and	  BDRS.	  	  The	  outcomes	  of	  dementia,	  death,	  and	  hospitalization	  were	  
ascertained	  using	  both	  the	  National	  Patient	  Register	  and	  the	  Cause	  of	  Death	  Register.	  In	  order	  to	  test	  
hypothesis	  1,	  logistic	  regression	  models	  with	  correction	  for	  generalized	  estimating	  equations	  (GEE)	  were	  
compared	  to	  conditional	  logistic	  models	  within	  MZ	  pairs.	  In	  order	  to	  test	  hypothesis	  2,	  Cox	  regression	  
models	  with	  and	  without	  DWM	  were	  compared.	  	  	  	  
RESULTS:	  In	  12835	  non-­‐demented	  individuals,	  ORD	  scores	  and	  CIND	  status	  predicted	  dementia,	  death,	  
and	  hospitalization	  in	  GEE	  analyses	  but	  not	  in	  within-­‐pair	  analyses.	  	  SCI	  predicted	  dementia	  in	  both	  GEE	  
and	  within-­‐pair	  analyses	  but	  predicted	  hospitalization	  only	  in	  GEE	  analyses.	  Difficulties	  with	  medication	  
predicted	  dementia	  and	  hospitalization	  in	  only	  Cox	  analyses	  with	  GEE	  adjustments	  and	  predicted	  
mortality	  in	  both	  GEE	  and	  within-­‐pair	  analyses.	  	  
CONCLUSION:	  There	  are	  genetic	  and	  shared	  environmental	  influences	  in	  the	  association	  between	  
objective	  cognitive	  impairment	  and	  dementia,	  death,	  and	  hospitalization.	  However,	  SCI	  is	  associated	  
with	  dementia	  independent	  of	  genetic	  and	  shared	  environmental	  confounding.	  Difficulties	  with	  




The	  few	  studies	  have	  examined	  the	  effect	  of	  Cognitive	  Impairment	  No	  Dementia	  (CIND)	  or	  Mild	  
Cognitive	  Impairment	  (MCI)	  on	  negative	  health	  outcomes	  have	  shown	  that	  it	  leads	  to	  higher	  rates	  of	  
institutionalization,	  dementia	  ,	  and	  death1.	  	  However,	  studies	  to	  date	  have	  not	  investigated	  the	  effect	  of	  
CIND	  or	  MCI	  on	  the	  occurrence	  of	  vascular	  events	  or	  hospitalization.	  	  Little	  is	  known	  about	  why	  CIND	  is	  
associated	  with	  negative	  health	  outcomes.	  One	  possible	  explanation	  is	  that	  CIND	  patients	  have	  
difficulties	  medication	  regimens	  prescribed	  by	  their	  doctors.	  	  Another	  possible	  explanation	  is	  that	  CIND	  
is	  purely	  a	  marker	  for	  an	  underlying	  disease	  process	  that	  in	  itself	  confers	  a	  risk	  of	  negative	  health	  
outcomes.	  Additionally,	  there	  is	  no	  clear	  consensus	  on	  the	  role	  of	  Subjective	  Cognitive	  Impairment	  (SCI)	  
in	  the	  pathogenesis	  of	  dementia.	  No	  studies	  have	  examined	  the	  effect	  of	  SCI	  on	  outcomes	  other	  than	  
cognition.	  	  
Twin	  models	  provide	  a	  framework	  to	  study	  the	  association	  between	  an	  exposure	  of	  interest	  and	  an	  
outcome	  while	  examining	  the	  role	  of	  genes	  and	  environment.	  Thus	  far,	  no	  studies	  have	  used	  a	  twin	  
model	  in	  order	  to	  determine	  whether	  genes	  and	  environment	  can	  contribute	  to	  the	  observed	  effect	  of	  
CIND	  and	  SCI	  on	  negative	  health	  outcomes.	  Therefore	  in	  this	  study,	  we	  aim	  to	  use	  a	  twin	  model	  to	  
determine	  the	  association	  between	  CIND	  and	  SCI	  and	  the	  negative	  health	  outcomes	  of	  hospitalization,	  
vascular	  events,	  dementia,	  and	  death.	  	  In	  addition,	  we	  explore	  the	  role	  of	  difficulties	  with	  medication	  in	  




Participants	  in	  this	  study	  were	  part	  of	  HARMONY,	  a	  study	  that	  derived	  its	  participants	  from	  the	  Swedish	  
Twin	  Registry	  (STR)	  2.	  Detailed	  methodology	  of	  HARMONY	  has	  been	  described	  elsewhere	  3.	  Briefly,	  all	  
members	  of	  the	  STR	  aged	  65	  and	  above	  were	  screened	  for	  cognitive	  impairment	  in	  a	  2.5	  year	  period	  
beginning	  March	  1998	  (screening	  phase)	  and	  a	  subset	  were	  invited	  to	  a	  clinical	  phase.	  All	  participants	  
who	  were	  deemed	  to	  have	  dementia	  or	  “questionable	  dementia”	  were	  excluded	  from	  this	  study.	  	  
Of	  a	  total	  of	  13,535	  persons	  that	  were	  screened	  in	  HARMONY	  (Figure	  1),	  700	  persons	  had	  a	  diagnosis	  of	  
dementia	  or	  questionable	  dementia	  and	  were	  therefore	  excluded	  from	  this	  study.	  The	  final	  study	  
population	  had	  12,835	  non-­‐demented	  persons	  (mean	  ±SD	  age	  73±6;	  44%	  male;	  mean	  ±SD	  education	  
8.7±3.0	  years).	  
	  Standard	  Protocol	  Approvals,	  Registrations,	  and	  Patient	  Consents	  
All	  participants	  provided	  informed	  consent	  and	  this	  study	  was	  approved	  by	  both	  the	  Regional	  Ethics	  
Board	  in	  Stockholm	  and	  the	  Institutional	  Review	  Board	  at	  the	  University	  of	  Southern	  California.	  
Cognitive	  Screening	  and	  Clinical	  Phase	  	  
Cognitive	  Screening	  was	  performed	  over	  the	  telephone	  with	  the	  TELE	  cognitive	  screening	  instrument	  
(details	  in	  supplementary	  section)4,	  5.	  	  For	  participants	  who	  were	  impaired	  on	  the	  TELE,	  an	  informant	  was	  
interviewed	  with	  the	  Blessed	  Dementia	  Rating	  Scale	  (BDRS)6.	  The	  TELE	  and	  BDRS	  were	  then	  combined	  
into	  an	  ordinal	  scale	  (ORD)	  with	  scores	  ranging	  from	  0	  (cognitively	  intact)	  to	  3	  (cognitively	  impaired).	  
Individuals	  with	  an	  ORD	  score	  of	  3,	  their	  twin	  partner,	  and	  a	  sample	  of	  35	  normal	  control	  twin	  pairs	  
were	  invited	  to	  the	  clinical	  phase.	  Clinical	  diagnoses	  of	  dementia	  were	  made	  in	  consensus	  conferences	  
in	  accordance	  to	  the	  DSM-­‐IV	  criteria7.	  An	  additional	  category	  of	  “questionable	  dementia”	  was	  added	  for	  
individuals	  who	  did	  not	  fulfill	  one	  of	  the	  three	  DSM-­‐	  IV	  diagnostic	  criteria,	  but	  did	  exhibit	  at	  least	  two	  of	  
the	  criteria:	  memory	  problems,	  problems	  in	  another	  area	  of	  cognition,	  or	  functional	  impairments.	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Cognitive	  Status	  
Cognitive	  status	  was	  classified	  in	  three	  ways:	  two	  measures	  of	  objective	  cognitive	  impairments	  (OCI),	  
ORD	  score	  and	  CIND,	  and	  one	  measure	  of	  SCI.	  	  Participants	  were	  classified	  as	  having	  CIND	  if	  they	  
performed	  at	  least	  two	  standard	  deviations	  below	  the	  age	  and	  education	  adjusted	  means	  in	  any	  of	  the	  
four	  cognitive	  tasks	  in	  the	  TELE.	  Participants	  were	  classified	  as	  having	  SCI	  if	  they	  had	  reported	  memory	  
change	  within	  the	  last	  three	  years.	  Being	  classified	  as	  having	  CIND	  did	  not	  preclude	  being	  classified	  as	  
SCI	  or	  having	  an	  ORD	  score	  of	  3	  and	  vice	  versa.	  Detailed	  methodology	  on	  the	  derivation	  of	  CIND	  and	  SCI	  
status	  is	  summarized	  in	  the	  supplementary	  material.	  Difficulty	  with	  medications	  (DWM)	  was	  derived	  
from	  a	  self-­‐reported	  answer	  to	  the	  question	  “Have	  you	  had	  problems	  with	  taking	  your	  medication”.	  	  
Negative	  Health	  Outcomes	  
In	  this	  study,	  the	  main	  study	  outcomes	  were	  derived	  from	  population-­‐based	  registers.	  Information	  
pertaining	  to	  dementia	  and	  vascular	  events	  were	  derived	  from	  the	  National	  Patient	  Register	  (NPR)8	  and	  
the	  Cause	  of	  Death	  Register	  (CDR)	  9.	  	  Information	  pertaining	  to	  hospitalization	  was	  derived	  from	  the	  NPR	  
only.	  Information	  in	  the	  registries	  as	  available	  until	  the	  following	  dates:	  NPR	  –	  Dec	  31st	  2009,	  CDR	  –	  Dec	  
31st	  2008.	  Information	  on	  death	  was	  available	  until	  Dec	  31st	  2010.	  Vascular	  event	  was	  a	  composite	  end	  
point	  which	  included	  seven	  different	  diagnoses:	  hemorrhagic	  stroke,	  ischemic	  stroke,	  transient	  ischemic	  
attacks,	  myocardial	  infarctions,	  unstable	  angina,	  stable	  angina,	  and	  ischemic	  heart	  disease.	  	  Further	  
information	  on	  the	  registries	  and	  the	  specific	  International	  Classification	  of	  Diseases	  codes	  included	  for	  
the	  outcomes	  of	  dementia	  and	  vascular	  events	  can	  be	  found	  in	  the	  appendix.	  	  
Interpreting	  Twin	  Analyses	  
Twin	  studies	  are	  an	  appropriate	  framework	  to	  study	  genetic	  and	  shared	  environmental	  influences	  on	  a	  
particular	  disease.	  Twin	  studies	  assume	  that	  dizygotic	  twins	  (DZ)	  share	  50%	  of	  their	  genes	  while	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monozygotic	  twins	  (MZ)	  share	  100%	  of	  their	  genes.	  	  All	  twins	  share	  100%	  of	  their	  shared	  environment.	  	  
Analyses	  in	  studies	  using	  twins	  control	  for	  this	  relatedness	  either	  by	  using	  General	  Estimating	  Equations	  
(GEE)	  which	  adjusts	  the	  confidence	  intervals	  to	  account	  for	  the	  correlation	  within	  pairs	  or	  by	  performing	  
within-­‐pair	  analyses	  which	  use	  the	  healthy	  co-­‐twin	  as	  a	  naturally	  matched	  control	  to	  the	  case,	  resulting	  
in	  estimates	  and	  confidence	  intervals	  adjusted	  for	  familial	  factors.	  Comparing	  the	  GEE	  analyses	  to	  the	  
within-­‐pair	  analyses	  allows	  one	  to	  test	  whether	  genetic	  and	  shared	  environmental	  confounders	  
influence	  the	  association	  of	  interest.	  	  
Statistical	  Analysis	  
The	  associations	  between	  demographic	  characteristics	  and	  ORD	  score	  were	  determined	  with	  analysis	  of	  
variance	  or	  chi-­‐squared	  analysis	  as	  appropriate.	  Multivariate	  regression	  analyses	  predicting	  the	  
outcomes	  of	  interest	  were	  performed	  in	  three	  different	  ways:	  1)	  Cox	  Regression	  Analysis	  with	  GEE	  
adjustments	  (Cohort	  Cox);	  2)	  Logistic	  Regression	  Analysis	  with	  GEE	  adjustments	  (Cohort	  Logistic);	  and	  3)	  
Co-­‐twin	  controlled	  Conditional	  Logistic	  Regression	  Analysis	  in	  which	  twins	  discordant	  for	  both	  cognitive	  
status	  and	  outcome	  are	  analyzed	  in	  a	  matched	  case-­‐control	  fashion	  in	  MZ	  Twins	  (within-­‐pair	  analysis).	  In	  
the	  within-­‐pair	  analyses,	  pairs	  in	  which	  the	  control	  twin	  was	  not	  alive	  when	  his	  or	  her	  partner	  became	  
demented,	  was	  hospitalized,	  or	  experienced	  a	  vascular	  event	  were	  excluded	  from	  the	  analyses.	  	  
All	  models	  were	  adjusted	  for	  age,	  gender,	  and	  education.	  Additionally,	  models	  for	  dementia	  adjusted	  for	  
having	  had	  a	  prior	  stroke	  while	  all	  other	  models	  adjusted	  for	  a	  prior	  vascular	  event.	  Additional	  analyses	  
stratified	  by	  time	  to	  dementia	  (within	  the	  first	  5	  years	  of	  screening	  and	  at	  least	  5	  years	  after	  screening)	  
were	  performed.	  Analyses	  were	  performed	  on	  Stata	  version	  11.010,	  and	  significance	  was	  determined	  
with	  a	  two-­‐tailed	  alpha	  of	  0.05.	  	  
Results	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Table	  1	  summarizes	  the	  demographic	  characteristics	  of	  the	  study	  population	  stratified	  by	  ORD	  score.	  
Persons	  with	  more	  cognitive	  impairment	  were	  more	  likely	  to	  be	  older,	  less	  educated,	  and	  performed	  
worse	  on	  the	  TELE.	  
Dementia	  
There	  were	  993	  incident	  cases	  of	  dementia,	  of	  which	  314	  were	  within	  5	  years	  of	  cognitive	  screening.	  In	  
both	  Cohort	  Cox	  and	  Cohort	  Logistic	  regression	  analyses,	  there	  was	  a	  dose	  response	  relationship	  
between	  the	  ORD	  score	  and	  the	  risk	  of	  dementia,	  with	  persons	  with	  ORD	  3	  having	  a	  3	  to	  4	  times	  
increased	  risk	  of	  dementia	  compared	  to	  persons	  with	  ORD	  0	  (Table	  2).	  	  However,	  in	  within-­‐pair	  analysis,	  
there	  was	  no	  longer	  a	  significant	  association	  between	  ORD	  score	  and	  risk	  of	  dementia.	  	  Similarly,	  
persons	  with	  CIND	  had	  an	  increased	  risk	  of	  dementia	  in	  cohort	  analyses,	  but	  did	  not	  exhibit	  an	  increased	  
risk	  of	  dementia	  in	  within-­‐pair	  analyses.	  	  In	  contrast,	  persons	  with	  SCI	  demonstrated	  increased	  risk	  of	  
dementia	  in	  both	  cohort	  and	  within-­‐pair	  analyses,	  suggesting	  that	  the	  association	  between	  SCI	  and	  
dementia	  is	  not	  confounded	  by	  genetic	  and	  shared	  environmental	  factors.	  	  
DWM	  resulted	  in	  an	  increased	  risk	  of	  dementia	  in	  cohort	  Cox	  regression	  analyses	  but	  not	  in	  cohort	  
logistic	  analyses.	  Incorporating	  the	  information	  about	  DWM	  within	  the	  same	  model	  as	  cognitive	  status	  
results	  in	  lower	  estimates	  for	  the	  cognitive	  exposures;	  it	  also	  results	  in	  DWM	  no	  longer	  predicting	  
dementia	  (Appendix).	  This	  suggests	  that	  DWM	  is	  one	  of	  the	  mechanisms	  by	  which	  cognitive	  impairment	  
progresses	  to	  dementia.	  Table	  3	  summarizes	  the	  results	  of	  Cox	  regression	  analyses	  predicting	  dementia	  
within	  the	  first	  5	  years	  or	  after	  5	  years	  of	  screening.	  	  Measures	  of	  OCI	  have	  larger	  effects	  in	  the	  short	  
term	  (first	  5	  years)	  while	  SCI	  has	  a	  larger	  effect	  in	  the	  long	  term	  (after	  5	  years).	  
Mortality	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A	  total	  of	  5,125	  study	  participants	  died	  during	  follow-­‐up.	  	  In	  both	  Cohort	  Cox	  and	  Cohort	  Logistic	  
regression	  analyses,	  there	  was	  a	  dose	  response	  relationship	  between	  ORD	  scores	  and	  mortality,	  with	  
persons	  with	  ORD	  3	  having	  a	  two	  to	  three	  times	  increased	  risk	  of	  death	  as	  compared	  to	  persons	  with	  
ORD	  0	  (Table	  4).	  	  Similarly,	  persons	  with	  CIND	  were	  also	  at	  increased	  risk	  of	  mortality	  in	  cohort	  analyses.	  
However,	  in	  within-­‐pair	  analyses,	  OCI	  was	  no	  longer	  predictive	  of	  death,	  suggesting	  that	  genetic	  and	  
shared	  environmental	  factors	  may	  influence	  the	  association	  between	  OCI	  and	  mortality.	  	  	  DWM	  was	  a	  
strong	  predictor	  of	  mortality	  in	  cohort	  analyses	  and	  also	  predicted	  mortality	  in	  within-­‐pair	  analyses.	  	  
Including	  DWM	  in	  models	  predicting	  mortality	  reduces	  the	  estimates	  associated	  with	  the	  ORD	  score,	  but	  
does	  not	  remove	  the	  independent	  association	  between	  difficulties	  with	  medication	  and	  mortality	  
(Appendix).	  There	  was	  no	  association	  between	  SCI	  and	  mortality.	  	  
Hospitalization	  and	  Vascular	  Events	  
Hospitalization	  
A	  total	  of	  10,184	  persons	  were	  hospitalized	  for	  any	  cause,	  including	  dementia,	  at	  a	  mean	  of	  6.6	  ±	  3.0	  
years	  after	  their	  cognitive	  screening.	  In	  cohort	  analyses	  (table	  5),	  OCI	  and	  DWM	  were	  predictive	  of	  
hospitalization	  in	  Cohort	  Cox	  models,	  but	  not	  in	  logistic	  models	  (Cohort	  Logistic	  and	  within-­‐pair).	  SCI	  was	  
predictive	  of	  hospitalization	  in	  both	  types	  of	  cohort	  analysis	  but	  not	  in	  within-­‐pair	  analysis.	  	  Analyses	  
including	  DWM	  in	  the	  same	  model	  as	  cognitive	  status	  did	  not	  result	  in	  significant	  changes	  (Appendix)	  in	  
the	  relationship	  between	  cognitive	  status	  and	  hospitalization.	  	  
Vascular	  Events	  
A	  total	  of	  5,196	  persons	  had	  experienced	  a	  vascular	  event	  prior	  to	  their	  cognitive	  screening,	  of	  which	  
2,307	  persons	  had	  a	  previous	  stroke	  or	  TIA.	  After	  undergoing	  cognitive	  screening,	  3,634	  people	  
experienced	  at	  least	  one	  vascular	  event.	  There	  were	  no	  significant	  cognitive	  predictors	  of	  vascular	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events	  in	  either	  cohort	  or	  within-­‐pair	  analyses.	  However,	  having	  a	  prior	  vascular	  event	  was	  strongly	  
associated	  with	  having	  a	  later	  vascular	  event.	  Detailed	  information	  can	  be	  found	  in	  the	  appendix.	  	  	  
Discussion	  
In	  this	  study,	  we	  examined	  two	  different	  hypotheses	  behind	  why	  persons	  with	  any	  form	  of	  cognitive	  
impairment	  may	  have	  an	  increased	  risk	  of	  negative	  health	  outcomes.	  The	  first	  hypothesis	  involved	  
persons	  with	  cognitive	  impairment	  having	  difficulties	  with	  medication	  use	  and	  therefore	  being	  at	  risk	  of	  
negative	  health	  outcomes.	  	  We	  were	  able	  to	  show	  that	  DWM	  was	  one	  of	  the	  mechanisms	  by	  which	  
persons	  with	  OCI	  had	  an	  increased	  risk	  of	  dementia	  and	  death.	  In	  the	  second	  hypothesis,	  we	  postulated	  
that	  OCI	  was	  a	  marker	  of	  an	  underlying	  disease	  process.	  	  Twins	  who	  share	  genetic	  markers	  of	  neuronal	  
frailty	  should	  show	  similar	  OCIs	  and	  similar	  increased	  risk	  of	  negative	  health	  outcomes.	  Our	  results	  that	  
confounding	  from	  genetic	  and	  shared	  environmental	  factors	  explained	  some	  of	  the	  association	  between	  
OCI	  and	  dementia,	  death,	  and	  hospitalization	  support	  the	  second	  hypothesis.	  Taken	  together,	  our	  
results	  suggest	  that	  while	  difficulties	  with	  medication	  may	  be	  one	  mechanism	  by	  which	  OCI	  may	  lead	  to	  
dementia,	  other	  mechanisms,	  particularly	  genetic	  and	  shared	  environmental	  factors,	  may	  be	  more	  
important	  in	  the	  progression	  of	  OCI	  to	  dementia.	  While	  we	  may	  not	  be	  able	  to	  change	  a	  person’s	  
underlying	  genetic	  risk,	  persons	  with	  OCI	  should	  be	  offered	  tools	  by	  which	  they	  may	  be	  able	  to	  reduce	  
medication	  errors,	  thereby	  improving	  their	  prognosis.	  One	  possible	  mechanism	  would	  be	  to	  enable	  
elderly	  persons	  to	  access	  their	  medication	  using	  multi-­‐dose	  drug	  dispensing	  methods	  such	  as	  Sweden’s	  
“Apodos”	  system11.	  	  	  
The	  role	  of	  genetics	  in	  the	  progression	  of	  MCI	  to	  dementia	  has	  been	  summarized	  recently,	  with	  both	  
APOE	  and	  SORL1	  being	  the	  genes	  that	  have	  been	  extensively	  studied12.	  A	  previous	  twin	  study	  from	  this	  
sample	  has	  estimated	  the	  heritability	  of	  Alzheimer’s	  disease	  (AD),	  the	  most	  common	  form	  of	  dementia,	  
to	  be	  79%	  13.	  However,	  the	  role	  of	  shared	  environment	  in	  the	  progression	  of	  MCI	  to	  dementia	  has	  not	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been	  as	  firmly	  established.	  The	  results	  from	  the	  current	  study	  further	  reiterate	  the	  need	  to	  look	  for	  
genetic	  and	  shared	  environmental	  factors	  that	  explain	  the	  progression	  of	  OCI	  to	  dementia.	  They	  also	  
support	  the	  hypothesis	  that	  OCI	  may	  be	  a	  marker	  of	  underlying	  disease	  processes	  that	  can	  be	  explained	  
by	  genetic	  and	  environmental	  factors.	  	  
One	  of	  the	  more	  clinically	  relevant	  findings	  in	  this	  study	  was	  the	  increased	  risk	  of	  dementia	  associated	  
with	  SCI,	  which	  was	  not	  explained	  by	  genetic	  and	  environmental	  factors.	  	  The	  increased	  risk	  of	  dementia	  
was	  present	  in	  those	  with	  SCI	  regardless	  of	  CIND.	  These	  results	  confirm	  the	  results	  from	  previous	  studies	  
that	  show	  that	  memory	  complaints	  are	  predictive	  of	  cognitive	  decline	  and	  dementia14-­‐17.	  These	  results	  
also	  suggest	  that	  it	  may	  be	  clinically	  useful	  for	  general	  physicians	  to	  ask	  the	  question	  “Have	  you	  noticed	  
,any	  change	  in	  your	  memory	  during	  the	  last	  three	  years”	  as	  a	  quick	  screen	  in	  order	  to	  identify	  persons	  at	  
increased	  risk	  of	  dementia.	  	  However,	  this	  should	  not	  be	  a	  substitute	  for	  more	  extensive	  screening.	  	  
When	  looking	  at	  the	  temporal	  relationship	  between	  cognitive	  status	  and	  dementia,	  we	  found	  that	  OCI	  is	  
a	  better	  indicator	  of	  short	  term	  (less	  than	  5	  years)	  risk	  of	  dementia,	  while	  SCI	  is	  a	  better	  indicator	  of	  long	  
term	  risk	  of	  dementia.	  	  This	  temporal	  gradient	  between	  CIND,	  SCI	  and	  dementia,	  combined	  with	  the	  fact	  
that	  most	  longitudinal	  studies	  have	  short	  follow-­‐ups	  or	  small	  sample	  sizes,	  may	  explain	  why	  several	  
studies	  have	  been	  unable	  to	  find	  an	  association	  between	  SCI	  and	  dementia	  18,	  19.	  However,	  our	  results	  
are	  in	  agreement	  with	  recent	  studies	  on	  the	  temporal	  evolution	  of	  AD,	  which	  have	  proposed	  that	  the	  
onset	  of	  SCI	  may	  precede	  that	  of	  OCI	  14,	  16,	  17,	  20.	  	  
Our	  finding	  that	  OCI	  was	  a	  risk	  factor	  for	  mortality	  confirms	  existing	  reports	  in	  the	  literature	  1,	  21,	  22	  .	  
While	  some	  of	  the	  effects	  of	  OCI	  on	  mortality	  was	  explained	  by	  DWM,	  both	  OCI	  and	  DWM	  were	  
independent	  predictors	  of	  mortality.	  	  This	  suggests	  that	  the	  increased	  risk	  of	  mortality	  from	  having	  OCI	  
may	  be	  both	  due	  to	  difficulties	  with	  medication	  use	  and	  due	  to	  the	  fact	  that	  OCI	  may	  be	  a	  marker	  for	  an	  
underlying	  disease	  process.	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In	  this	  study,	  we	  also	  found	  that	  both	  objective	  and	  subjective	  cognitive	  impairment	  predicted	  all	  cause	  
hospitalization.	  Comparison	  with	  other	  studies	  is	  difficult,	  as	  no	  previous	  reports	  have	  examined	  the	  
association	  between	  OCI	  or	  SCI	  and	  hospitalization.	  However,	  one	  study	  found	  that	  persons	  with	  CIND	  
are	  two	  and	  a	  half	  more	  times	  likely	  to	  get	  institutionalized	  in	  nursing	  homes	  as	  compared	  to	  persons	  
with	  no	  cognitive	  impairment	  1.	  	  In	  this	  study,	  we	  were	  able	  to	  demonstrate	  an	  increased	  risk	  in	  the	  less	  
severe	  outcome	  of	  all	  cause	  hospitalization.	  	  
This	  study	  has	  several	  strengths.	  	  It	  is	  a	  large	  study	  with	  a	  long	  follow	  up	  time	  and	  complete	  
ascertainment	  of	  outcome.	  However,	  this	  study	  also	  has	  several	  limitations.	  The	  outcome	  of	  dementia	  in	  
this	  study	  should	  be	  considered	  to	  be	  hospitalization	  for	  or	  death	  due	  to	  dementia,	  as	  it	  was	  derived	  
from	  population	  based	  registers	  (NPR	  and	  CDR).	  Previous	  studies	  have	  estimated	  that	  only	  about	  half	  of	  
all	  dementia	  cases	  are	  captured	  in	  the	  registers	  since	  hospitalization	  or	  death	  due	  to	  dementia	  as	  the	  
primary	  cause	  is	  relatively	  uncommon	  (the	  specificity	  and	  positive	  predictive	  value	  of	  dementia	  
diagnoses	  are	  close	  to	  100%)	  23.	  In	  addition,	  dementia	  cases	  that	  are	  captured	  in	  the	  NPR	  are	  likely	  to	  be	  
more	  severe.	  Another	  limitation	  is	  that	  persons	  who	  had	  an	  ORD	  score	  of	  3	  in	  this	  study	  fell	  into	  the	  
following	  categories:	  (a)	  false	  positives,	  meaning	  that	  they	  were	  visited	  and	  worked	  up	  and	  it	  was	  
determined	  that	  they	  were	  not	  demented;	  (b)	  those	  who	  refused	  to	  be	  worked	  up;	  (c)	  those	  who	  were	  
deliberately	  not	  worked	  up	  because	  their	  twin	  partner	  was	  already	  dead.	  This	  introduces	  the	  possibility	  
that	  some	  of	  those	  with	  an	  ORD	  score	  of	  3	  were	  actually	  demented,	  and	  therefore	  should	  have	  been	  
excluded	  from	  the	  study.	  However,	  the	  presence	  of	  a	  dose	  response	  relationship	  between	  the	  ORD	  
score	  and	  the	  risk	  of	  dementia,	  death,	  or	  hospitalization	  suggests	  that	  the	  underlying	  findings	  are	  valid.	  
We	  also	  performed	  additional	  analyses	  limiting	  the	  cohort	  analyses	  to	  the	  persons	  in	  the	  within-­‐pair	  
analyses	  to	  ensure	  that	  the	  underlying	  findings	  are	  valid.	  	  In	  addition,	  while	  the	  use	  of	  the	  TELE	  
facilitates	  cognitive	  testing	  in	  large	  scale	  studies	  such	  as	  HARMONY,	  they	  do	  not	  allow	  for	  subtype	  
analyses	  that	  may	  be	  undertaken	  if	  neuropsychological	  test	  batteries	  were	  used	  instead.	  Unfortunately,	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we	  only	  have	  genetic	  data	  for	  those	  who	  underwent	  clinical	  workup,	  and	  therefore	  are	  unable	  to	  
directly	  examine	  the	  role	  of	  genes	  in	  this	  study.	  Lastly,	  the	  cross	  sectional	  nature	  of	  our	  cognitive	  data	  
limits	  our	  ability	  to	  disentangle	  the	  effect	  of	  cognitive	  status	  from	  that	  of	  cognitive	  decline	  in	  attempting	  
to	  look	  at	  the	  relationship	  between	  cognition	  and	  negative	  health	  outcomes.	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Table	  1:	  Demographic	  characteristics	  of	  study	  population	  stratified	  by	  ORD	  score	  









Age	  at	  screening	   Mean(SD)	   72(6)	   73(6)	   76(7)	   77(7)	   <0.001	  
Education,	  0-­‐7	   N(%)	   3176(45)	   1579(53)	   1258(66)	   605(65)	   <0.001	  
Gender,	  Male	   N(%)	   3099(44)	   1336(45)	   844(44)	   414(44)	   0.78	  
Zygosity*	   	   	   	   	   	   	  
Monozygous	   N(%)	   1684(24)	   687(23)	   435(23)	   232(25)	   0.48	  
Dizygous	   N(%)	   5246(75)	   2226(75)	   1439(75)	   675(72)	   	  
TELE	  score	   Mean(SD)	   17.0(1.2)	   15.1(0.9)	   12.5(1.5)	   11.4(2.5)	   <0.001	  
	   	   	   	   	   	   	  
*Zygosity	  is	  unknown	  for	  211	  individuals.	  ORD	  =	  Ordinal	  Score,	  TELE	  =	  Cognitive	  Screening	  Instrument
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Table	  2:	  Regression	  analyses	  predicting	  dementia.	  	  
	  	   N	  in	  group	   N=12,835	   	   	   N=12,835	   	   	   MZ	  only,	  N=3,038	   	  
	  	   (N	  with	   Cox	  regression	  with	  GEE	   Logistic	  regression	  with	  GEE	   Conditional	  logistic	  regression	  
	  	   DEM)	   HR	   95%	   CI	   OR	   95%	   CI	   N	  (DEM)	   OR	   95%	   CI	  
Cognitive	  variables	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	   	  	   	  	   	  	  
ORD	  0	  (Ref)	   7024(336)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1684(78)	   1.00	   -­‐	   -­‐	  
ORD	  1	   2959(227)	   1.54	   1.30	   1.82	   1.52	   1.27	   1.81	   687(50)	   1.07	   0.53	   2.15	  
ORD	  2	   1919(245)	   2.47	   2.08	   2.93	   2.15	   1.78	   2.59	   435(53)	   0.62	   0.22	   1.80	  
ORD	  3	   933(185)	   4.38	   3.61	   5.32	   3.36	   2.72	   4.15	   232(54)	   1.11	   0.37	   3.39	  
No	  CIND,	  No	  SCI	  (Ref)	   4392(181)	   1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1043(36)	   1.00	   -­‐	   -­‐	  
No	  CIND,	  SCI	   4742(364)	   1.73	   1.45	   2.08	   1.75	   1.45	   2.11	   1153(97)	   3.38	   1.37	   8.32	  
No	  SCI,	  CIND	   1194(98)	   2.20	   1.72	   2.82	   1.96	   1.51	   2.54	   266(25)	   2.83	   0.53	   15.09	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SCI	  and	  CIND	   1580(178)	   2.72	   2.20	   3.34	   2.61	   2.09	   3.25	   356(35)	   1.93	   0.54	   6.92	  
No	  CIND	  (Ref)	   8993(528)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   2162(129)	   1.00	   -­‐	   -­‐	  
CIND	   2915(293)	   1.86	   1.61	   2.15	   1.73	   1.48	   2.01	   657(68)	   1.03	   0.45	   2.35	  
No	  SCI	  (Ref)	   5080(241)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1193(53)	   1.00	   -­‐	   -­‐	  
SCI	   6181(525)	   1.64	   1.41	   1.92	   1.69	   1.44	   1.99	   1474(132)	   3.17	   1.22	   8.22	  
No	  DWM	  (ref)	   11908(846)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   2812(196)	   1.00	   -­‐	   -­‐	  
DWM	   173(23)	   2.49	   1.58	   3.92	   1.01	   0.61	   1.67	   48(9)	   1.32	   0.15	   11.67	  
ORD	  =	  Ordinal	  Score,	  CIND	  =	  Cognitive	  Impairment	  No	  Dementia,	  SCI	  =	  Subjective	  Cognitive	  Impairment,	  VE=	  Vascular	  event,	  MZ=	  Monozygotic	  
twins,	  GEE=	  General	  Estimating	  Equations,	  DWM	  =	  Difficulties	  with	  medication.	  	  
All	  models	  adjusted	  for	  age,	  gender,	  education	  and	  previous	  stroke.	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Table	  3:	  Cox	  regression	  analysis	  predicting	  dementia	  either	  within	  the	  first	  5	  years	  after	  screening	  or	  after	  5	  years	  
	  
Within	  5	  years	  of	  cognitive	  
screen	  
5	  years	  after	  cognitive	  
screen	  
	  	   N=12,835,	  N	  DEM=314	   N=10,664,	  N	  DEM=	  679	  
	  	   HR	  	   95%	   CI	   HR	  	   95%	   CI	  
Cognitive	  variables	   	  	   	  	   	  	   	  	   	  	   	  	  
ORD	  0	  (Ref)	  
1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	  
ORD	  1	   1.49	   1.03	   2.15	   1.56	   1.29	   1.89	  
ORD	  2	   3.60	   2.60	   4.99	   2.15	   1.74	   2.65	  
ORD	  3	   7.99	   5.71	   11.17	   3.05	   2.36	   3.96	  
	   	   	   	   	   	   	  
No	  CIND,	  No	  SCI	  (Ref)	  
1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	  
No	  CIND,	  SCI	   2.11	   1.41	   3.16	   1.66	   1.35	   2.03	  
No	  SCI,	  CIND	   3.55	   2.91	   5.74	   1.86	   1.39	   2.49	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SCI	  and	  CIND	   4.22	   2.75	   6.49	   2.35	   1.84	   3.00	  
	   	   	   	   	   	   	  
No	  CIND	  (Ref)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	  
CIND	  
2.73	   2.08	   3.56	   1.61	   1.35	   1.91	  
	  
	   	   	   	   	   	  
No	  SCI	  (Ref)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	  
SCI	  
1.52	   1.13	   2.06	   1.69	   1.41	   2.02	  
	  
	   	   	   	   	   	  
No	  DWM	  (ref)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	  
DWM	  
2.51	   1.35	   4.67	   2.36	   1.17	   4.74	  
ORD	  =	  Ordinal	  Score,	  CIND	  =	  Cognitive	  Impairment	  No	  Dementia,	  SCI	  =	  Subjective	  Cognitive	  Impairment,	  BDRS	  =	  Blessed	  Dementia	  Rating	  Scale,	  
TELE=	  Cognitive	  Screening	  Instrument,	  DEM	  =	  Dementia,	  DWM	  =	  Difficulties	  with	  medication	  
All	  models	  adjusted	  for	  age,	  gender,	  education,	  and	  previous	  stroke.	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Table	  4:	  Regression	  analyses	  predicting	  death	  
	  	   N	  in	  group	   N=12,835	   	   	   N=12,835	   	   	   MZ	  only,	  N=3,038	   	  
	  	   (N	  who	   Cox	  regression	  with	  GEE	   Logistic	  regression	  with	  GEE	   Conditional	  logistic	  regression	  
	  	   died)	   HR	   95%	   CI	   OR	   95%	   CI	   N	  (died)	   OR	   95%	   CI	  
Cognitive	  variables	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	   	  	   	  	   	  	  
ORD	  0	  (Ref)	   7024(2264)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1684(566)	   1.00	   -­‐	   -­‐	  
ORD	  1	   2959(1158)	   1.13	   1.05	   1.21	   1.12	   1.01	   1.23	   687(251)	   0.80	   0.53	   1.21	  
ORD	  2	   1919(1132)	   1.51	   1.40	   1.63	   1.82	   1.61	   2.05	   435(282)	   1.11	   0.63	   1.97	  
ORD	  3	   933(661)	   2.03	   1.84	   2.25	   2.96	   2.48	   3.53	   232(172)	   2.03	   0.84	   4.90	  
No	  CIND,	  No	  SCI	  (Ref)	   4392(1477)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1043(375)	   1.00	   -­‐	   -­‐	  
No	  CIND,	  SCI	   4742(1779)	   1.08	   1.00	   1.16	   0.98	   0.89	   1.08	   1153(434)	   0.62	   0.39	   0.96	  
No	  SCI,	  CIND	   1194(494)	   1.42	   1.28	   1.57	   1.34	   1.15	   1.56	   266(120)	   0.92	   0.48	   1.74	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SCI	  and	  CIND	   1580(731)	   1.35	   1.23	   1.48	   1.40	   1.22	   1.60	   356(160)	   0.87	   0.42	   1.79	  
No	  CIND	  (Ref)	   8993(3193)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   2162(791)	   1.00	   -­‐	   -­‐	  
CIND	   2915(1288)	   1.29	   1.20	   1.38	   1.43	   1.30	   1.57	   657(298)	   0.91	   0.57	   1.43	  
No	  SCI	  (Ref)	   5080(1786)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1193(446)	   1.00	   -­‐	   -­‐	  
SCI	   6181(2447)	   1.00	   0.94	   1.07	   1.00	   0.92	   1.10	   1474(576)	   0.68	   0.44	   1.06	  
No	  DWM	  (ref)	   11908(4495)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   2812(1077)	   1.00	   -­‐	   -­‐	  
DWM	   173(146)	   2.62	   2.18	   3.15	   5.01	   3.26	   7.71	   48(42)	   Model	  does	  not	  converge	  
ORD	  =	  Ordinal	  Score,	  CIND	  =	  Cognitive	  Impairment	  No	  Dementia,	  SCI	  =	  Subjective	  Cognitive	  Impairment,	  VE=	  Vascular	  event,	  MZ=	  Monozygotic	  
twins,	  GEE=	  General	  Estimating	  Equations,	  DWM	  =	  Difficulties	  with	  medication.	  	  
All	  models	  adjusted	  for	  age,	  gender,	  education	  and	  previous	  vascular	  event.	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Table	  5:	  Regression	  analysis	  predicting	  hospitalizations	  	  
	  	   N	  in	  group	   N=12,835	   	   	   N=12,835	   	   	   MZ	  only,	  N=3,038	   	  
	  	   (N	  who	  were	   Cox	  regression	  with	  GEE	   Logistic	  regression	  with	  GEE	   Conditional	  logistic	  regression	  
	  	   hospitalized)	   HR	   95%	   CI	   OR	   95%	   CI	   N	  (hosp)	   OR	   95%	   CI	  
Cognitive	  variables	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	   	  	   	  	   	  	  
ORD	  0	  (Ref)	   7024(5417)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1684(1291)	   1.00	   -­‐	   -­‐	  
ORD	  1	   2959(2368)	   1.05	   1.00	   1.10	   1.07	   0.96	   1.20	   687(565)	   1.02	   0.68	   1.53	  
ORD	  2	   1919(1618)	   1.16	   1.10	   1.23	   1.08	   0.94	   1.26	   435(367)	   0.88	   0.44	   1.78	  
ORD	  3	   933(781)	   1.30	   1.20	   1.42	   0.92	   0.75	   1.12	   232(193)	   1.03	   0.40	   2.63	  
No	  CIND,	  No	  SCI	  (Ref)	   4392(3335)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1043(804)	   1.00	   -­‐	   -­‐	  
No	  CIND,	  SCI	   4742(3828)	   1.11	   1.06	   1.16	   1.17	   1.05	   1.30	   1153(926)	   0.75	   0.48	   1.19	  
No	  SCI,	  CIND	   1194(943)	   1.17	   1.09	   1.26	   1.11	   0.94	   1.31	   266(215)	   0.79	   0.40	   1.58	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SCI	  and	  CIND	   1580(1309)	   1.16	   1.08	   1.23	   1.27	   1.08	   1.49	   356(293)	   1.04	   0.52	   2.05	  
No	  CIND	  (Ref)	   8993(7050)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   2162(1703)	   1.00	   -­‐	   -­‐	  
CIND	   2915(2365)	   1.10	   1.05	   1.15	   1.12	   0.99	   1.24	   657(536)	   0.89	   0.56	   1.42	  
No	  SCI	  (Ref)	   5080(3887)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1193(929)	   1.00	   -­‐	   -­‐	  
SCI	   6181(5024)	   1.09	   1.04	   1.13	   1.19	   1.08	   1.31	   1474(1191)	   0.75	   0.48	   1.19	  
No	  DWM	  (ref)	   11908(9405)	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   2812(2228)	   1.00	   -­‐	   -­‐	  
DWM	   173(150)	   1.46	   1.21	   1.77	   0.83	   0.51	   1.34	   48(42)	   0.18	   0.02	   1.75	  
	   	   	   	   	   	   	   	   	   	   	   	  
ORD	  =	  Ordinal	  Score,	  CIND	  =	  Cognitive	  Impairment	  No	  Dementia,	  SCI	  =	  Subjective	  Cognitive	  Impairment,	  VE=	  Vascular	  event,	  MZ=	  Monozygotic	  
twins,	  GEE=	  General	  Estimating	  Equations,	  DWM	  =	  Difficulties	  with	  medication.	  	  
All	  models	  adjusted	  for	  age,	  gender,	  education	  and	  previous	  vascular	  event.	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  Supplementary	  information	  on	  methodology	  
Cognitive	  assessment	  and	  definition	  of	  CIND	  and	  SCI	  
	  The	  TELE,	  a	  telephone	  based	  tool	  for	  cognitive	  screening	  [1],	  includes	  four	  cognitive	  tasks	  which	  
measure	  different	  cognitive	  areas:	  orientation,	  attention,	  episodic	  memory	  and	  reasoning.	  The	  
orientation	  task	  includes	  10	  items	  from	  the	  Mental	  Status	  Questionnaire	  (MSQ)[2]	  while	  attention	  is	  
measured	  by	  counting	  backwards	  by	  threes[3].	  Episodic	  memory	  is	  evaluated	  using	  three-­‐item	  
recall[4]	  and	  reasoning	  is	  evaluated	  with	  questions	  about	  similarities	  and	  differences	  between	  pairs	  
of	  nouns[5,	  6]	  In	  case	  of	  a	  participant’s	  failure	  to	  recall	  all	  three	  items,	  the	  participant	  was	  given	  the	  
possibility	  to	  recall	  the	  missed	  items	  with	  a	  recognition	  task,	  which	  consisted	  of	  presenting	  a	  list	  of	  
distractors	  along	  with	  the	  recall	  items	  from	  which	  a	  correct	  word	  or	  words	  were	  to	  be	  identified.	  
Participants	  could	  receive	  a	  score	  that	  ranges	  from	  0	  (worst	  performance)	  to	  19	  (best	  performance)	  
on	  the	  TELE.	  
Cognitive	  Impairment	  No	  Dementia	  (CIND)	  was	  defined	  according	  to	  current	  criteria[7]	  with	  the	  
following	  two	  criteria:	  1)	  presence	  of	  cognitive	  impairment	  defined	  as	  a	  performance	  two	  standard	  
deviations	  below	  the	  age	  and	  education	  specific	  mean	  at	  any	  of	  the	  four	  cognitive	  tasks	  of	  TELE;	  2)	  
absence	  of	  dementia	  based	  on	  clinical	  diagnosis	  following	  the	  DSM-­‐IV	  criteria.	  The	  age	  and	  education	  
specific	  means	  of	  TELE’s	  cognitive	  tasks	  were	  based	  on	  the	  average	  performance	  of	  the	  dementia-­‐
free	  population	  classified	  in	  eight	  age	  and	  education	  specific	  groups.	  	  
The	  TELE	  also	  includes	  a	  section	  on	  cognitive	  complaints,	  with	  both	  general	  questions	  such	  as	  	  “Have	  
you	  noticed	  any	  change	  in	  your	  memory	  during	  the	  last	  three	  years?”,	  as	  well	  as	  more	  specific	  
questions	  such	  as	  forgetting	  errands,	  forgetting	  people’s	  name,	  forgetting	  appointments,	  forgetting	  
known	  places,	  and	  forgetting	  words.	  	  
Subjective	  Cognitive	  Impairment	  (SCI)	  was	  defined	  as	  any	  cognitive	  change	  in	  the	  last	  three	  years	  in	  
the	  absence	  of	  dementia.	  The	  specific	  criteria	  of	  SCI	  were	  as	  follows:	  1)	  presence	  of	  subjective	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cognitive	  complaint	  as	  defined	  as	  self-­‐reported	  memory	  change	  within	  the	  last	  three	  years,	  and	  2)	  
absence	  of	  dementia	  based	  on	  clinical	  diagnosis	  following	  the	  DSM-­‐IV	  criteria.	  
The	  different	  classifications	  of	  ORD	  score,	  CIND,	  and	  SCI	  were	  not	  mutually	  exclusive.	  The	  following	  
table	  describes	  the	  overlap	  between	  the	  ORD	  scores,	  CIND,	  and	  SCI.	  CIND	  is	  derived	  from	  age	  and	  
education	  adjusted	  means,	  while	  ORD	  scores	  do	  not	  take	  age	  and	  education	  into	  account.	  	  
	   ORD	  0	   ORD	  1	   ORD	  2	   ORD	  3	   Total	  
No	  CIND,	  No	  SCI	   3380	   830	   175	   3	   4392	  
SCI,	  no	  CIND	   3392	   1068	   243	   39	   4742	  
CIND,	  no	  SCI	   107	   479	   498	   110	   1194	  
CIND	  and	  SCI	   145	   582	   641	   212	   1580	  
	  
Registry	  based	  outcome	  derivation	  
The	  Swedish	  Twin	  Registry	  is	  linked	  by	  the	  Swedish	  10-­‐digit	  personal	  identification	  number	  to	  several	  
population-­‐based	  health	  registers	  that	  may	  be	  used	  as	  sources	  of	  diagnoses	  for	  dementia	  and	  
vascular	  events.	  The	  National	  Patient	  Register	  (NPR)	  covers	  all	  hospital	  discharges	  in	  Sweden	  since	  
1987	  (with	  partial	  coverage	  since	  1964)	  and	  the	  Cause	  of	  Death	  Register	  (CDR)	  covers	  all	  deaths	  since	  
1961.	  At	  the	  time	  of	  the	  study	  the	  National	  Patient	  Register	  was	  available	  until	  the	  end	  of	  2009	  and	  
the	  Cause	  of	  Death	  Register	  was	  available	  until	  the	  end	  of	  2008.	  In	  the	  registers,	  a	  primary	  cause	  of	  
hospitalization	  or	  underlying	  cause	  of	  death	  is	  recorded	  as	  well	  as	  up	  to	  6	  contributory	  causes	  in	  the	  
NPR	  and	  up	  to	  20	  contributory	  causes	  in	  the	  CDR.	  Diagnoses	  are	  recorded	  with	  the	  Swedish	  versions	  
of	  International	  Classification	  of	  Diseases	  (ICD)	  codes.	  	  
Only	  about	  half	  of	  all	  dementia	  cases	  are	  captured	  in	  the	  registers	  since	  hospitalization	  or	  death	  due	  
to	  dementia	  as	  the	  primary	  cause	  is	  relatively	  uncommon.	  The	  specificity	  and	  positive	  predictive	  
value	  of	  dementia	  diagnoses	  are	  close	  to	  100%[8].	  Previous	  validation	  studies	  have	  shown	  capture	  is	  
much	  better	  with	  vascular	  events	  such	  as	  stroke	  and	  myocardial	  infarctions[9,	  10].	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ICD	  codes	  	  
Table	  S1	  summarizes	  the	  list	  of	  ICD	  codes	  used	  in	  this	  study.	  	  The	  ICD	  codes	  used	  are	  from	  the	  
Swedish	  version	  of	  the	  ICD.	  The	  major	  difference	  between	  the	  Swedish	  and	  the	  international	  version	  
of	  ICD	  is	  that	  in	  ICD9	  the	  last	  character	  of	  the	  code	  is	  a	  letter	  instead	  of	  a	  number.	  The	  equivalents	  
are	  as	  follows:	  0=A,	  1=B,	  2=C,	  3=D,	  4=E,	  8=W,	  9=X.	  
The	  outcome	  of	  dementia	  was	  a	  composite	  outcome,	  incorporating	  those	  with	  Alzheimer’s	  disease,	  
Vascular	  Dementia	  or	  Other	  Dementia.	  Similarly,	  the	  outcome	  of	  vascular	  event	  was	  a	  composite	  
outcome,	  incorporating	  the	  outcomes	  of	  hemorrhagic	  or	  ischemic	  stroke,	  transient	  ischemic	  attack,	  
myocardial	  infarction,	  stable	  or	  unstable	  angina,	  and	  ischemic	  heart	  disease.	  
Missing	  Education	  information	  
In	  the	  12,835	  people	  included	  in	  this	  study,	  education	  was	  missing	  for	  94	  persons	  (0.7%).	  	  To	  avoid	  
excluding	  persons	  with	  missing	  data	  on	  education	  from	  the	  multivariate	  analyses,	  number	  of	  years	  of	  
education	  was	  imputed	  by	  rounding	  down	  from	  the	  relevant	  age	  group’s	  mean.	  For	  example,	  for	  a	  
person	  aged	  84	  for	  whom	  education	  was	  unknown,	  the	  mean	  of	  the	  age	  group	  of	  80	  to	  85	  was	  
ascertained	  (8.64	  years),	  and	  the	  nearest	  0.5	  was	  then	  imputed	  (8.5	  years).	  	  
Zygosity	  
In	  this	  study,	  information	  on	  zygosity	  was	  derived	  from	  several	  sources.	  	  DNA	  information	  was	  
available	  for	  1,849	  twins	  (14.4%),	  and	  registry	  based	  records	  were	  available	  for	  a	  further	  9,864	  twins	  
(76.9%).	  	  	  Registry	  based	  records	  were	  derived	  from	  questionnaire	  and	  screening	  reponses	  to	  the	  
following	  question:	  “During	  childhood,	  were	  you	  and	  your	  twin	  partner	  as	  similar	  as	  berries	  (the	  
Swedish	  equivalent	  of	  ‘as	  alike	  as	  two	  peas	  in	  a	  pod’)	  or	  not	  more	  alike	  than	  siblings	  in	  general?”.	  For	  
the	  remaining	  1,122	  twins,	  zygosity	  was	  determined	  using	  answers	  to	  the	  same	  question	  during	  the	  
telephone	  screen.	  	  Twin	  pairs	  that	  did	  not	  agree,	  or	  where	  only	  one	  member	  of	  the	  pair	  responded	  
were	  classified	  as	  indeterminate	  (N=211,	  1.6%).	  	  Earlier	  validation	  studies	  using	  DNA	  have	  shown	  that	  
this	  question	  is	  98%	  accurate	  [11].	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Supplementary	  information	  on	  results	  
Distribution	  of	  exposures	  and	  outcomes	  in	  MZ	  twins	  
Since	  only	  pairs	  in	  which	  there	  is	  discordant	  exposure	  and	  discordant	  outcome	  information	  are	  
contributory	  in	  within-­‐pair	  analyses,	  we	  have	  listed	  the	  numbers	  of	  pairs	  discordant	  for	  outcomes	  
and	  exposures	  in	  the	  following	  table.	  
	   Discordant	   Concordant	  (exposed)	   Concordant(unexposed)	  
Exposures	   N	  pairs	   N	  pairs	   N	  pairs	  
ORD	  score	   390	   189	   412	  
CIND	   260	   56	   601	  
SCI	   316	   304	   220	  
DWM	   17	   1	   915	  
Outcomes	   	   	   	  
Dementia	   89	   10	   892	  
Death	   288	   180	   523	  
Hospitalization	   302	   606	   83	  
Vascular	  events	   277	   97	   617	  
	  
For	  the	  within	  pair	  analyses,	  these	  reduce	  to	  the	  following	  numbers	  of	  pairs	  in	  each	  analysis	  (table	  
below).	  
	   ORD	  score	   CIND	   SCI	   DWM	  
Dementia	   89	   77	   69	   76	  
Death	   288	   265	   240	   266	  
Hospitalization	   302	   283	   258	   289	  
Vascular	  events	   277	   258	   237	   259	  
	  
Vascular	  events	  
The	  results	  of	  regression	  analyses	  predicting	  vascular	  events	  is	  summarized	  in	  Table	  2.	  While	  ORD	  2	  
was	  a	  significant	  predictor	  of	  vascular	  events	  in	  Cox	  Regression	  analyses,	  there	  was	  no	  trend	  within	  
ORD	  score	  of	  increasing	  severity	  of	  impairment	  conferring	  additional	  risk	  of	  vascular	  events.	  	  We	  are	  
therefore	  unable	  to	  conclude	  if	  worse	  performance	  on	  ORD	  scale	  increases	  the	  risk	  of	  vascular	  
events.	  	  	  The	  strongest	  predictor	  of	  vascular	  events	  was	  having	  a	  prior	  vascular	  event.	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Difficulty	  with	  medication	  
Difficulty	  with	  medications	  is	  one	  of	  the	  possible	  ways	  in	  which	  persons	  with	  CIND	  may	  be	  at	  
increased	  risk	  of	  negative	  health	  outcomes.	  Therefore	  we	  examined	  the	  effect	  of	  difficulties	  with	  
medications	  on	  negative	  health	  outcomes	  in	  both	  regression	  models	  accounting	  for	  cognitive	  
impairment	  (Tables	  S3-­‐S6	  below),	  and	  in	  independent	  regression	  models	  (Tables	  2,	  4,	  and	  5	  in	  the	  
main	  paper	  and	  Table	  S2	  in	  the	  supplementary	  section).	  	  
Including	  an	  indicator	  of	  difficulties	  with	  medication	  in	  the	  models	  that	  predicted	  dementia	  (Table	  
S3)	  reduced	  the	  hazards	  ratios	  (HR)	  and	  odds	  ratios	  (OR)	  for	  the	  ORD	  score	  and	  for	  the	  combination	  
of	  SCI	  and	  CIND,	  but	  not	  for	  CIND	  or	  SCI	  scores	  (Tables	  2	  versus	  S3).	  Difficulties	  with	  medication	  no	  
longer	  predicted	  for	  incidence	  of	  dementia.	  This	  suggests	  that	  while	  difficulties	  with	  medication	  may	  
be	  one	  mechanism	  by	  which	  cognitive	  impairment	  may	  lead	  to	  dementia,	  other	  mechanisms,	  
particularly	  genetic	  and	  familial	  factors	  may	  be	  more	  important	  in	  the	  progression	  of	  CIND	  to	  
dementia.	  	  
Including	  an	  indicator	  of	  difficulties	  with	  medication	  in	  models	  predicting	  mortality	  (Table	  S4)	  
reduces	  the	  HRs	  and	  ORs	  associated	  with	  the	  ORD	  score	  (Table	  4	  versus	  S4).	  However,	  difficulties	  
with	  medication	  remain	  independently	  predictive	  of	  mortality.	  This	  suggests	  that	  while	  some	  of	  the	  
effect	  of	  CIND	  on	  mortality	  may	  be	  explained	  by	  difficulties	  with	  medication,	  difficulties	  with	  
medication	  itself	  remains	  a	  strong	  independent	  predictor	  of	  all	  cause	  mortality.	  	  
In	  regression	  models	  predicting	  hospitalization	  (Table	  S5),	  including	  an	  indicator	  of	  difficulties	  with	  
medication	  did	  not	  significantly	  change	  the	  HRs	  or	  ORs	  of	  the	  cognitive	  exposures	  (Table	  5	  versus	  S5).	  
However,	  difficulties	  with	  medication	  remained	  an	  independent	  predictor	  of	  hospitalization.	  	  	  In	  
regression	  models	  predicting	  vascular	  events	  (Table	  S6),	  including	  an	  indicator	  of	  difficulties	  with	  
medication	  did	  not	  significantly	  change	  the	  HRs	  or	  ORs	  of	  the	  cognitive	  exposures	  (Tables	  S2	  versus	  
S6).	  	  Having	  had	  a	  prior	  vascular	  event	  perfectly	  predicted	  for	  having	  a	  vascular	  event	  during	  the	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Table	  S1:	  ICD	  codes	  used	  in	  this	  study	  
	   ICD7	   ICD8	   ICD9	   ICD10	  
Dementia	   	   	   	   	  
Alzheimer’s	  Disease	   305,304	   290	   290A/B/X,	  331A	   F00,	  G30,	  F03	  
Vascular	  Dementia	   306	   293.0,	  293.1	   290E	   F01	  




Vascular	  Event	   	   	   	   	  
Hemorrhagic	  Stroke	   331	   432-­‐434	   432-­‐434	   I61	  
Ischemic	  Strokes	   332	   431	   431-­‐432	   I63	  
Transient	  Ischemic	  Attack	   333	   435	   435	   G45X,	  I66,	  G46	  
Myocardial	  Infarction	  OR	  
Unstable	  Angina	  
420	   410-­‐411	   410-­‐411	   I21,	  I22	  
Stable	  Angina	  OR	  
Ischemic	  Heart	  Disease	  
420	   412-­‐414	   412-­‐414	   I20,	  I24,	  I25	  
ICD	  =	  International	  Classification	  of	  Diseases
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  Table	  S2:	  Regression	  analysis	  predicting	  vascular	  events	  
	  	   N	  in	  group	   N=12,835	   	  	   	  	   N=12,835	   	  	   	  	   MZ	  only,	  N=3,038	   	  	  
	  	   (N	  with	  	   Cox	  regression	  with	  GEE	   Logistic	  regression	  with	  GEE	   Conditional	  logistic	  regression	  
	  	   VE)	   HR	   95%	   CI	   OR	  	   95%	   CI	   N	  (VE)	   OR	   95%	   CI	  
Cognitive	  variables	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	   	  	   	  	   	  	  
ORD	  0	  (Ref)	   7024(1832)	   1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1684(418)	   1.00	   -­‐	   	  
ORD	  1	   2959(852)	   1.06	   0.98	   1.15	  
1.04	   0.90	   1.21	   687(188)	   0.93	   0.59	   1.47	  
ORD	  2	   1919(645)	   1.16	   1.05	   1.27	  
0.99	   0.84	   1.18	   435(147)	   0.95	   0.56	   1.63	  
ORD	  3	   933(305)	   1.14	   1.00	   1.30	  
0.70	   0.57	   0.86	   232(74)	   1.53	   0.73	   3.22	  
	   	   	   	   	  
	   	   	   	   	   	   	  
No	  CIND,	  No	  SCI	  (Ref)	   4392(1141)	   1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1043(265)	   1.00	   -­‐	   	  
No	  CIND,	  SCI	   4742(1386)	   0.99	   0.92	   1.07	  
0.91	   0.79	   1.05	   1153(310)	   0.58	   0.20	   1.69	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No	  SCI,	  CIND	   1194(317)	   1.06	   0.93	   1.20	  
0.85	   0.68	   1.06	   266(73)	   1.40	   0.11	   17.26	  
SCI	  and	  CIND	   1580(479)	   0.98	   0.88	   1.09	  
0.83	   0.69	   1.01	   356(104)	   1.29	   0.28	   5.86	  
	   	   	   	   	  
	   	   	   	   	   	   	  
No	  CIND	  (Ref)	   8993(2487)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   2162(567)	   1.00	   -­‐	   	  
CIND	   2915(836)	   1.03	   0.95	   1.11	   0.91	   0.79	   1.05	   657(185)	   1.37	   0.47	   4.00	  
	   	   	   	   	   	   	   	   	   	   	   	  
No	  SCI	  (Ref)	   5080(1324)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1193(302)	   1.00	   -­‐	   	  
SCI	   6181(1825)	   0.97	   0.90	   1.04	   0.94	   0.82	   1.07	   1474(406)	   0.77	   0.26	   2.23	  
	   	   	   	   	   	   	   	   	   	   	   	  
No	  DWM	  (ref)	   11908(3319)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   2812(742)	   1.00	   -­‐	   -­‐	  
DWM	   76(173)	   1.15	   0.90	   1.48	   0.93	   0.58	   1.49	   48(20)	   1.03	   0.15	   6.85	  
Demographic	  variables	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Age	  (years)	   12835(3634)	   1.03	   1.02	   1.04	  
1.01	   1.01	   1.02	   3038(827)	   1.32	   0.33	   5.41	  
Education,	  0-­‐7	  as	  ref	   12835(3634)	   0.95	   0.89	   1.01	  
0.94	   0.83	   1.06	   3038(827)	   2.52	   0.60	   10.63	  
Gender,	  male	  as	  ref	   12835(3634)	   0.82	   0.77	   0.88	  
0.88	   0.79	   1.00	   3038(827)	   Not	  applicable	   	  
Prior	  VE,	  none	  as	  ref	   12835(3634)	   416	   271	   639	  
804	   521	   1239	   3038(827)	  
Model	  did	  not	  converge	  
ORD	  =	  Ordinal	  Score,	  CIND	  =	  Cognitive	  Impairment	  No	  Dementia,	  SCI	  =	  Subjective	  Cognitive	  Impairment,	  VE=	  Vascular	  event,	  MZ=	  Monozygotic	  twins,	  GEE=	  
General	  Estimating	  Equations,	  DWM	  =	  Difficulties	  with	  medication.	  	  
All	  models	  adjusted	  for	  age,	  gender,	  education	  and	  previous	  vascular	  event.	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  Table	  S3:	  Regression	  analyses	  predicting	  dementia	  (with	  adjustment	  for	  DWM)	  
	  	   N	  in	  group	   N=12,835	   	  	   	  	   N=12,835	   	  	   	  	   MZ	  only,	  N=3,038	   	  	  
	  	   (N	  with	  	   Cox	  regression	  with	  GEE	   Logistic	  regression	  with	  GEE	   Conditional	  logistic	  regression	  
	  	   DEM)	   HR	   95%	   CI	   OR	  	   95%	   CI	   N	  (DEM)	   OR	   95%	   CI	  
Cognitive	  variables	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	   	  	   	  	   	  	  
ORD	  0	  (Ref)	   7024(336)	   1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1684(78)	   1.00	   -­‐	   -­‐	  
ORD	  1	   2959(227)	   1.54	   1.30	   1.83	  
1.52	   1.27	   1.82	   687(50)	   0.98	   0.46	   2.11	  
ORD	  2	   1919(245)	   2.43	   2.02	   2.92	  
2.27	   1.86	   2.76	   435(53)	   0.33	   0.09	   1.28	  
ORD	  3	   933(185)	   3.67	   2.94	   4.58	  
3.30	   2.60	   4.19	   232(54)	   1.05	   0.23	   4.89	  
	   	   	   	   	  
	   	   	   	   	   	   	  
No	  CIND,	  No	  SCI	  (Ref)	   4392(181)	   1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1043(36)	   1.00	   -­‐	   -­‐	  
No	  CIND,	  SCI	   4742(364)	   1.85	   1.53	   2.24	  
1.89	   1.55	   2.29	   1153(97)	   4.35	   1.53	   12.34	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No	  SCI,	  CIND	   1194(98)	   2.34	   1.83	   3.02	  
2.16	   1.66	   2.82	   266(25)	   3.20	   0.56	   18.26	  
SCI	  and	  CIND	   1580(178)	   2.91	   2.34	   3.61	  
2.87	   2.29	   3.60	   356(35)	   2.17	   0.55	   8.47	  
	   	   	   	   	  
	   	   	   	   	   	   	  
No	  CIND	  (Ref)	   8993(528)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   2162(129)	   1.00	   -­‐	   -­‐	  
CIND	   2915(293)	   1.86	   1.60	   2.15	   1.76	   1.50	   2.05	   657(68)	   0.99	   0.39	   2.49	  
	   	   	   	   	   	   	   	   	   	   	   	  
No	  SCI	  (Ref)	   5080(241)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1193(53)	   1.00	   -­‐	   -­‐	  
SCI	   6181(525)	   1.64	   1.41	   1.92	   1.69	   1.44	   1.99	   1474(132)	   3.18	   1.22	   8.25	  
Demographic	  variables	   	  	   	  	   	  	   	  	  
	   	   	   	   	   	   	  
Age	  (years)	   12835(993)	   1.11	   1.10	   1.13	  
1.08	   1.07	   1.09	   3038(235)	   2.82	   0.32	   24.67	  
Education,	  0-­‐7	  as	  ref	   12835(993)	   1.04	   0.91	   1.19	  
1.08	   0.94	   1.25	   3038(235)	   0.66	   0.22	   2.01	  
Gender,	  male	  as	  ref	   12835(993)	   0.96	   0.83	   1.10	  
1.15	   0.99	   1.33	   3038(235)	  
Not	  applicable	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Prior	  Stroke,	  none	  as	  ref	   12835(993)	   1.91	   1.64	   2.22	  
1.84	   1.56	   2.15	   3038(235)	  
3.18	   1.25	   8.10	  
No	  DWM	  (ref)	   11908(846)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   2812(196)	   1.00	   -­‐	   -­‐	  
DWM	   173(23)	   1.59	   0.99	   2.55	   0.68	   0.41	   1.14	   48(9)	   1.31	   0.14	   12.71	  
ORD	  =	  Ordinal	  Score,	  CIND	  =	  Cognitive	  Impairment	  No	  Dementia,	  SCI	  =	  Subjective	  Cognitive	  Impairment,	  MZ=	  Monozygotic	  twins,	  GEE=	  General	  Estimating	  
Equations,	  DWM	  =	  Difficulties	  with	  medication.	  	  
All	  models	  adjusted	  for	  age,	  gender,	  education	  and	  previous	  stroke.	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  Table	  S4:	  Regression	  analyses	  predicting	  death	  (with	  adjustment	  for	  DWM)	  
	  	   N	  in	  group	   N=12,835	   	  	   	  	   N=12,835	   	  	   	  	   MZ	  only,	  N=3,038	   	  	  
	  	   (N	  who	   Cox	  regression	  with	  GEE	   Logistic	  regression	  with	  GEE	   Conditional	  logistic	  regression	  
	  	   died)	   HR	   95%	   CI	   OR	  	   95%	   CI	   N	  (died)	   OR	   95%	   CI	  
Cognitive	  variables	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	   	  	   	  	   	  	  
ORD	  0	  (Ref)	   7024(2264)	   1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1684(566)	   1.00	   -­‐	   -­‐	  
ORD	  1	   2959(1158)	   1.27	   1.04	   1.21	  
1.11	   	  1.01	   1.23	   687(251)	   0.79	   0.52	   1.21	  
ORD	  2	   1919(1132)	   1.36	   1.24	   1.48	  
1.58	   1.39	   1.80	   435(282)	   1.06	   0.56	   2.01	  
ORD	  3	   933(661)	   1.68	   1.50	   1.89	  
2.20	   1.81	   2.67	   232(172)	   1.26	   0.43	   3.69	  
	   	   	   	   	  
	   	   	   	   	   	   	  
No	  CIND,	  No	  SCI	  (Ref)	   4392(1477)	   1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1043(375)	   1.00	   -­‐	   -­‐	  
No	  CIND,	  SCI	   4742(1779)	   1.03	   0.96	   1.10	  
0.99	   0.90	   1.10	   1153(434)	   0.65	   0.41	   1.03	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No	  SCI,	  CIND	   1194(494)	   1.31	   1.17	   1.46	  
1.36	   1.17	   1.59	   266(120)	   0.94	   0.49	   1.78	  
SCI	  and	  CIND	   1580(731)	   1.26	   1.15	   1.38	  
1.43	   1.25	   1.64	   356(160)	   0.83	   0.40	   1.74	  
	   	   	   	   	  
	   	   	   	   	   	   	  
No	  CIND	  (Ref)	   8993(3193)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   2162(791)	   1.00	   -­‐	   -­‐	  
CIND	   2915(1288)	   1.26	   1.18	   1.35	   1.42	   1.28	   1.56	   657(298)	   0.99	   0.62	   1.59	  
	   	   	   	   	   	   	   	   	   	   	   	  
No	  SCI	  (Ref)	   5080(1786)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1193(446)	   1.00	   -­‐	   -­‐	  
SCI	   6181(2447)	   1.00	   0.95	   1.07	   1.00	   0.92	   1.09	   1474(576)	   0.69	   0.43	   1.04	  
Demographic	  variables	   	  	   	   	   	  
	   	   	   	   	   	   	  
Age	  (years)	   12835(5125)	   1.10	   1.09	   1.10	  
1.16	   1.15	   1.17	   3038(1271)	   2.77	   1.09	   7.08	  
Education,	  0-­‐7	  as	  ref	   12835(5125)	   0.92	   0.87	   0.98	  
0.91	   0.83	   0.99	   3038(1271)	   1.48	   0.88	   2.47	  
Gender,	  male	  as	  ref	   12835(5125)	   0.67	   0.63	   0.71	  
0.58	   0.53	   0.64	   3038(1271)	  
Not	  applicable	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Prior	  VE,	  none	  as	  ref	   12835(5125)	   1.80	   1.69	   1.91	  
2.50	   2.29	   2.72	   3038(1271)	  
2.20	   1.41	   3.42	  
No	  DWM	  (ref)	   11908(4495)	  	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   2812(1077)	   1.00	   -­‐	   -­‐	  
DWM	   173(146)	   2.19	   1.80	   2.66	   3.37	   2.18	   5.21	   48(42)	   Model	  does	  not	  converge	  
ORD	  =	  Ordinal	  Score,	  CIND	  =	  Cognitive	  Impairment	  No	  Dementia,	  SCI	  =	  Subjective	  Cognitive	  Impairment,	  VE=	  Vascular	  event,	  MZ=	  Monozygotic	  twins,	  GEE=	  
General	  Estimating	  Equations,	  DWM	  =	  Difficulties	  with	  medication.	  	  
All	  models	  adjusted	  for	  age,	  gender,	  education	  and	  previous	  vascular	  event.	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Table	  S5:	  Regression	  analyses	  predicting	  hospitalization	  (with	  adjustment	  for	  DWM)	  
	  	   N	  in	  group	   N=12,835	   	  	   	  	   N=12,835	   	  	   	  	   MZ	  only,	  N=3,038	   	  	  
	  	   (N	  who	  were	   Cox	  regression	  with	  GEE	   Logistic	  regression	  with	  GEE	   Conditional	  logistic	  regression	  
	  	   hospitalized)	   HR	   95%	   CI	   OR	  	   95%	   CI	   N	  (hosp)	   OR	   95%	   CI	  
Cognitive	  variables	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	   	  	   	  	   	  	  
ORD	  0	  (Ref)	   7024(5417)	   1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1684(1291)	   1.00	   -­‐	   -­‐	  
ORD	  1	   2959(2368)	   1.04	   0.99	   1.09	  
1.06	   0.95	   1.19	   687(565)	   1.07	   0.71	   1.62	  
ORD	  2	   1919(1618)	   1.13	   1.06	   1.21	  
1.12	   0.96	   1.32	   435(367)	   1.22	   0.57	   2.64	  
ORD	  3	   933(781)	   1.25	   1.14	   1.37	  
1.16	   0.91	   1.48	   232(193)	   1.42	   0.48	   4.22	  
	   	   	   	   	  
	   	   	   	   	   	   	  
No	  CIND,	  No	  SCI	  (Ref)	   4392(3335)	   1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1043(804)	   1.00	   -­‐	   -­‐	  
No	  CIND,	  SCI	   4742(3828)	   1.12	   1.07	   1.17	  
1.19	   1.07	   1.32	   1153(926)	   0.81	   0.51	   1.29	  
No	  SCI,	  CIND	   1194(943)	   1.17	   1.09	   1.26	  
1.15	   0.97	   1.36	   266(215)	   0.81	   0.40	   1.61	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SCI	  and	  CIND	   1580(1309)	   1.16	   1.09	   1.24	  
1.31	   1.12	   1.54	   356(293)	   1.08	   0.54	   2.15	  
	   	   	   	   	  
	   	   	   	   	   	   	  
No	  CIND	  (Ref)	   8993(7050)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   2162(1703)	   1.00	   -­‐	   -­‐	  
CIND	   2915(2365)	   1.09	   1.05	   1.15	   1.12	   1.01	   1.26	   657(536)	   1.00	   0.61	   1.63	  
	   	   	   	   	   	   	   	   	   	   	   	  
No	  SCI	  (Ref)	   5080(3887)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1193(929)	   1.00	   -­‐	   -­‐	  
SCI	   6181(5024)	   1.09	   1.04	   1.14	   1.17	   1.06	   1.29	   1474(1191)	   0.81	   0.51	   1.29	  
Demographic	  variables	   	  	   	   	   	  
	   	   	   	   	   	   	  
Age	  (years)	   12835(10184)	   1.04	   1.04	   1.04	  
1.08	   1.07	   1.09	   3038(2416)	   2.21	   0.84	   5.84	  
Education,	  0-­‐7	  as	  ref	   12835(10184)	   1.01	   0.97	   1.05	  
1.00	   0.91	   1.10	   3038(2416)	   0.95	   0.57	   1.59	  
Gender,	  male	  as	  ref	   12835(10184)	   0.90	   0.86	   0.93	  
0.92	   0.84	   1.02	   3038(2416)	  
Not	  applicable	   	  	  
Prior	  VE,	  none	  as	  ref	   12835(10184)	   2.25	   2.17	   2.35	  
5.96	   5.24	   6.78	   3038(2416)	  
5.02	   2.73	   9.22	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No	  DWM	  (ref)	   11908(9405)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   2812(2228)	   1.00	   -­‐	   -­‐	  
DWM	   173(150)	   1.36	   1.12	   1.65	   0.60	   0.36	   1.01	   48(42)	   0.35	   0.04	   2.86	  
ORD	  =	  Ordinal	  Score,	  CIND	  =	  Cognitive	  Impairment	  No	  Dementia,	  SCI	  =	  Subjective	  Cognitive	  Impairment,	  VE=	  Vascular	  event,	  MZ=	  Monozygotic	  twins,	  GEE=	  
General	  Estimating	  Equations,	  DWM	  =	  Difficulties	  with	  medication.	  	  
All	  models	  adjusted	  for	  age,	  gender,	  education	  and	  previous	  vascular	  event.	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  Table	  S6:	  Regression	  analyses	  predicting	  vascular	  events	  (with	  adjustment	  for	  DWM)	  	  
	  	   N	  in	  group	   N=12,835	   	  	   	  	   N=12,835	   	  	   	  	   MZ	  only,	  N=3,038	   	  	  
	  	   (N	  with	  	   Cox	  regression	  with	  GEE	   Logistic	  regression	  with	  GEE	   Conditional	  logistic	  regression	  
	  	   VE)	   HR	   95%	   CI	   OR	  	   95%	   CI	   N	  (VE)	   OR	   95%	   CI	  
Cognitive	  variables	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	   	  	   	  	   	  	  
ORD	  0	  (Ref)	   7024(336)	   1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1684(418)	   1.00	   -­‐	   -­‐	  
ORD	  1	   2959(227)	   1.07	   0.99	   1.16	  
1.06	   0.91	   1.23	   687(188)	   1.58	   0.59	   4.27	  
ORD	  2	   1919(245)	   1.15	   1.04	   1.27	  
1.07	   0.89	   1.30	   435(147)	   2.48	   0.77	   7.82	  
ORD	  3	   933(185)	   1.10	   0.95	   1.27	  
0.87	   0.69	   1.11	   232(74)	   1.60	   0.26	   9.99	  
	   	   	   	   	  
	   	   	   	   	   	   	  
No	  CIND,	  No	  SCI	  (Ref)	   4392(181)	   1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1043(265)	   1.00	   -­‐	   -­‐	  
No	  CIND,	  SCI	   4742(364)	   0.99	   0.92	   1.07	  
0.94	   0.81	   1.09	   1153(310)	   0.72	   0.22	   2.32	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No	  SCI,	  CIND	   1194(98)	   1.06	   0.93	   1.21	  
0.90	   0.72	   1.13	   266(73)	   1.62	   0.13	   20.18	  
SCI	  and	  CIND	   1580(178)	   0.98	   0.88	   1.09	  
0.87	   0.72	   1.06	   356(104)	   1.48	   0.32	   6.88	  
	   	   	   	   	  
	   	   	   	   	   	   	  
No	  CIND	  (Ref)	   8993(528)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   2162(567)	   1.00	   -­‐	   -­‐	  
CIND	   2915(293)	   1.02	   0.94	   1.11	   0.92	   0.79	   1.06	   657(185)	   1.55	   0.50	   4.85	  
	   	   	   	   	   	   	   	   	   	   	   	  
No	  SCI	  (Ref)	   5080(241)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   1193(302)	   1.00	   -­‐	   -­‐	  
SCI	   6181(525)	   0.97	   0.90	   1.04	   0.94	   0.82	   1.07	   1474(406)	   0.88	   0.29	   2.68	  
Demographic	  variables	   	  	   	   	   	  
	   	   	   	   	   	   	  
Age	  (years)	   12835(3634)	   1.03	   1.02	   1.04	  
1.02	   1.01	   1.03	   3038(827)	   1.37	   0.33	   5.69	  
Education,	  0-­‐7	  as	  ref	   12835(3634)	   0.96	   0.89	   1.02	  
0.97	   0.83	   1.10	   3038(827)	   2.41	   0.53	   10.97	  
Gender,	  male	  as	  ref	   12835(3634)	   0.83	   0.77	   0.88	  
0.89	   0.79	   1.01	   3038(827)	  
Not	  applicable	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Prior	  VE,	  none	  as	  ref	   12835(3634)	   Model	  did	  not	  converge	  
Model	  did	  not	  converge	   3038(827)	  
Model	  did	  not	  converge	  
No	  DWM	  (ref)	   11908(3319)	  
1.00	   -­‐	   -­‐	  
1.00	   -­‐	   -­‐	   2812(742)	   1.00	   -­‐	   -­‐	  
DWM,	  No	  DWM	  as	  ref	   76(173)	   1.12	   0.87	   1.44	   0.63	   0.43	   0.91	   48(20)	   0.32	   0.03	   3.22	  
ORD	  =	  Ordinal	  Score,	  CIND	  =	  Cognitive	  Impairment	  No	  Dementia,	  SCI	  =	  Subjective	  Cognitive	  Impairment,	  VE=	  Vascular	  event,	  MZ=	  Monozygotic	  twins,	  GEE=	  
General	  Estimating	  Equations,	  DWM	  =	  Difficulties	  with	  medication.	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BACKGROUND:	  	  Few	  studies	  have	  looked	  at	  the	  association	  between	  antidepressant	  medication	  and	  risk	  
of	  dementia,	  and	  those	  that	  do	  have	  not	  controlled	  for	  depressive	  and	  cognitive	  status.	  While	  
cardiovascular	  medications	  have	  been	  shown	  to	  protect	  against	  dementia,	  little	  is	  known	  about	  whether	  
persons	  at	  high	  risk	  are	  getting	  these	  medications	  
METHODS:	  	  Members	  of	  the	  Swedish	  Twin	  Registry	  aged	  65	  and	  above	  were	  evaluated	  for	  Cognitive	  
Impairment	  No	  Dementia	  (CIND),	  Subjective	  Cognitive	  Impairment	  (SCI),	  and	  depression.	  Information	  on	  
antidepressant	  and	  cardiovascular	  medication	  use	  was	  determined	  from	  the	  Swedish	  Prescription	  Drug	  
Register.	  	  Cox	  proportional	  hazards	  models	  were	  used	  to	  determine	  whether	  1)	  antidepressant	  and	  
cardiovascular	  medication	  use	  was	  associated	  with	  dementia,	  2)	  whether	  these	  associations	  changed	  
the	  relationship	  between	  dementia	  and	  CIND,	  SCI	  or	  depression,	  and	  3)	  whether	  individuals	  with	  CIND,	  
SCI,	  or	  depression	  received	  more	  antidepressant	  or	  cardiovascular	  medication	  than	  their	  unimpaired	  
counterparts.	  Subtypes	  of	  antidepressant	  and	  cardiovascular	  medications	  were	  also	  evaluated	  for	  their	  
association	  with	  dementia.	  
FINDINGS:	  A	  total	  of	  11,151	  non-­‐demented	  individuals	  with	  information	  on	  CIND,	  SCI	  and	  depression	  
status	  were	  identified.	  In	  this	  study,	  we	  found	  that	  antidepressant	  use,	  particularly	  the	  use	  of	  Selective	  
Serotonin	  Reuptake	  Inhibitors	  (SSRIs)	  were	  at	  doubled	  the	  risk	  of	  dementia	  regardless	  of	  depression.	  
Cardiovascular	  medications,	  particularly	  antihypertensive	  and	  lipid	  lowering	  agents	  halved	  the	  risk	  of	  
dementia.	  Neither	  antidepressant	  nor	  cardiovascular	  medication	  use	  altered	  the	  associations	  between	  
dementia	  and	  CIND	  or	  SCI.	  We	  also	  found	  that	  persons	  with	  CIND	  and	  SCI	  received	  less	  cardiovascular	  
and	  more	  antidepressant	  medications	  than	  their	  non-­‐impaired	  counterparts.	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INTERPRETATION:	  	  As	  late	  life	  onset	  of	  depression	  may	  be	  a	  prodrome	  of	  dementia	  rather	  than	  a	  risk	  
factor,	  treating	  patients	  with	  depression	  as	  a	  manifestation	  of	  prodromal	  dementia	  with	  
antidepressants,	  particularly	  with	  SSRIs,	  may	  tip	  them	  to	  manifest	  dementia	  rather	  than	  protect	  them.	  In	  
addition,	  more	  attention	  needs	  to	  be	  paid	  to	  the	  need	  for	  cardiovascular	  medication	  in	  persons	  with	  
cognitive	  impairment	  in	  order	  to	  prevent	  dementia.	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  from	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  and	  the	  





There	  has	  been	  an	  ongoing	  debate	  as	  to	  whether	  depression	  is	  a	  prodrome	  or	  a	  risk	  factor	  for	  
dementia[1].	  Recent	  evidence	  leans	  more	  towards	  depression	  being	  a	  prodromal	  symptom	  of	  dementia,	  
with	  a	  previous	  study	  from	  this	  study	  sample	  suggesting	  that	  late-­‐life	  depression	  may	  be	  a	  prodrome	  
rather	  than	  a	  risk	  factor	  for	  dementia[2].	  	  Although	  it	  has	  been	  established	  that	  depression	  is	  related	  to	  
dementia	  development,	  several	  studies	  [3,	  4]	  to	  date	  have	  shown	  that	  depression	  does	  not	  have	  a	  role	  
in	  the	  progression	  of	  Mild	  Cognitive	  Impairment	  (MCI)	  to	  dementia.	  	  However,	  while	  trials	  [5]	  have	  
estimated	  the	  efficacy	  of	  antidepressant	  therapy	  in	  ameliorating	  depressive	  symptoms	  in	  AD	  patients,	  
few	  studies	  have	  focused	  on	  the	  efficacy	  of	  antidepressant	  therapy	  in	  relieving	  in	  persons	  with	  MCI,	  
Cognitive	  Impairment	  No	  Dementia	  (CIND),	  or	  Subjective	  Cognitive	  Impairment	  (SCI).	  	  Additionally,	  while	  
studies	  of	  antidepressant	  therapy	  have	  evaluated	  efficacy	  in	  terms	  of	  ameliorating	  depressive	  
symptoms,	  only	  one	  large	  study	  has	  evaluated	  the	  outcome	  of	  dementia,	  and	  it	  did	  not	  control	  for	  
depressive	  or	  cognitive	  status	  [6].	  	  
Recently,	  there	  has	  been	  an	  evolution	  in	  the	  concepts	  behind	  dementia	  subtypes,	  with	  more	  evidence	  of	  
mixed	  pathology	  rather	  than	  ‘pure’	  AD	  or	  ‘pure’	  vascular	  dementia	  (VAD)	  in	  persons	  with	  a	  late	  life	  
onset	  of	  dementia[7].	  Several	  studies	  have	  shown	  that	  lifestyle	  factors	  such	  as	  diabetes,	  hypertension,	  
obesity,	  and	  ischemic	  heart	  disease	  increase	  the	  risk	  of	  dementia.	  Epidemiologic	  studies	  have	  also	  
shown	  that	  the	  use	  of	  cardiovascular	  medications,	  particularly	  antihypertensives	  and	  lipid	  lowering	  
agents,	  decrease	  the	  risk	  of	  dementia	  [8,	  9].	  	  
In	  this	  population	  based	  cohort	  study	  with	  10	  years	  of	  follow	  up,	  we	  had	  three	  main	  aims.	  Firstly,	  we	  
aimed	  to	  determine	  whether	  use	  of	  antidepressant	  or	  cardiovascular	  medications	  were	  associated	  with	  
dementia.	  Secondly,	  we	  aimed	  to	  evaluate	  whether	  use	  of	  antidepressant	  or	  cardiovascular	  medication	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changed	  the	  association	  between	  dementia	  and	  either	  CIND,	  SCI,	  or	  depression.	  	  Lastly,	  we	  aimed	  to	  
determine	  if	  individuals	  with	  CIND,	  SCI,	  or	  depression	  received	  more	  antidepressant	  or	  cardiovascular	  
medications	  compared	  to	  their	  unimpaired	  counterparts.	  
Methods	  
Participants	  
Participants	  in	  this	  study	  were	  part	  of	  HARMONY,	  a	  study	  which	  derived	  its	  participants	  from	  the	  
Swedish	  Twin	  Registry	  (STR)	  [10].	  The	  STR	  is	  a	  population	  based	  register	  that	  comprises	  over	  170,000	  
Swedish	  twins	  born	  since	  1886.	  	  Detailed	  methodology	  of	  HARMONY	  has	  been	  described	  elsewhere	  [11].	  
Briefly,	  all	  members	  of	  the	  STR	  aged	  65	  and	  above	  were	  screened	  for	  cognitive	  impairment	  in	  a	  2.5	  year	  
period	  beginning	  March	  1998	  (screening	  phase).	  Participants	  who	  were	  suspected	  of	  cognitive	  
impairment,	  their	  twin	  partners,	  and	  a	  subset	  of	  cognitively	  intact	  controls	  were	  invited	  for	  a	  clinical	  
phase	  in	  which	  dementia	  status	  was	  ascertained.	  	  All	  participants	  who	  were	  deemed	  to	  have	  dementia	  
or	  “questionable	  dementia”	  during	  the	  clinical	  phase	  were	  excluded	  from	  this	  study.	  All	  participants	  
provided	  informed	  consent	  and	  this	  study	  was	  approved	  by	  both	  the	  Regional	  Ethics	  Board	  in	  Stockholm	  
and	  the	  Institutional	  Review	  Board	  at	  the	  University	  of	  Southern	  California.	  
Of	  a	  total	  of	  20,269	  persons	  aged	  65	  and	  above	  in	  the	  STR,	  5,771	  could	  not	  be	  reached,	  712	  were	  
reached	  but	  could	  not	  be	  interviewed,	  30	  had	  missing	  data,	  and	  221	  were	  recently	  seen	  in	  other	  studies,	  
resulting	  in	  a	  total	  of	  13,535	  persons	  that	  were	  screened	  in	  HARMONY	  (Figure	  1).	  Of	  these	  13,535	  
persons,	  700	  persons	  had	  a	  diagnosis	  of	  dementia	  or	  questionable	  dementia	  and	  were	  therefore	  
excluded	  from	  this	  study.	  	  An	  additional	  1,674	  had	  no	  CIND	  or	  depression	  information,	  resulting	  in	  a	  final	  
study	  population	  had	  11,151	  non-­‐demented	  persons	  (mean	  ±SD	  age	  73±6;	  45%	  male;	  mean	  ±SD	  
education	  8.8±3.3	  years).	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Cognitive	  Screening	  	  
Cognitive	  Screening	  was	  performed	  over	  the	  telephone	  with	  the	  TELE	  cognitive	  screening	  instrument	  
[12,	  13].	  The	  TELE	  consists	  of	  a	  10-­‐item	  mental	  status	  questionnaire	  (MSQ),	  three	  other	  cognitive	  
domains	  (three	  word	  recall,	  three	  word	  pair	  similarities,	  counting	  backwards	  in	  threes),	  and	  questions	  
about	  health	  and	  daily	  functioning.	  The	  TELE	  also	  includes	  a	  section	  investigating	  cognitive	  complaints,	  
including	  a	  general	  question	  investigating	  subjective	  cognitive	  change	  “Have	  you	  noticed	  any	  change	  in	  
your	  memory	  during	  the	  last	  three	  years?”.	  For	  participants	  who	  were	  impaired	  on	  the	  TELE,	  an	  
informant	  was	  interviewed	  with	  the	  Blessed	  Dementia	  Rating	  Scale	  (BDRS)[14].	  	  
The	  TELE	  and	  BDRS	  were	  then	  combined	  into	  an	  ordinal	  scale	  (ORD)	  with	  scores	  ranging	  from	  0	  
(cognitively	  intact)	  to	  3	  (cognitively	  impaired).	  The	  following	  are	  examples	  of	  what	  constituted	  an	  ORD	  
score	  of	  3:	  More	  than	  3	  errors	  on	  the	  MSQ;	  functional	  impairment	  in	  activities	  of	  daily	  living	  due	  to	  
memory	  impairments;	  failed	  one	  third	  of	  the	  items	  on	  the	  TELE	  or	  impaired	  in	  2	  domains	  of	  the	  MSQ	  
with	  a	  BDRS	  of	  at	  least	  1.5.	  These	  are	  based	  on	  established	  cutoffs	  for	  functional	  impairment[14].	  	  
Clinical	  Phase	  
Individuals	  with	  an	  ORD	  score	  of	  3	  were	  referred	  for	  clinical	  workup.	  If	  the	  participant	  was	  suspected	  of	  
dementia,	  his	  or	  her	  twin	  partner	  was	  invited	  for	  clinical	  workup	  regardless	  of	  screen	  status.	  
Additionally,	  a	  sample	  of	  35	  normal	  control	  twin	  pairs	  in	  which	  both	  twin	  members	  screened	  negative	  
were	  included	  in	  the	  clinical	  phase.	  The	  clinical	  phase	  comprised	  of	  physical	  and	  neurological	  
examinations,	  neuropsychological	  evaluations	  including	  screening	  for	  depression,	  biochemical	  
evaluations,	  as	  well	  as	  referrals	  for	  neuroimaging.	  Clinical	  diagnoses	  of	  dementia	  were	  made	  in	  
consensus	  conferences	  based	  on	  the	  above	  information	  in	  accordance	  to	  the	  DSM-­‐IV	  criteria[15].	  An	  
additional	  category	  of	  “questionable	  dementia”	  was	  added	  for	  individuals	  who	  did	  not	  fulfill	  one	  of	  the	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three	  DSM-­‐	  IV	  diagnostic	  criteria,	  but	  did	  exhibit	  at	  least	  two	  of	  the	  criteria:	  memory	  problems,	  
problems	  in	  another	  area	  of	  cognition,	  or	  functional	  impairments.	  	  
Cognitive	  and	  Depressive	  Status	  
Participants	  were	  classified	  as	  having	  CIND	  if	  they	  performed	  two	  standard	  deviations	  below	  the	  age	  and	  
education	  adjusted	  means	  in	  any	  of	  the	  four	  cognitive	  tasks	  in	  the	  TELE	  but	  did	  not	  fulfill	  the	  criteria	  for	  
dementia.	  Participants	  were	  classified	  as	  having	  SCI	  if	  they	  responded	  positively	  to	  the	  following	  
question	  “Have	  you	  noticed	  any	  change	  in	  your	  memory	  during	  the	  last	  three	  years?”	  	  Participants	  were	  
classified	  as	  having	  had	  depression	  if	  they	  fulfilled	  four	  or	  more	  criteria	  on	  the	  International	  Diagnostic	  
Interview	  Short	  Form	  (CIDI-­‐SF)	  adapted	  to	  asses	  lifetime	  major	  depression[16,	  17],	  or	  had	  score	  of	  eight	  
points	  or	  above	  on	  the	  eleven	  item	  version	  of	  the	  Center	  for	  Epidemiologic	  Studies	  Depression	  (CES-­‐D)	  
scale[18].	  
Medication	  Exposure	  
Information	  about	  medication	  use	  was	  derived	  from	  the	  Swedish	  Prescribed	  Drug	  Register	  (PDR),	  which	  
contains	  individual-­‐based	  data	  for	  all	  prescriptions	  dispensed	  to	  the	  whole	  population	  of	  Sweden	  (about	  
9	  million	  inhabitants)[19].	  We	  used	  information	  on	  medication	  use	  from	  the	  when	  the	  registry	  started	  
on	  July	  1st	  2005	  to	  July	  1st	  2009.	  In	  the	  registry,	  medications	  are	  categorized	  by	  the	  Anatomical	  
Therapeutic	  Chemical	  (ATC)	  Classification	  system,	  as	  recommended	  by	  the	  World	  Health	  
Organization[20].	  Antidepressants	  were	  identified	  by	  the	  ATC	  code	  N06A,	  and	  two	  different	  subtypes,	  
tricyclic	  antidepressants	  (TCAs)	  with	  the	  ATC	  code	  N06AA,	  and	  Selective	  Serotonin	  Reuptake	  Inhibitors	  
(SSRIs)	  with	  the	  ATC	  code	  N06AB	  were	  identified.	  Cardiovascular	  mediations	  were	  identified	  by	  the	  
following	  ATC	  codes:	  C01AA	  (digitalis),	  C03A	  (thiazide	  diuretics),	  C03C	  (loop	  diuretics),	  C03D	  (potassium	  
sparring	  diuretics),	  C07A	  (beta	  blockers),	  C08	  (calcium	  channel	  blockers),	  C09A	  (ACE	  inhibitors),	  C09C	  
(angiotensin	  II	  inhibitors),	  and	  C10A	  (lipid	  lowering	  agents).	  	  For	  subtypes	  of	  cardiovascular	  medication,	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we	  combined	  all	  the	  antihypertensives	  into	  one	  subtype	  (thiazide,	  loop,	  and	  potassium	  sparring	  
diuretics,	  calcium	  channel	  blockers,	  ACE	  inhibitors,	  and	  angiotensin	  II	  antagonists),	  and	  considered	  
digitalis,	  beta	  blockers,	  and	  lipid	  lowering	  agents	  as	  separate	  subtypes.	  Medication	  use	  was	  stratified	  
into	  intervals	  of	  6	  months	  corresponding	  to	  the	  1st	  and	  2nd	  halves	  of	  each	  calendar	  year.	  	  	  
Determination	  of	  outcomes	  
In	  this	  study,	  the	  primary	  outcome,	  dementia,	  was	  derived	  from	  both	  the	  National	  Patient	  Register	  
(NPR)[21]	  and	  the	  Cause	  of	  Death	  Register	  (CDR)	  [22].	  The	  NPR	  is	  a	  national	  register	  that	  records	  the	  
relevant	  International	  Classification	  of	  Diseases	  (ICD)	  codes	  for	  all	  inpatient	  (overnight)	  admissions	  at	  all	  
hospitals	  in	  Sweden.	  	  Information	  in	  the	  NPR	  was	  available	  until	  the	  end	  of	  2009,	  while	  information	  in	  
the	  CDR	  was	  available	  until	  the	  end	  of	  2008.	  However,	  updated	  date	  of	  death	  information	  was	  available	  
monthly	  through	  linkage	  of	  STR	  to	  the	  National	  Population	  Register,	  thereby	  allowing	  all	  study	  
participants	  to	  be	  censored	  until	  the	  end	  of	  follow	  up	  (July	  1st	  2009).	  The	  ICD	  codes	  used	  to	  define	  
dementia	  were	  as	  follows:	  codes	  304-­‐306	  in	  ICD	  7,	  codes	  290,	  293.0/.1	  in	  ICD	  8,	  codes	  290	  A/B/E/X/W,	  
294B,	  331A/B/C/X	  in	  ICD	  9,	  and	  codes	  F00-­‐F03,	  F051,	  G30,	  G311,	  and	  G318A	  in	  ICD	  10.	  	  
Covariates	  
As	  prior	  stroke	  is	  a	  risk	  factor	  for	  dementia,	  we	  used	  the	  NPR	  to	  identify	  whether	  study	  participants	  had	  
a	  previous	  admission	  for	  hemorrhagic	  or	  ischemic	  stroke.	  Demographic	  information	  such	  as	  age,	  gender,	  
and	  education	  were	  collected	  at	  baseline	  as	  part	  of	  the	  study.	  Education	  was	  dichotomized	  into	  0-­‐7	  
years	  of	  education	  versus	  more	  than	  7	  years	  of	  education.	  
Statistical	  Analysis	  
Univariate	  and	  multivariable	  Cox	  proportional	  hazards	  models	  were	  used	  to	  determine	  the	  time	  to	  
dementia.	  All	  multivariable	  models	  were	  adjusted	  for	  age	  at	  baseline,	  gender,	  education,	  and	  previous	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stroke.	  	  Information	  on	  medication	  use	  was	  treated	  as	  time	  varying	  exposure.	  In	  both	  the	  general	  and	  
subtype	  analyses,	  medication	  use	  was	  considered	  a	  dichotomous	  exposure	  (yes/no).	  As	  the	  study	  
sample	  consists	  of	  twins,	  General	  Estimating	  Equations	  (GEE)	  was	  used	  to	  control	  for	  relatedness.	  Since	  
the	  PDR	  began	  several	  years	  after	  the	  baseline	  evaluation,	  information	  on	  medication	  use	  is	  only	  
available	  on	  a	  subset	  of	  the	  total	  population.	  Therefore	  we	  present	  the	  analyses	  both	  as	  a	  whole	  cohort,	  
and	  to	  a	  limited	  subset	  to	  of	  those	  alive	  and	  non-­‐demented	  at	  the	  start	  of	  the	  PDR	  (July	  1st	  2005).	  All	  
participants	  are	  considered	  unexposed	  before	  the	  start	  of	  the	  PDR.	  	  
While	  means	  and	  standard	  errors	  are	  presented	  in	  Figure	  2a-­‐f,	  the	  Mann	  Whitney	  U	  test	  was	  used	  to	  
compare	  the	  number	  of	  prescriptions	  for	  antidepressant	  or	  cardiovascular	  medications	  by	  CIND,	  SCI,	  or	  
depressive	  status.	  Analyses	  were	  performed	  on	  Stata	  version	  11.0[23],	  and	  significance	  was	  determined	  
with	  a	  two-­‐tailed	  alpha	  of	  0.05.	  	  
Results	  
Of	  the	  11,151	  persons	  in	  this	  study,	  9,112(81%)	  participants	  were	  alive	  and	  non-­‐demented	  at	  the	  start	  of	  
the	  PDR.	  Of	  the	  2,039	  who	  were	  not	  included	  in	  the	  subset	  analyses,	  1898	  died	  and	  141	  were	  alive	  but	  
demented.	  Participants	  who	  died	  during	  the	  study	  period	  were	  more	  likely	  to	  be	  older,	  male,	  less	  
educated,	  have	  had	  a	  prior	  stroke,	  CIND,	  SCI,	  or	  depression	  at	  baseline	  (Table	  1).	  	  Participants	  who	  
developed	  dementia	  after	  the	  start	  of	  the	  NPR	  were	  more	  likely	  to	  be	  older,	  female,	  less	  educated,	  to	  
have	  had	  a	  prior	  stoke,	  CIND,	  SCI,	  or	  depression,	  at	  baseline	  (Table	  1).	  
Antidepressants	  and	  dementia	  
In	  both	  whole	  cohort	  analyses,	  and	  analyses	  restricted	  to	  those	  alive	  and	  non-­‐demented	  at	  the	  start	  of	  
the	  PDR,	  antidepressant	  medication	  use	  doubled	  the	  risk	  of	  dementia	  (Table	  2).	  	  In	  both	  whole	  cohort	  
130
analyses,	  and	  subset	  analyses,	  SSRIs	  more	  than	  doubled	  the	  risk	  of	  dementia	  while	  TCAs	  were	  not	  
associated	  with	  dementia	  (Table	  3).	  	  
In	  both	  univariate	  and	  multivariable	  models,	  CIND	  and	  SCI	  were	  significant	  predictors	  of	  dementia.	  
Antidepressant	  medication	  did	  not	  modify	  the	  association	  between	  dementia	  and	  CIND	  (HR	  1.87	  to	  HR	  
1.57)	  or	  SCI	  (HR	  1.63	  to	  HR	  1.58).	  However,	  depression	  was	  a	  significant	  predictor	  of	  dementia	  in	  
univariate	  models	  and	  multivariable	  models	  that	  did	  not	  control	  for	  medication	  use,	  but	  was	  no	  longer	  
significantly	  associated	  with	  dementia	  when	  controlling	  for	  antidepressant	  use	  (HR	  1.24	  to	  HR	  1.12).	  	  	  
Cardiovascular	  medications	  and	  dementia	  
In	  both	  whole	  cohort	  analyses,	  and	  analyses	  restricted	  to	  those	  alive	  and	  non-­‐demented	  at	  the	  start	  of	  
the	  PDR,	  cardiovascular	  medication	  use	  approximately	  halved	  the	  risk	  of	  dementia	  (Table	  2).	  	  In	  both	  
whole	  cohort	  analyses,	  and	  subset	  analyses,	  antihypertensive	  medication	  use	  reduced	  the	  risk	  of	  
dementia	  by	  approximately	  30%,	  lipid	  lowering	  agents	  reduced	  the	  risk	  of	  dementia	  by	  approximately	  
50%.	  Beta	  blockers	  and	  digitalis	  were	  not	  associated	  with	  dementia	  (Table	  3).	  Cardiovascular	  medication	  
did	  not	  modify	  the	  association	  between	  dementia	  and	  either	  CIND	  (HR	  1.87	  to	  HR	  1.57)	  or	  SCI	  (HR	  1.63	  
to	  HR	  1.60).	  However,	  depression	  was	  a	  significant	  predictor	  of	  dementia	  in	  univariate	  models	  and	  
multivariable	  models	  that	  did	  not	  control	  for	  medication	  use,	  but	  was	  no	  longer	  significantly	  associated	  
with	  dementia	  when	  controlling	  for	  cardiovascular	  medication	  use	  (HR	  1.24	  to	  HR	  1.16).	  	  	  
Medication	  use	  by	  cognitive	  or	  depressive	  status	  
Figures	  2a,	  2b,	  and	  2c	  summarize	  the	  mean	  and	  standard	  errors	  of	  antidepressant	  medications	  that	  
were	  dispensed	  to	  participants	  with	  CIND,	  SCI,	  or	  depression	  at	  baseline.	  Persons	  with	  CIND	  (p=0.03),	  
SCI	  (p<0.0001),	  and	  depression	  (p<0.0001)	  received	  more	  antidepressants	  than	  their	  non-­‐impaired	  
counterparts.	  Figures	  2d,	  2e,	  and	  2f	  summarize	  the	  mean	  and	  standard	  errors	  of	  cardiovascular	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medications	  that	  were	  dispensed	  to	  persons	  with	  CIND,	  SCI,	  or	  depression	  at	  baseline.	  Participants	  with	  
CIND	  (p=0.0007)	  and	  SCI	  (p=0.03)	  at	  baseline	  received	  significantly	  less	  cardiovascular	  medications	  than	  
their	  non-­‐impaired	  counterparts.	  However,	  there	  was	  no	  difference	  in	  the	  number	  of	  prescriptions	  of	  
cardiovascular	  medication	  between	  those	  with	  and	  without	  depression	  at	  baseline	  (p=0.84)	  	  
Discussion	  
In	  this	  study,	  we	  found	  that	  antidepressant	  medication,	  particularly	  SSRIs,	  doubled	  the	  risk	  of	  dementia.	  
Conversely,	  we	  were	  able	  to	  demonstrate	  that	  the	  use	  of	  cardiovascular	  medications,	  particularly	  
antihypertensives	  and	  lipid	  lowering	  agents,	  halved	  the	  risk	  of	  dementia.	  We	  also	  found	  that	  medication	  
use	  did	  not	  alter	  the	  association	  between	  dementia	  and	  CIND	  or	  SCI,	  but	  that	  depression	  was	  no	  longer	  
a	  significant	  predictor	  of	  dementia	  after	  adjustment	  for	  medication	  use.	  Another	  finding	  was	  that	  
persons	  with	  CIND	  and	  SCI	  received	  more	  prescriptions	  for	  antidepressants	  and	  less	  cardiovascular	  
medications	  than	  their	  non-­‐impaired	  counterparts.	  	  
Our	  finding	  that	  SSRIs	  doubled	  the	  risk	  of	  dementia	  agrees	  with	  the	  only	  large	  population-­‐based	  study	  
that	  has	  evaluated	  the	  effect	  of	  antidepressant	  medication	  on	  dementia	  [6].	  	  Using	  prescription	  
information	  from	  the	  Danish	  registry,	  they	  showed	  that	  compared	  to	  persons	  with	  only	  one	  prescription	  
of	  antidepressant	  medication,	  persons	  with	  no	  prescriptions	  had	  30%	  of	  the	  risk	  of	  dementia,	  and	  that	  
those	  with	  more	  than	  one	  prescription	  had	  an	  increased	  risk	  of	  dementia.	  However,	  as	  their	  study	  was	  
entirely	  registry	  based,	  they	  were	  not	  able	  to	  correct	  for	  cognitive	  or	  depressive	  status	  in	  their	  analyses	  
as	  we	  do	  in	  the	  current	  study.	  
While	  antidepressant	  treatment	  has	  been	  shown	  to	  have	  a	  strong	  effect	  on	  severely	  depressed	  patients,	  
recent	  meta-­‐analyses	  indicate	  that	  there	  is	  a	  slight	  or	  negligible	  effect	  on	  persons	  with	  mild	  to	  moderate	  
depression[24].	  	  In	  light	  of	  these	  findings,	  and	  in	  light	  of	  the	  fact	  that	  late-­‐onset	  depression	  may	  be	  a	  
prodrome	  of	  dementia	  rather	  than	  a	  risk	  factor,	  one	  wonders	  whether	  the	  late-­‐onset	  depression	  should	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be	  treated	  at	  all.	  While	  they	  may	  alleviate	  depressive	  symptoms,	  antidepressant	  use	  may	  tip	  an	  elderly	  
person	  at	  high	  risk	  to	  manifest	  dementia.	  	  	  
A	  recent	  editorial[25]	  has	  put	  forth	  four	  different	  neurobiological	  hypotheses	  pertaining	  to	  the	  
association	  between	  depression	  and	  dementia.	  The	  first	  hypothesis	  is	  that	  depression	  directly	  causes	  
dementia	  via	  either	  excessive	  glucocorticoid	  secretion	  or	  via	  the	  vascular	  depression	  hypothesis[26].	  If	  
this	  hypothesis	  was	  true,	  then	  antidepressant	  medication	  should	  prevent	  dementia	  rather	  than	  
increasing	  it	  as	  seen	  in	  this	  study.	  The	  second	  hypothesis,	  the	  “reverse	  causality”	  hypothesis,	  states	  that	  
depression	  is	  an	  emotional	  response	  to	  an	  evolving	  cognitive	  impairment.	  However,	  this	  hypothesis	  has	  
also	  been	  refuted	  by	  a	  study	  that	  is	  able	  to	  demonstrate	  that	  depressive	  symptoms	  show	  little	  change	  
during	  the	  development	  and	  progression	  of	  AD	  [4].	  	  
The	  third	  hypothesis	  is	  that	  the	  same	  neurodegenerative	  process	  that	  causes	  the	  cognitive	  impairments	  
also	  causes	  the	  depressive	  symptoms.	  On	  a	  neuronal	  level,	  cognitive	  impairments	  have	  been	  shown	  to	  
correspond	  to	  dysfunction	  of	  both	  cholinergic	  and	  serotonergic	  neurons	  while	  depressive	  symptoms	  
have	  been	  linked	  to	  the	  dysfunction	  of	  serotonergic	  neurons	  [27,	  28].	  If	  serotonergic	  neurons	  were	  
dysfunctional,	  treatment	  with	  SSRIs	  may	  initially	  improve	  cognitive	  status	  and	  mood.	  However,	  
eventually,	  this	  will	  lead	  to	  the	  down	  regulation	  of	  postsynaptic	  serotonergic	  receptors	  and	  the	  down	  
regulation	  of	  serotonin	  secretion	  in	  the	  presynaptic	  cell	  [29].	  	  These	  down	  regulations	  may	  result	  in	  a	  
deterioration	  of	  the	  cognitive	  function	  that	  may	  be	  attributable	  to	  serotonergic	  neuronal	  activity.	  
Therefore,	  in	  addition	  to	  the	  preexisting	  cholinergic	  and	  serotonergic	  dysfunctions,	  SSRIs	  may	  
exacerbate	  the	  serotonergic	  dysfunction,	  tipping	  a	  person	  to	  manifest	  dementia.	  	  
The	  last	  hypothesis	  involves	  a	  synergistic	  interaction	  between	  depression	  and	  cognitive	  impairment	  for	  
the	  development	  of	  dementia.	  However,	  several	  studies	  [3,	  4]	  have	  already	  shown	  that	  depression	  does	  
not	  modify	  the	  progression	  of	  MCI	  to	  dementia.	  Based	  on	  existing	  literature	  and	  the	  results	  of	  this	  study,	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we	  agree	  with	  the	  third	  hypothesis	  that	  the	  same	  neurodegenerative	  process	  that	  contributes	  to	  the	  
development	  of	  cognitive	  impairment	  contributes	  to	  the	  development	  of	  depression.	  	  Therefore,	  we	  
propose	  that	  elderly	  persons	  with	  depression	  be	  treated	  with	  antidepressants	  only	  if	  symptoms	  are	  
severe.	  	  
Our	  results	  that	  persons	  with	  CIND,	  SCI	  and	  depression	  receive	  more	  antidepressants	  than	  their	  
unimpaired	  counterparts	  are	  cause	  for	  worry.	  These	  results,	  taken	  together	  with	  the	  results	  that	  
antidepressant	  medications	  increase	  the	  risk	  of	  dementia,	  suggest	  that	  the	  persons	  at	  an	  already	  high	  
risk	  of	  dementia	  are	  being	  exposed	  to	  medication	  that	  may	  hasten	  their	  conversion	  to	  dementia.	  	  
Our	  results	  that	  cardiovascular	  medications,	  particularly	  antihypertensives	  and	  lipid	  lowering	  agents,	  
reduce	  the	  risk	  of	  dementia	  confirm	  the	  results	  of	  previous	  studies	  on	  the	  same	  subject	  [8,	  9].	  However,	  
the	  fact	  that	  persons	  with	  CIND	  and	  SCI	  receive	  less	  of	  these	  medications	  than	  their	  unimpaired	  
counterparts	  is	  further	  cause	  for	  worry.	  Persons	  with	  cognitive	  impairment	  may	  not	  be	  as	  attentive	  or	  
vocal	  in	  their	  interactions	  with	  their	  physicians,	  and	  these	  results	  suggest	  that	  physicians	  may	  need	  to	  
pay	  closer	  attention	  to	  the	  overall	  medication	  regimens	  that	  their	  cognitively	  impaired	  patients	  are	  on.	  	  
This	  study	  has	  several	  strengths.	  	  It	  is	  a	  large	  population-­‐based	  study	  with	  a	  10	  years	  of	  follow	  up	  time	  
and	  complete	  ascertainment	  of	  outcome	  and	  medication	  exposure.	  	  In	  addition,	  it	  is	  the	  first	  study	  that	  
is	  able	  to	  look	  at	  the	  associations	  between	  antidepressant	  use	  and	  development	  of	  dementia	  while	  
controlling	  for	  cognitive	  and	  depressive	  symptoms.	  	  
However,	  this	  study	  also	  has	  several	  limitations.	  The	  outcome	  of	  dementia	  in	  this	  study	  should	  be	  
considered	  to	  be	  hospitalization	  for	  or	  death	  due	  to	  dementia,	  as	  it	  was	  derived	  from	  population	  based	  
registers	  (NPR	  and	  CDR).	  Previous	  studies	  have	  estimated	  that	  only	  about	  half	  of	  all	  dementia	  cases	  are	  
captured	  in	  the	  registers	  since	  hospitalization	  or	  death	  due	  to	  dementia	  as	  the	  primary	  cause	  is	  
relatively	  uncommon	  (the	  specificity	  and	  positive	  predictive	  value	  of	  dementia	  diagnoses	  are	  close	  to	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100%)	  [30].	  In	  addition,	  dementia	  cases	  that	  are	  captured	  in	  the	  NPR	  are	  likely	  to	  be	  more	  severe.	  The	  
cross	  sectional	  nature	  of	  our	  cognitive	  and	  depression	  data	  limits	  our	  ability	  to	  disentangle	  the	  effects	  of	  
the	  temporal	  evolutions	  of	  depression	  and	  cognitive	  impairment	  in	  this	  study.	  The	  large	  gap	  in	  time	  
between	  the	  evaluation	  of	  the	  cognitive	  and	  depressive	  symptoms	  and	  the	  beginning	  of	  the	  PDR	  may	  
introduce	  biases	  in	  the	  dataset	  as	  persons	  may	  have	  evolved	  in	  both	  depressive	  and	  cognitive	  status.	  
However,	  we	  were	  able	  to	  see	  strong	  associations	  between	  medication	  use	  in	  both	  whole	  cohort	  and	  
the	  restricted	  analyses	  and	  therefore	  do	  not	  believe	  that	  these	  results	  are	  an	  artifact.	  	  Another	  limitation	  
is	  that	  while	  we	  are	  able	  to	  ascertain	  who	  purchased	  the	  antidepressant	  and	  cardiovascular	  medication,	  
we	  are	  unable	  to	  determine	  whether	  these	  medications	  are	  actually	  consumed.	  	  	  Duration	  of	  treatment	  
and	  the	  dose	  of	  medication	  could	  also	  not	  be	  controlled	  for	  in	  both	  cardiovascular	  and	  antidepressant	  
medication.	  	  	  
In	  conclusion,	  we	  were	  able	  to	  show	  that	  antidepressant	  use,	  particularly	  SSRIs,	  increase	  the	  risk	  of	  
dementia	  even	  when	  controlling	  for	  depression.	  	  Persons	  with	  CIND,	  SCI,	  and	  depression	  receive	  more	  
antidepressants	  than	  their	  unimpaired	  counterparts.	  Additionally,	  cardiovascular	  medications	  halve	  the	  
risk	  of	  dementia,	  which	  is	  important	  because	  persons	  with	  CIND	  and	  SCI	  receive	  less	  cardiovascular	  
medications	  than	  their	  unimpaired	  counterparts.	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Table	  1:	  Demographic	  characteristics	  of	  study	  population	  stratified	  by	  dementia	  status	  
	  	   	  	  





study	  end	  or	  death	  
before	  dementia	  
	   	   N=2039	   N=474	   N=8638	  
Age	   mean(SD)	   77(7)	   76(6)	   72(5)	  
Males	   N(%)	   1095(54)	   187(40)	   3701(43)	  
Education	  (0-­‐7)	   N(%)	   1139(56)	   246(52)	   4192(49)	  
Prior	  Stroke	   N(%)	   494(24)	   138(29)	   1274(15)	  
CIND	   N(%)	   623(31)	   149(31)	   1931(22)	  
SCI	   N(%)	   1173(58)	   325(69)	   4628(54)	  
Depression	   N(%)	   461(23)	   99(21)	   1675(19)	  
CIND	  =	  Cognitive	  impairment	  no	  dementia,	  SCI	  =	  subjective	  cognitive	  impairment,	  SD	  =	  Standard	  Deviation
Table	  2:	  Results	  of	  Cox	  regression	  analyses	  predicting	  for	  dementia	  
	  	   	  	   Univariate	   Multivariable	   Multivariable	   Multivariable	  
	   	  	   	   No	  medication	   DEP	  medication	   CVD	  medication	  
	  	   	  	   HR	   95%	   CI	   HR	   95%	   CI	   HR	   95%	   CI	   HR	   95%	   CI	  
Whole	  cohort	  analysis	  	   	   	   	   	   	   	   	   	   	   	   	   	   	  
DEP	  medication	  -­‐-­‐	  None	   	   1.00	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
DEP	  medication	  -­‐-­‐	  Any	   	   1.89	   (1.39	   2.57)	   -­‐	   -­‐	   -­‐	   2.00	   (1.45	   2.73)	   -­‐	   -­‐	   -­‐	  
CVD	  medication	  -­‐-­‐	  None	   	   1.00	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	  
CVD	  medication	  -­‐-­‐	  Any	   	   0.53	   (0.43	   0.66)	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   0.56	   (0.45	   0.70)	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	  
CIND	   	   1.89	   (1.62	   2.19)	   1.84	   (1.58	   2.14)	   1.54	   (1.25	   1.89)	   1.54	   (1.25	   1.89)	  
SCI	   	   1.84	   (1.58	   2.15)	   1.59	   (1.36	   1.86)	   1.55	   (1.27	   1.91)	   1.57	   (1.25	   1.89)	  
No	  depression	   	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	  
Depression	  before	  age	  65	   	   0.86	   (0.62	   1.21)	   1.22	   (0.86	   1.73)	   0.89	   (0.56	   1.43)	   0.94	   (0.59	   1.50)	  
Depression	  after	  age	  65	   	   1.30	   (1.09	   1.57)	   1.11	   (0.91	   1.35)	   1.04	   (0.80	   1.35)	   1.06	   (0.82	   1.38)	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Those	  alive	  at	  July	  1st	  2005	   	   	   	   	   	   	   	   	   	   	   	   	   	  
DEP	  medication	  -­‐-­‐	  None	   	   1.00	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
DEP	  medication	  -­‐-­‐	  Any	   	   1.89	   (1.39	   2.57)	   -­‐	   -­‐	   -­‐	   1.99	   (1.45	   2.73)	   -­‐	   -­‐	   -­‐	  
CVD	  medication	  -­‐-­‐	  None	   	   1.00	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	  
CVD	  medication	  -­‐-­‐	  Any	   	   0.53	   (0.43	   0.66)	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   0.56	   (0.45	   0.70)	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	  
CIND	   	   1.61	   (1.32	   1.95)	   1.84	   (1.58	   2.14)	   1.54	   (1.25	   1.89)	   1.54	   (1.25	   1.89)	  
SCI	   	   1.87	   (1.55	   2.28)	   1.59	   (1.36	   1.86)	   1.55	   (1.27	   1.91)	   1.57	   (1.28	   1.93)	  
No	  depression	   	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	   1.00	   -­‐	   -­‐	  
Depression	  before	  age	  65	   	   0.72	   (0.45	   1.14)	   1.22	   (0.86	   1.73)	   0.89	   (0.56	   1.43)	   0.94	   (0.59	   1.50)	  
Depression	  after	  age	  65	   	   1.21	   (0.95	   1.53)	   1.11	   (0.91	   1.35)	   1.04	   (0.80	   1.35)	   1.06	   (0.82	   1.38)	  
Multivariable	  models	  control	  for	  age,	  education,	  gender,	  previous	  stroke	  
CIND	  =	  Cognitive	  Impairment	  No	  Dementia,	  SCI	  =	  Subjective	  Cognitive	  Impairment,	  CVD	  =	  Cardiovascular	  Medication,	  DEP	  =	  Depression,	  
HR=Hazards	  Ratio,	  CI=	  Confidence	  Interval
Table	  3:	  Results	  of	  Cox	  regression	  subtype	  analyses	  predicting	  dementia	  
	  	   	  	   Multivariable	   Multivariable	   Multivariable	  
Exposure	  in	  the	  model	   CIND	   SCI	   Depression	  
	  	   	  	   HR	   95%	   CI	   HR	   95%	   CI	   HR	   95%	   CI	  
Whole	  cohort	  analysis	  	   	   	   	   	   	   	   	   	   	  
SSRIs	   2.23	   (1.55	   3.21)	   2.17	   (1.51	   3.12)	   2.23	   (1.55	   3.17)	  
Tricyclic	  Antidepressants	   0.35	   (0.05	   2.46)	   0.35	   (0.05	   2.48)	   0.34	   (0.05	   2.39)	  
	   	   	   	   	   	   	   	   	   	  
Antihypertensives	   0.68	   (0.51	   0.89)	   0.68	   (0.51	   0.89)	   0.68	   (0.51	   0.89)	  
Beta	  Blockers	   	   0.69	   (0.45	   1.06)	   0.69	   (0.45	   1.06)	   0.69	   (0.45	   1.06)	  
Digitalis	   	   1.71	   (0.54	   5.43)	   1.73	   (0.54	   5.49)	   1.71	   (0.54	   5.45)	  
Lipid	  Lowering	  Agents	   0.48	   (0.31	   0.73)	   0.48	   (0.31	   0.73)	   0.48	   (0.31	   0.73)	  
	   	   	   	   	   	   	   	   	   	   	  
Those	  alive	  at	  July	  1st	  2005	   	   	   	   	   	   	   	   	   	  
SSRIs	   2.23	   (1.55	   3.21)	   2.17	   (1.51	   3.12)	   2.23	   (1.55	   3.19)	  
Tricyclic	  Antidepressants	   0.35	   (0.05	   2.46)	   0.35	   (0.05	   2.48)	   0.34	   (0.05	   2.39)	  
	   	   	   	   	   	   	   	   	   	  
Antihypertensives	   0.68	   (0.51	   0.89)	   0.68	   (0.51	   0.89)	   0.68	   (0.51	   0.89)	  
Beta	  Blockers	   	   0.69	   (0.45	   1.06)	   0.69	   (0.45	   1.06)	   0.69	   (0.45	   1.06)	  
Digitalis	   	   1.71	   (0.54	   5.43)	   1.73	   (0.54	   5.49)	   1.71	   (0.54	   5.45)	  
Lipid	  Lowering	  Agents	   0.48	   (0.31	   0.73)	   0.48	   (0.31	   0.73)	   0.48	   (0.31	   0.73)	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Multivariable	  models	  control	  for	  age,	  education,	  gender,	  previous	  strokes	  
CIND	  =	  Cognitive	  Impairment	  No	  Dementia,	  SCI	  =	  Subjective	  Cognitive	  Impairment,	  CVD	  =	  Cardiovascular	  Medication,	  DEP	  =	  Depression,	  
HR=Hazards	  Ratio,	  CI=	  Confidence	  Interval	  
	  
Figure	  1:	  Study	  Figure	  
	  
Figure	  2:	  Antidepressant	  and	  cardiovascular	  medications	  prescriptions	  by	  CIND,	  SCI,	  and	  depression	  status.	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